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1 Introduction 
 
1.1  Diabetes mellitus & diabetic cardiomyopathy 
 
Diabetes mellitus (DM) is a metabolic disorder that is characterized by a chronic 
increase of blood glucose concentrations due to defects in insulin signaling. Details of 
insulin signaling defects are further described in chapter 1.8.1. DM can be classified into 
the following general categories: type 1 diabetes mellitus (T1DM) and type 2 diabetes 
mellitus (T2DM). T1DM occurs due to destruction of the insulin secreting β-cells, usually 
leading to an insulin deficiency. T2DM develops because of insulin resistance and a 
defect in compensatory insulin secretion (Craig et al., 2014, American Diabetes, 2015).  
In 2014 approx. 422 million adults worldwide have suffered from DM compared to 108 
million in 1980. During this period, the global prevalence of diabetes in age-
standardized adults raised from 4.7 to 8.5 % (WHO, 2016). The rising prevalence of DM 
is mainly attributed to the increase in T2DM and its main risk factors such as overweight 
and obesity (Chatzigeorgiou et al., 2009, Wang et al., 2014). DM can lead to clinical 
complications such as cardiovascular disease (CVD), stroke, nephropathy, leg 
amputation, retinopathy and neuropathy (WHO, 2016). For example, the risk for diabetic 
patients to suffer from heart failure (HF) is increased by the factor of two to five 
compared to non-diabetic patients (de Simone et al., 2010, Nichols et al., 2004, Kannel 
et al., 1974, Dandamudi et al., 2014). Approx. half of the mortality of diabetic patients is 
related to CVD (Authors/Task Force et al., 2013, Paneni, 2014, Park and Peters, 2014). 
In 1972, Rubler and colleagues published post-mortem data from diabetic patients with 
HF but lacking evidence for the most common causal factors hypertension, myocardial 
ischemia or congenital or vascular heart disease, respectively (Rubler et al., 1972). 
Nowadays this is described by the term “diabetic cardiomyopathy” (DCM) and 
characterized by any abnormality of myocardial diastolic and/or systolic function in 
diabetic subjects without hypertension or coronary artery disease (CAD). The 
prevalence of DCM is rising in parallel with the increasing incidence of obesity and 
T2DM (Jia et al., 2016). So far, the pathophysiology of DCM is not fully elucidated. 
Several molecular mechanisms are described that contribute to its development, e.g. 
altered insulin signaling, impaired calcium (Ca2+) handling, increased fatty acid (FA) 
utilization and oxidative stress (figure 1.1; Bugger and Bode, 2015, Yilmaz et al., 2015, 
Bugger and Abel, 2014). To date, intense research is focusing on the mechanisms of 
DCM to develop therapeutic strategies for the treatment of DCM. Diabetic mouse 
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models are important research tools to elucidate the mechanisms of DCM. One 
advantage is that diabetic mice do not manifest severe atherosclerosis, a main cause 
for CAD (Back and Hansson, 2015, Pjanic et al., 2016, Vikramadithyan et al., 2005). 
Thus, heart failure development is not “contaminated” by CAD. 
 
 
 
Figure 1.1 The pathophysiology of diabetic cardiomyopathy (DCM): several molecular mechanisms are 
described that contribute to the development of DCM, e.g. altered insulin signaling, impaired calcium (Ca
2+
) 
handling and oxidative stress (AGEs = advanced glycation endproducts, RAAS = renin–angiotensin–aldosterone 
system, FA = fatty acid, miRNAs = micro ribonucleic acids, ER = endoplasmatic reticulum; Bugger and Abel, 
2014). 
 
1.2  Principles of cardiac function - calcium & excitation-contraction 
coupling 
 
Intracellular Ca2+ is an essential signaling molecule that controls important cellular 
processes. It is important in regulating action potentials (APs), excitation-contraction 
coupling, mitochondrial energy production, Ca2+/calmodulin-dependent protein kinase II 
activity and nuclear gene expression (Winslow et al., 2016). Cardiac excitation-
contraction coupling is defined as the process of sarcolemmal depolarization leading to 
an increase of the cytosolic Ca2+ concentration that initiates contraction of the heart 
(Winslow et al., 2016). In detail, depolarization of the cardiac myocyte membrane 
activates L-type Ca2+ channels (LTCCs) that lead to an initial Ca2+ influx. As illustrated 
in figure 1.2, the Ca2+ influx induces the release of further Ca2+ from the sarcoplasmic 
reticulum (SR) via the ryanodine receptor (RyR), a process called calcium-induced 
calcium-release (CICR). This increase of intracellular Ca2+ enables muscle contraction 
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by binding of Ca2+ to the myofilament protein troponin C. For myocyte relaxation the 
intracellular Ca2+ concentration has to decline so that Ca2+ dissociates from troponin C 
(Bers, 2002). Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) and its 
endogenous inhibitor phospholamban (PLN) are important for mediating the SR Ca2+ 
uptake from the cytosol (Feijoo-Bandin et al., 2015). Lowering of intracellular Ca2+ can 
also be achieved via the sarcolemmal Ca2+-ATPase, the sarcolemmal               
Na+/Ca2+-exchanger or mitochondrial Ca2+ uniport (Bers, 2002). Since Ca2+ plays such 
an important role in heart function, impaired Ca2+ handling is associated with various 
forms of cardiac diseases (Winslow et al., 2016). 
 
 
Figure 1.2 Calcium signaling in cardiomyocytes and excitation-contraction coupling.  Upon depolarization of 
the cardiomyocyte membrane L-type Ca
2+
 channels (LTCCs) generate a Ca
2+
 influx. The increasing Ca
2+
 
concentration induces the release of further Ca
2+
 from the sarcoplasmic reticulum (SR) via the ryanodine receptor 
(RyR) and finally induces muscle contraction. Myocyte relaxation is mediated via mechanisms that decline the Ca
2+
 
concentration, e.g. sarcoplasmic/endoplasmic reticulum calcium ATPase2 (SERCA2) activation and  
phospholamban (PLN) phosphorylation (modified from Feijoo-Bandin et al., 2015).  
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1.3  Voltage-dependent calcium channels  
  
Voltage-dependent calcium channels (VDCCs) are involved in several physiological 
processes such as muscle contraction, glandular secretion, neurotransmission and 
gene expression (Catterall et al., 2003). The molecular composition of VDCCs is 
characterized by a heteromeric polypeptide complex that consists of a transmembrane 
pore-forming α1-subunit and accessory ß- and α2-δ-subunits as well as an accessory γ-
subunit in several calcium channel subtypes (figure 1.3, Campiglio and Flucher, 2015). 
γ-subunits are unlikely to play a role as part of the cardiac VDCC complex, although 
they are able to modulate cardiac calcium channel functions in recombinant expression 
systems (Yang et al., 2011).  
 
 
Figure 1.3 Molecular subunit composition of VDCCs: the heteromeric proteins consist of a pore-forming           
α1-subunit, accessory ß- as well as α2-δ-subunits and possibly a γ-subunit (Buraei and Yang, 2010). 
 
Each type of VDCC subunit is encoded by several genes, reflecting the diversity of Ca2+ 
channel structure and function (Zamponi et al., 2015, Catterall, 2011). Based on 
structural relationships among the different α1-subunit isoforms, VDCCs are classified 
in three α1-subunit gene subfamilies, i.e. Cav1, Cav2 and Cav3. Each subfamily contains 
several isoforms, such as Cav1.1, Cav1.2, Cav1.3 and Cav1.4 in case of the CaV1 
subfamily. Cav1.2 is the predominant cardiac α1-subunit isoform (encoded by the 
cacna1c gene) and  mainly responsible for the Ca2+ influx during excitation-contraction 
coupling (Ertel et al., 2000, Zamponi et al., 2015).  
VDCCs can be further distinguished by their (electro-)physiological and pharmacological 
properties leading to a differentiation in L-, P/Q-, N-, R- and T-type Ca2+ currents 
(Catterall et al., 2005). L-Type Ca2+ currents are named according to their long-lasting 
currents if barium is the charge carrier and are mediated by L-Type calcium channels 
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(LTCCs). LTCCs show a slow voltage-dependent inactivation and a large single-
channel conductance. These channels start to activate at membrane potentials above   
-40 mV and therefore belong to the so-called high-voltage activated channels. LTCCs 
can be blocked by several ligands such as dihydropyridines, phenylalkylamines and 
benzothiazepines (Neumaier et al., 2015, Catterall, 2011).  
 
LTCCs exist in three different conformations: closed (C), open (O) and inactive (I) state, 
as demonstrated in figure 1.4. At the resting membrane potential of about -80 mV, 
LTCCs are in the closed conformation. Upon depolarization, voltage-gated LTCCs open 
(conducting state) and Ca2+ ions enter the cell. Subsequently, open channels change to 
either the closed or the inactivated (non-conducting) state. The inactivated conformation 
is provoked by time- or rather Ca2+-dependent inactivation (CDI) and/or by voltage-
dependent inactivation (VDI). Repolarization is necessary for recovery from inactivation 
after that channels can be activated again. If a depolarizing pulse arrives prior to 
complete recovery, less or even no Ca2+ ions enter the cell. Taken together, the Ca2+ 
entry is regulated by the membrane potential, the LTCC kinetics of opening, the kinetics 
of inactivation (CDI, VDI) and the kinetics of recovery from inactivation (Hering et al., 
2000). CDI and VDI are regulated by the interaction of the Cav1.2 α1-subunit with the 
Cavß-subunit and/or the calcium sensor calmodulin (CaM) (Neumaier et al., 2015, Van 
Petegem and Minor, 2006).  
 
 
Figure 1.4 LTCC conformations: LTCCs can exist in a closed (C), open (O) and inactive (I) state (Karmazinova 
and Lacinova, 2010). 
 
Since this study focused on cardiac LTCCs, their properties are explained in more detail 
here. 
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1.3.1 The pore-forming Cav1.2 α1-subunit 
 
The pore-forming Cav1.2 α1-subunit is responsible for ion trafficking and represents the 
largest LTCC subunit of approx. 210-240 kDa. Varying band sizes in Western Blots are 
mainly attributed to truncations of the proteins’ C-terminus due to the expression system 
or experimental conditions (De Jongh et al., 1996, Weiss et al., 2013, Shaw and 
Colecraft, 2013). As demonstrated in figure 1.5, the Cav1.2 subunit consists out of four 
homologous domains (I–IV). Each domain is composed of six membrane-spanning 
segments that include the voltage-sensing domain (VSD) and the pore domain (PD) 
with the Ca2+ selectivity filter. The Cav1.2 α1-subunit further contains the Cavβ-subunit 
binding site (referred to as α1-interaction domain/AID) as well as structural domains 
responsible  for CDI, VDI and ligand binding (Neely and Hidalgo, 2014, Hofmann et al., 
2014). 
 
Figure 1.5 Structure of the Cav1.2 α1-subunit: The pore-forming protein mediates most of the LTCC functions 
and consists of four homologous domains (I–IV). The subunit contains the β-subunit binding site (referred to as α1-
interaction domain/AID), the voltage-sensing domain (VSD), the pore domain (PD) including the selectivity filter 
and binding sites for ligands (modified from Neely and Hidalgo, 2014).  
 
1.3.2 The Cavß-subunit 
 
The auxiliary Cavβ-subunit (approx. 55 kDa) modulates LTCC gating properties and 
consists of a Src homology 3 domain (SH3) and a guanylate kinase (GK) domain. Both 
domains are linked by the so-called HOOK region and flanked by N- and C-termini (NT 
and CT), as shown in figure 1.6 (A) (Buraei and Yang, 2010). The GK domain contains 
the α1-binding pocket which interacts with the AID of the Cavα1-subunit (figure 1.5 (B); 
Chen et al., 2004, Almagor et al., 2012, Van Petegem et al., 2004).  
VSD
PD
AID
C-terminus
N-terminus
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Figure 1.6  Structure of the Cavß-subunit: figure (A) illustrates the domain organization and three-dimensional 
structure. The subunit consists of a core region flanked by N- and C-termini (NT and CT). The core region is built 
by the Src homology 3 (SH3) and the guanylate kinase (GK) domains connected via the so-called HOOK region. 
The GK domain interacts with the AID of the α1-subunit (B) (modified from Neely and Hidalgo, 2014). 
 
Up to now, four Cavß-subunit isoforms (Cavβ1-Cavβ4) have been identified. Cavβ1, 
Cavβ2 and Cavβ3 are expressed in the heart, while Cavβ4 was only found in young rat 
atrial myocytes, so far (Buraei and Yang, 2010, Chu et al., 2004).  
Cavß-subunits increase LTCC activity, regulate LTCC membrane expression and 
possess binding sites for several proteins such as RGK proteins. These characteristics 
are pronounced differentially among the several subtypes. E.g. Cavβ2, the predominant 
cardiac isoform, increases LTCC activity most (Colecraft et al., 2002, Hullin et al., 2003, 
Hullin et al., 2007, Buraei and Yang, 2013). 
 
1.3.1 The Cavα2-δ-subunit 
 
The auxiliary Cavα2-δ-subunit (approx. 170 kDa) consists of a large, extracellular α2-
subunit and a small transmembranic δ-subunit which has a short intracellular region. 
Both subunits are linked through a disulfide bridge. The Cavα2-δ-subunit is encoded by 
a single gene and post-translationally cleaved into the α2 and the δ polypeptides. So 
far, at least 4 mammalian isoforms (Cavα2-δ-1 - Cavα2-δ-4), encoded by different 
genes, have been identified (Bodi et al., 2005, Catterall, 2011). All isoforms were 
reported to be present in the cardiovascular system. However, functional differences on 
LTCC regulation are not known so far (Hofmann et al., 2014). Indeed, the functional role 
of the Cavα2-δ-subunit is poorly understood. In heterologous expression systems it 
increases the channel expression and enhances its function, but to a lesser extent and 
in a more channel-specific way compared to Cavß-subunits (Catterall, 2011). 
BA
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1.4  RGK proteins 
 
The RGK proteins belong to the RAS GTPase superfamily and are represented by four 
related proteins: Rad, Gem/Kir, Rem 1 and Rem 2. The monomeric G proteins have low 
molecular masses ranging from 20 to 40 kDa (Neely and Hidalgo, 2014). All RGK 
proteins share a common structure including (I) a variable N-terminal segment, (II) a   
G-domain, involved in guanine nucleotide binding, and (III) a C-terminal segment, that 
contains a CaM binding site and the poly-basic membrane targeting sequence (Sasson 
et al., 2011). Although RGK proteins are structurally related they show different tissue 
expressions (Flynn and Zamponi, 2010): 
 
 Rad and Rem 1 are mainly expressed in cardiac, skeletal and smooth muscle 
cells (Chang and Colecraft, 2015). 
 Rem 2 is abundantly expressed in the nervous system, in kidney and liver, but is 
barely detectable in heart (Finlin et al., 2000, Liput et al., 2016).  
 Gem/Kir is found in diverse tissues, including heart, thymus, spleen, kidney, lung 
(Maguire et al., 1994, Murata et al., 2004). 
 
1.4.1 RGK-VDCC interaction 
 
One main function of RGK proteins is the inhibition of VDCCs (Correll et al., 2008). Up 
to now, three different mechanisms of inhibition are suggested:  
 
1. RGK proteins inhibit the channel trafficking to the cell surface and decrease its 
surface expression (Yada et al., 2007, Jhun et al., 2012, Yang et al., 2010, 
Sasaki et al., 2005, Yang et al., 2012, Beguin et al., 2006, Beguin et al., 2001).  
2. RGK proteins suppress membrane-resident VDCCs via immobilization of the 
voltage sensor (Yang et al., 2010, Yang et al., 2012, Meza et al., 2013, 
Magyar et al., 2012). 
3. RGK proteins suppress membrane-resident VDCCs via reduction of the open 
probability (Yang et al., 2012, Xu et al., 2010, Yang et al., 2010).  
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As illustrated in figure 1.7, it has been suggested that the Cavß-subunit binds to the 
AID of the Cavα1-subunit and induces a conformational change (ß primes α1) (Fan et 
al., 2010). Then, VDCC inhibition can be induced by either RGK-Cavα1 binding (A), by a 
tripartite complex (B) or by RGK-Cavß binding (C) (Fan et al., 2010, Correll et al., 
2008, Béguin et al., 2007, Finlin et al., 2006, Yang et al., 2007, Buraei and Yang, 
2015).  
 
Figure 1.7 Mechanisms of VDCC inhibition by RGK proteins: the interaction of the Cavß-subunit with the AID 
of the Cavα1-subunit induces a conformational change in Cavα1 (ß primes α1). Then, VDCC inhibition can be 
induced by either RGK-Cavα1 binding (A), by a tripartite complex (B) or by RGK-Cavß binding (C) (modified from 
Buraei and Yang, 2015). 
 
1.5  LTCCs in heart failure 
 
Heart failure (HF) is a clinical syndrome that occurs due to structural and/or functional 
cardiac abnormalities which impair the ventricle to pump blood with normal efficiency. 
This leads to a reduced cardiac output and/or elevated intracardiac blood pressures 
(Ponikowski et al., 2016). Cardiac LTCCs are important for proper excitation-contraction 
coupling (Rougier and Abriel, 2016). Therefore, alterations in LTCC expression and 
function are of high interest to elucidate the pathophysiology of HF.  It was consistently 
found that LTCC whole-cell Ca2+ current density in cardiomyocytes from failing human 
ventricles or animal models of HF was (almost) unchanged compared with non-failing 
Introduction 
- 10 - 
ventricles (Mukherjee and Spinale, 1998, Richard et al., 1998). Interestingly, a 
significantly increased single-channel activity was shown in ventricular myocytes from 
human end-stage failing hearts (Schroeder et al., 1998). The finding of an increased 
single-channel activity might result from an enhanced ß-adrenergic stimulation, that is 
known to be increased in case of developing HF (Madamanchi, 2007). This is consistent 
with findings of a blunted response to β-adrenergic receptor agonists in human failing 
hearts (Chen et al., 2002). Another reason for the increased single-channel activity 
might be the cardiac upregulation of the Cavß2-subunits in human failing hearts (Hullin 
et al., 2007). In a mouse model of cardiac Cavß2-subunit overexpression observed 
LTCC properties were similar to LTCC function in chronic human HF (Beetz et al., 
2009). Hong and colleagues determined the total amount of transmembrane Cav1.2 
channels in failing human hearts; the amount of the protein expression was unchanged 
but the channels were less abundant in the T-tubuli (Hong et al., 2012). These findings 
fit earlier radioligand binding studies (Takahashi et al., 1992, Gruver et al., 1994). Taken 
together, a more active state of present channels accompanied by less surface 
channels was suggested to occur in failing ventricles (Schroeder et al., 1998). 
 
1.6  RGK-LTCC interaction in the context of DCM 
 
In human HF LTCC density was unchanged, while the activity of single LTCCs was 
increased (described in the previous chapter). Candidates that might be involved in 
modulation of expression and function of LTCCs are RGK proteins, such as Rad. Rad 
expression was found to be reduced in human HF (Chang et al., 2007) and in Rad-
knockout (k.o.) mice whole-cell Ca2+ current densities were increased (Manning et al., 
2013). The effect of Rad on LTCC function and expression in a diabetic context is still 
unclear. Rad was initially identified and named as “RAS-related protein associated with 
diabetes” because its expression was upregulated in skeletal muscle of humans with 
T2DM (Reynet and Kahn, 1993). Since insulin infusion induced a significant increase in 
the mRNA level in percutaneous biopsies of human vastus lateralis muscles (Laville et 
al., 1996), the Rad gene is suggested to be insulin-regulated. Therefore, Rad might be 
an important candidate for LTCC modulation in DCM. Studies to investigate this issue 
were initially conducted by our group, as outlined in figure 1.8 (Fabisch, 2010, 
unpublished data). Protein analysis of Rad and Cav1.2 α1-subunit expression 
(henceforward only referred to Cav1.2) in ventricular tissue of mice with diabetes-
associated metabolic disturbances were positively correlated suggesting a rather 
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compensatory role of Rad, e.g. to prevent Ca2+ overload. Of note, there have been 
differences in the extent and/or direction of altered Cav1.2 and Rad expression 
compared to wildtype (wt) littermates (figure 1.8; Fabisch, 2010, unpublished data). In a 
mouse model associated with DCM (the so-called db/db mice with leptin receptor 
deficiency) our group detected a reduced whole-cell Ca2+ current density with 
unchanged single-channel activity (Pereira, 2006). The reduced whole-cell Ca2+ current 
density was attributed to a reduced expression of the LTCC pore Cav1.2 (Pereira, 
2006). These results are in contrast to the findings in human HF. Therefore, putative 
differential effects of Rad on modulating LTCCs might exist depending on the diabetic or 
non-diabetic context. 
 
 
Figure 1.8 Rad and Cav1.2 protein expression in ventricular tissues of mice with diabetes-associated metabolic 
disturbances. The expression of Rad and Cav1.2 protein was found to be positively correlated (ob/ob mice = mice 
that are deficient for leptin, MIRKO mice = muscle-specific insulin receptor knockout mice, IRS-2
-/-
 = mice lacking 
the insulin receptor substrate 2, db/db mice = mice with leptin receptor deficiency; Fabisch, 2010, unpublished data). 
 
1.7  Animal models of DCM 
 
As mentioned in chapter 1.6, Rad and Cav1.2 protein expression seem to be positively 
correlated in ventricular tissues of mice with diabetes-associated metabolic 
disturbances. We chose two of the previously screened mouse models differing mainly 
by body weight and amount of blood glucose enhancement for further analysis, i.e. mice 
that are deficient for leptin (ob/ob) and mice lacking the insulin receptor substrate 2 (IRS 
2). Mice of different ages (16 and 28 weeks) were chosen for experiments to take time-
dependent onset of obesity and disease progression of T2DM into account. Age-
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matched wildtype (wt) mice were used as controls. So far, other studies solely focused 
on a complete (and thus artificial) k.o. of RGK proteins, while this study focused on a 
differential rather “secondary” change of RGK protein expression. Rad-k.o. mice served 
as internal control mice and should reveal the maximum effect of a loss of Rad protein 
on LTCC expression and function. Furthermore, ob/ob x Rad-k.o. mice were generated 
in order to check whether the role of Rad differs depending on the murine background. 
 
1.7.1 ob/ob mice 
 
Ob/ob mice are globally deficient for leptin due to a spontaneously occurred mutation in 
the gene Lepob of the mouse strain V/Le in The Jackson Laboratory, Bar Harbor, USA in 
1949 (Ingalls et al., 1950). After backcrossing for more than 45 generations mice have 
been available on a C57BL/6J background (Mouse Genome Database, 2017). The 
autosomal recessive, single gene mutation is located on chromosome six of leptin and 
based on the nonsense mutation in codon 105. In detail, a stop codon occurs because 
of an amino acid change and these mice release a truncated version of the adipocyte 
peptide hormone leptin. In ob/ob mice leptin mRNA levels are highly increased by the 
factor 20 compared to wt mice. However, this mRNA is mutated and resulting proteins 
are not functional (Zhang et al., 1994, Moon and Friedman, 1997, Wang et al., 2014). 
Leptin is known as a negative regulator of food intake; its lack results in an increased 
availability of the potent appetite-stimulant neuropeptide Y (Lee and Cox, 2011). 
Therefore, ob/ob mice possess an obese phenotype (Chatzigeorgiou et al., 2009), 
exhibit early-onset hyperglycemia, hyperinsulinemia and insulin resistance already four 
to six weeks after birth (Lindstrom, 2007, Mazumder et al., 2004, Haluzik et al., 2004, 
Buchanan et al., 2005).  
 
1.7.2 IRS 2-knockout mice 
 
Mice lacking the insulin receptor substrate 2 (IRS 2-k.o. mice) were first described in the 
late 20th century (Withers et al., 1998, Kubota et al., 2000). IRS 2-k.o. mice exhibit 
early-onset hyperglycemia, hyperinsulinemia and insulin resistance at an age of approx. 
six weeks. This mouse line shows no or only mild obesity (Sesti et al., 2001, Burks et 
al., 2000, Withers et al., 1998, Kubota et al., 2000). 
IRS 2 is an ubiquitously expressed cytoplasmic protein that regulates biological 
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processes such as glucose metabolism, protein synthesis and cell survival. It is an 
important molecule in insulin signaling (Oliveira et al., 2014, Mardilovich et al., 2009). To 
date, four closely related insulin receptor substrates (IRS 1- 4) have been identified that 
differ in tissue distribution, subcellular localization, developmental expression, binding to 
the insulin receptor and interaction with SH2 domain containing proteins (Sesti et al., 
2001). Both, IRS 1 and IRS 2 are the predominant family members expressed in the 
heart (Riehle and Abel, 2016). 
 
1.8  Leptin and insulin  
 
1.8.1 Insulin function and signaling pathway 
 
Insulin is a key metabolic peptide hormone involved in carbohydrate, lipid and protein 
metabolism (Newsholme and Dimitriadis, 2001). It is synthesized by β-cells of the 
pancreas and secreted in response to enhanced concentrations of blood glucose. 
Although insulin mainly acts in liver, adipose tissue and skeletal muscle, insulin 
receptors (IRs) are widely expressed in the mammalian body (Belfiore et al., 2009). 
Binding of insulin to the IR leads to an autophosphorylation and IR activation (figure 
1.9). Following IR activation two canonical signaling pathways are possible: 
 
1. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is responsible for metabolic 
effects. In the PI3K/Akt pathway the IR phosphorylates tyrosine residues of 
IRS1/IRS2, which act as docking platforms for the Src homology 2 domain of 
PI3K. This finally promotes an activation of protein kinase B (PKB) or Akt 
(Baumgard et al., 2016). In the heart signaling via PI3K/Akt mediates metabolic 
effects such as an increase in glucose uptake, coronary vasodilation, substrate 
flexibility and energy homeostasis (Jia et al., 2016). 
 
2. The Ras/mitogen-activated protein kinase pathway is accountable for effects on 
cell growth and proliferation (Jia et al., 2016). 
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Figure 1.9 Insulin signaling pathway: binding of insulin to the insulin receptor (IR) can activate two canonical 
signaling pathways: the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, responsible for metabolic effects, and 
the Ras/mitogen-activated protein kinase pathway, accountable for effects on cell growth and proliferation.  
 
The impairment of key insulin signaling molecules such as IRS, PI3K or Akt might be 
involved in the development of insulin resistance (Yang et al., 2016). Insulin resistance 
as a key feature of type 2 diabetes is caused by various factors, e.g. by obesity, 
hyperglycemia, hyperlipidemia, hyperinsulinemia and/or activation of the RAAS/the 
sympathetic nervous system. These factors are suggested to contribute to an increased 
activation of enzymes that phosphorylate IRS proteins. A serine phosphorylation of IRS 
proteins attenuates IRS tyrosine phosphorylation. Other molecular mechanisms leading 
to a diminished strength of the PI3K/Akt pathway are proteasomal degradation of IRS 
proteins and decreased activation of downstream signaling molecules such as Akt 
(Aroor et al., 2012, Ye, 2013, Kim et al., 2008). Therefore insulin resistant tissues 
exhibit an imbalance in the metabolic and growth effects of insulin signaling, with the 
actions of the Ras/mitogen-activated protein kinase pathway dominating (Jia et al., 
2016, Wang et al., 2004). In the prediabetic state insulin resistant individuals 
compensate the disturbed PI3K/Akt signaling by secreting more insulin (Hardie, 2012). 
The compensatory mechanism also includes an increase in glucose oxidation, in fatty 
acid oxidation and in glycerolipid-free fatty acid cycling (Wortham and Sander, 2016). 
Such an adaption mechanism may predispose ß-cells to lipotoxicity. This term 
describes a process that results in down-regulation of insulin, ß-cell dysfunction and 
apoptosis (Fu et al., 2013). Upon exhaustion of ß-cells this failure in compensation 
mechanism may lead to T2DM (Hardie, 2012). Generalized insulin resistance is also 
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associated with HF (Velez et al., 2014) and insulin resistance of the heart might directly 
contribute to cardiac dysfunction (Aroor et al., 2012). 
 
1.8.2 Leptin function and signaling pathway 
 
Leptin is a known negative regulator of food intake and regulates a variety of other 
functions such as neuroendocrine functions, fertility, angiogenesis and long-term energy 
balance (Chan and Leung, 2015). Leptin is primarily produced in the adipose tissue 
(Fernandez-Formoso et al., 2015). The hormone is secreted into the bloodstream by 
adipocytes (Zhou and Rui, 2013) and mediates its effects through leptin receptors. 
Leptin receptors are widely expressed in the mammalian body, e.g. in liver, heart, 
kidneys, lungs, pancreas and adipose tissue (Margetic et al., 2002). Among the known 
six leptin receptor isoforms, the Lepr-b receptor, which is highly expressed in the 
hypothalamus, is known to mediate its main effects via the JAK (janus kinase)/STAT 
(signal transducer and activator of transcription) pathway, as outlined in figure 1.10 
(Fernandez-Formoso et al., 2015).  
 
Figure 1.10 Leptin signaling pathway: binding of leptin to the leptin receptor (Lepr-b) activates JAK2, which 
phosphorylates JAK2 itself and three tyrosine residues on Lepr-b. Each of these phosphorylation sites triggers a 
specific signaling pathway. A phosphorylated JAK2 leads to a phosphorylation of IRS molecules and activation of 
PI3K. 
 
In brief, leptin binding to Lepr-b activates JAK2 which phosphorylates itself and three 
tyrosine residues on Lepr-b. Each of these phosphorylation sites triggers a specific 
signaling pathway, as demonstrated in figure 1.10. A phosphorylated JAK2 leads to a 
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phosphorylation of IRS molecules and activation of PI3K, a pathway necessary for 
leptin’s effects on food intake and sympathetic nerve activity (Munzberg and Morrison, 
2015). Similar to the manifestation of insulin resistance and compensatory 
hyperinsulinemia, leptin resistance and hyperleptinemia can develop, especially in 
obese patients and rodents (Konner and Bruning, 2012).  
 
1.8.3 Link between insulin and leptin 
 
Insulin and leptin receptors are widely expressed in mammalian tissues. Co-expression 
in the same tissue might enable an interaction of both receptors. Insulin and leptin 
mediate some of their physiological effects via IRS signaling. An interaction between 
both pathways is possible via IRS 2, but also via other downstream elements such as 
PI3K or STAT (Szanto and Kahn, 2000, Carvalheira et al., 2003, Carvalheira et al., 
2001). Especially in obese mammals insulin and leptin signaling may be altered. Both 
hormones are of major importance for cardiac contractility, growth and metabolism 
(Westermeier et al., 2016, Feijoo-Bandin et al., 2015). Leptin and insulin signaling might 
be involved in the regulation of LTCCs (Ballou et al., 2015, Viard et al., 2004).  
 
1.9  Aim of the study 
 
Cardiovascular disease (CVD) is a leading cause of death for diabetic patients (Sowers 
and Lester, 1999, Balakumar et al., 2016). Diabetic cardiomyopathy (DCM) is 
characterized by an abnormality of myocardial diastolic and/or systolic function in 
diabetic subjects without the major heart failure risk factors hypertension and/or (overt) 
coronary artery disease (Jia et al., 2016). Since cardiac L-Type calcium channels 
(LTCCs) are known to be involved in proper excitation-contraction coupling, they are of 
high interest in the research of CVD, such as DCM and resulting heart failure (HF). In 
human (non-diabetic) HF whole-cell Ca2+ current density of ventricular LTCCs was 
unchanged compared to non-pathophysiological conditions, while single-channel activity 
was significantly increased (Mukherjee and Spinale, 1998, Schroeder et al., 1998). 
These findings suggest changes in both, expression and function of LTCCs. In contrast 
to humans, whole-cell Ca2+ current density was reduced in a mouse model associated 
with DCM (the so-called db/db mice with leptin receptor deficiency), while single-
channel activity was unchanged (Pereira, 2006).  
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It has been shown that RGK proteins, like the diabetes-associated Rad, might be 
involved in LTCC regulation, both regarding its function and expression. Rad expression 
is reduced in human heart failure (Chang et al., 2007) and whole-cell Ca2+ current 
densities are increased in cardiomyocytes of Rad-k.o. mice (Manning et al., 2013). So 
far, the effect of Rad on cardiac LTCCs even in a diabetic context is unclear. Previous 
data suggest that the ventricular expression levels of Rad and Cav1.2 proteins are 
positively correlated in several mouse models with diabetes-associated metabolic 
disturbances (Fabisch, 2010). Differences in the extent and/or direction of altered 
Cav1.2 and Rad protein expression might be due to a differential regulation depending 
on e.g. the genotype, age and/or the onset and severity of metabolic disturbances. For 
a more detailed analysis two diabetic mouse models were investigated in the present 
study: leptin-deficient obese ob/ob mice and mice lacking insulin receptor substrate 2 
(IRS 2), respectively. Though experiments with Rad-k.o. and Rem 1-k.o. mice suggest 
an impressive inhibitory effect of RGK proteins on native cardiac LTCCs (Magyar et al., 
2012, Manning et al., 2013), it remains unclear whether differential expression of RGK 
proteins might be compensatory, causative or both regarding LTCC regulation. Thus, 
the present study aims at the role of an in vivo regulation of Rad expression on 
ventricular LTCCs in two established diabetes mouse models (ob/ob and IRS 2-
knockout mice). Therefore, ventricular whole-cell L-type calcium current densities were 
obtained by patch-clamp recordings and compared to those of wildtype littermates in the 
context of ventricular expression levels of Rad and Cav1.2 mRNA and protein. In order 
to further evaluate the role of Rad in ob/ob mice, we generated and analyzed ob/ob 
mice lacking Rad. In summary, it should be elucidated whether there is an unifying 
effect of Rad on LTCCs in diabetic hearts that might suggest a mechanism underlying 
diabetic cardiomyopathy.    
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2 Materials and methods 
2.1  Materials 
2.1.1 Chemicals 
 
Description Order No. Supplier/manufacturer 
Acetic acid 3738.2 Roth 
Magnesium-adenosine 5′-
triphosphate (Mg-ATP) 
A9187-1G Sigma-Aldrich 
Agarose powder 2267.4 Roth 
Amberlite® K306.1 Roth 
Ammonium peroxodisulfate (APS) 9592.3 Roth 
Boric acid 3678542 Merck 
Bovine serum albumin (BSA) A6003-25G Sigma-Aldrich 
Bromphenol blue 8122 Merck 
Caesium chloride (CsCl) 8627.3 Roth 
Calcium chloride dihydrate 
(CaCl2*2H2O) 
T885.2 Roth 
Coomassie 3862.1 Roth 
Diethylpyrocarbonate (DEPC) K028.1 Roth 
DNA-ExitusPlusTMBC A7089,0500 AppliChem 
DNA Gel Loading Dye (10 x) R0611 Thermo Fisher Scientific 
Dulbecco’s Modified Eagle’s Medium 31966-021 Gibco Thermo Scientific 
Ethanol 2246.2500 Th.Geyer 
Ethidium bromide 2218.3 Roth 
Ethylenediaminetetraacetic acid 
(EDTA) 
8043 Roth 
Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic 
acid (EGTA) 
E-4378 Sigma-Aldrich 
Fetal calf serum (FCS) S0115 Biochrom 
D(+)-Glucose monohydrate X997.2 Roth 
Glycerol 3783.1 Roth 
Glycin G7126-1KG Sigma-Aldrich 
Glyoxal 50649-25ml Sigma-Aldrich 
Heparin H3393.100KU Sigma-Aldrich 
Iodoacetic acid sodium salt I2512 Sigma-Aldrich 
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Description Order No. Supplier/manufacturer 
Magnesium chloride hexahydrate 
(MgCl2*6H2O) 
1.05833.0250 Merck 
Magnesium sulfate heptahydrate 
(MgSO4*7H2O) 
1.05886 Merck 
2-mercaptoethanol M6250-100ml Sigma-Aldrich 
Methanol (MeOH) 4627.5 Roth 
Milk powder T145.1 Roth 
N,N-bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES) 
9134.3 Roth 
Nonidet®P40 BioChemica A16940250 Applichem 
Orange G 6x Loading Dye  845-ST-
4010003 
Analytik Jena AG 
Penicillin/Streptomycin (100 x) P11-010 PAA Laboratories 
GmbH 
Percoll 17-0891-01 GE Healthcare Life 
Sciences 
Phosphate-Buffered Saline (PBS) 14190-094 Gibco Thermo Scientific 
Pierce®Protein A/G Magnetic Beads 88802 /88803 Thermo Fisher Scientific 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
(HEPES) 
H3375-500G Sigma-Aldrich 
Polysorbate 20 (Tween 20) A4974,0250 AppliChem 
Ponceau S P3504 Sigma-Aldrich 
Potassium chloride (KCl) 6781.1 Roth 
Rotiphorese®Gel 40 (19:1) 3030.1 Roth 
Saline 0.9 % 6340501 AlleMan Pharma GmbH 
Sodium dodecyl sulfate (SDS) 2326.1 Roth 
Sodium azide 8223350100 Merck 
Sodium chloride (NaCl) 3957.2 Merck 
Sodium dihydrogen phosphate 
monohydrate (NaH2PO4*1H2O) 
6346 Merck 
Sodium hydroxide (NaOH) C238798 Merck 
Sucrose S-0389 Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) T9281-50ml Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane 
(Tris) 
4855.2 Roth 
Triton®X-100 12298 Merck 
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2.1.2 Enzymes / antibodies / plasmids / kits / ladder 
 
Description Order No. Supplier/manufacturer 
Anti-Calcium Channel C1603 Sigma-Aldrich 
Anti-HA High Affinity 11 867 423 001 Roche 
Anti-RRAD antibody produced in 
goat 
SAB2502049 Sigma-Aldrich 
Collagenase type 1, 41.6 U/ml - Worthington Biochemical 
Corporation 
Collagenase type 2, 47.4 U/ml - Worthington Biochemical 
Corporation 
Donkey anti-goat IgG-HRP sc-2020 SantaCruz 
Gene RulerTM 100 bp DNA ladder SM0241 Thermo Fisher Scientific 
HindIII 10 U/µl ER0501 Thermo Fisher Scientific 
KAPA Mouse Genotyping Hot Start 
Kit 
KK7302 PEQLAB Biotechnologie 
GmbH 
NucleoBond® Xtra Maxi Kit 740414.10 Macherey-Nagel 
Polyclonal Swine Anti-Rabbit 
Immunoglobulins/HRP 
P0399 Dako 
QuantiTect® Reverse Transcription 
Kit 
205311  Qiagen 
QuantiTect SYBR® Green PCR Kit 204243  Qiagen 
Rad cDNA clone (mouse, pCMv-6-
Entry vector, Rrad-Myc-DDK-tagged) 
MR204351 Origene Technologies Inc 
RNeasy® Fibrous Tissue Mini Kit 74704 Qiagen 
RNA ladder 0.5-10 kbp 15623-200 Life Technologies GmbH 
SigmaFASTTM Protease Inhibitor 
Cocktail Tablet, EDTA-Free 
S8830 Sigma-Aldrich 
Spectra Multicolor Broad Range 
Protein Ladder 
26634 Life Technologies GmbH 
Super Signal West Pico 
Chemiluminescent Substrate 
34087 Thermo Fisher Scientific 
Trypsin 25300-054 Gibco Thermo Scientific 
 
  
 Materials and methods 
- 21 - 
2.1.3 Consumables 
 
Description Supplier/manufacturer 
Accu-Chek® Aviva Test Strips Roche Diagnostics 
Deutschland GmbH 
BD DiscarditTM II syringes (2, 5, 10, 20, 50 ml; sterile)  Braun 
BD MicrolanceTM 3 injection needles (27G) Becton Dickinson 
BD PlastipakTM 1ml, sterile Becton Dickinson 
Biosphere® filter tips 10, 20, 100 µl Sarstedt 
Borosilicate glass capillaries (1.7 mm OD; 1.133 mm 
ID, 0.283 mm wall thickness) 
Hilgenberg 
BRANDplates®pureGradeTM, 96-well BRANDTECH 
Buffer solution pH 4, pH 7, pH 9 Roth 
Disposable transfer pipettes 3 ml  VWR 
Falcon® tissue culture dishes, polystyrene, sterile  
35 x 10 mm)  
Corning 
Falcon tubes (15 and 50 ml) Sarstedt  
GE Healthcare AmershamTM ProtranTM Premium NC  
200 mm x 4 m (0.45 µm) 
Ge Healthcare 
Biosciences 
Immun-Blot® PVDF-Membrane 20 x 20 cm (0.2 μm) Bio-Rad 
Microcentrifuge tubes, 1.7 ml VWR 
Perfusor®-Line Braun 
PCR tubes 0.2 ml VWR 
Roche Light Cycler ® capillaries Roche 
Scalpel No. 22 Pfm medical AG 
Serological pipettes (1, 2, 5, 10, 25, 50 ml; sterile)  Sarstedt 
Silver wire AG-15W Science Products GmbH 
Sterifix injection filter 0.2 µm Braun 
THOMAPOR®  mesh filter, polyamide 250 µm 
(948362) 
THOMAPOR 
Ultracentrifuge tubes, 1.5 ml BECKMAN 
WhatmanTM 3MM Chromatography Paper  
15 cm x 100 m 
Ge Healthcare 
Biosciences 
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2.1.4 Equipments 
 
Description Supplier/manufacturer 
Accu-Chek® Aviva Blood Glucose Meter System Roche Diagnostics 
Deutschland GmbH 
Axopatch 200B amplifier Axon Instruments 
BioTek™ Synergy™ 2 Multi-Mode Microplate 
Reader 
Thermo Fisher Scientific 
Centrifuge 5425 R Eppendorf AG 
CO2-incubator HERAcell 150i Thermo Fisher Scientific 
CV 203BU headstage (5285012) Axon Instruments 
Digidata 1440A AC/DA-converter Axon Instruments 
Eppendorf Mastercycler Eppendorf AG 
F423 heated circulating bath  Haake 
Faraday cage Self supplied 
Finn pipettes (2, 10, 20, 100, 200, 1000 µl)  Thermo Fisher Scientific  
Fluorescence microscope Nikon Eclipse Ti-U Nikon Instruments 
Halogen sold light source KL 1500 Schott 
Heating plate RET control IKAMAG  IKA 
Heating plate IKA RH basic 2 IKA 
Horizon®11-14 Horizontal Gel Electrophoresis 
System 
Thermo Fisher Scientific 
Hielscher UP50H Sonicator Hielscher Ultrasonics GmbH 
Langendorff column  Self supplied 
Light Cycler®2.0 System Roche Diagnostics 
Deutschland GmbH 
Light Cycler Carousel Centrifuge Roche Diagnostics 
Deutschland GmbH 
Microcentrifuge Galaxy MiniStar VWR 
International  
VWR 
Micromanipulator MHW-103  Narishige International 
Micropipette polisher: type MF-83  Narishige International 
Micropump Ismatec SA 
Mini-PROTEAN Tetra Cell (SDS gel casting 
components and chamber) 
Bio-Rad 
Mini Trans-Blot® Cell  Bio-Rad 
MultiImage®  II system Alpha Innotech 
 Materials and methods 
- 23 - 
Description Supplier/manufacturer 
Nano Drop 2000c Thermo Fisher Scientific 
OptimaTM TLX Ultracentrifuge; rotor: TLA 55 Beckman Coulter Deutschland 
Pipetboy acu  Integra Biosciences 
Pipette puller P-97  Sutter instruments 
Polymax 1040 Heidolph 
Potter S Sartorius 
PowerPacTM Universal Power Supply Bio-Rad 
Seven Easy pH-meter  Mettler Toledo 
Sterile bench HS 12/2 Heraeus Instruments 
Sterilizing oven Heraeus Instruments  
Thermomixer compact  Eppendorf AG 
Thermo Shaker and Block  HLC 
Tube Roller RS-TR05  Phoenix instruments 
Ultra Turrax ®  IKA 
Vibration-cushioned table  Self supplied 
Vortex Genie2TM Scientific Industries 
 
2.1.5 Computer software / programs 
 
Description Supplier/manufacturer 
AlphaDigiDoc®Pro Imaging System Alpha Innotech 
Clampfit10.2 Axon Instruments 
Gen5TM Data Analysis Software BIOTEK 
GraphPad Prism®6 GraphPad Software 
ImageJ National Institutes of Health 
Microsoft®Office2007 Microsoft 
pClamp10.2 Axon Instruments 
Net Primer PREMIER Biosoft Premier Biosoft 
NCBI / Basic Local Alignment Search Tool  NCBI 
Primer 3 Whitehead Institute for 
Biomedical Research 
REST-2009© Qiagen 
Roche Assay Design Center Roche Diagnostics  
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2.2  Animals 
 
2.2.1 Origin of animals 
 
First breeding animals of the ob/ob mice (leptin B6.Cg-Lep ob/J) were purchased from 
the Jackson Laboratory, Bar Harbor, USA. First breeding mice lacking the IRS 2 were 
kindly provided by Prof. Dr. J. Brüning, CECAD Coordinator, University Hospital of 
Cologne (former: Institute for Genetics, University of Cologne). First Rad-k.o. animals 
were kindly provided by D. A. Andres, Ph.D. Professor and Chair, Department of 
Molecular & Cellular Biochemistry, University of Kentucky, College of Medicine, 
Lexington, USA. This was in agreement with Prof. Dr. C. R. Kahn, Chief Academic 
Officer, Joslin Diabetes Center/Professor of Medicine, Harvard Medical School, Boston, 
USA. Furthermore a cross-breeding was established to raise ob/ob x Rad-k.o. mice. All 
mouse lines had a C57BL/6J background. Age-matched wt mice (homozygous 
C57BL/6J mice of all breedings) were used as controls. 
 
2.2.2 Breeding and maintenance  
 
Animals were raised and maintained in an in-house animal facility of the Center of 
Pharmacology, Institute II, University Hospital of Cologne. Rad-k.o. mice were also 
raised in the Center for Molecular Medicine Cologne (CMMC), University Hospital of 
Cologne. All mice were kept in ventilated cages with food and water ad libitum, 
maintained in a 12h/12h dark/light cycle. All animals were fed with ssniff® complete 
diets (mouse maintenance: V1534-703, mouse breeding: V1124-703, ssniff 
Spezialitäten GmbH, Soest, Germany). Heterozygous (hz) ob/+ animals were 
necessary to breed ob/ob mice, whereas IRS 2-k.o. and Rad-k.o. mice could also be 
generated using homozygous knockouts. Animal breeding, maintenance and 
experiments were approved by the responsible federal state authority (Landesamt fuer 
Natur-, Umwelt- und Verbraucherschutz North Rhine-Westphalia; reference:               
84-02.05.20.12.294/84-02.05.20.13.060). All animal experiments were in accordance 
with the guidelines from directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes.  
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2.2.3 Determination of blood glucose, body weights and ventricle weights 
 
Body weights were determined immediately before killing the mice. Blood glucose 
concentration was measured shortly after cervical dislocation using a blood glucose 
meter (Accu-Check® Aviva, Roche Diagnostics Deutschland GmbH, Mannheim, 
Germany) with a drop of blood leaking from the excised tail (approx. 2 mm). For 
determination of ventricular heart weight hearts were excised immediately, atria and 
aorta were dissected and intraventricular blood removed. An increased ventricle-to-body 
weight ratio is a common indicator for cardiac hypertrophy.  
 
2.2.4 Sample preparation 
 
After cervical dislocation murine hearts were dissected in ice-cold PBS. For Western 
Blot and quantitative real-time PCR (qRT-PCR) ventricles were quick-frozen in liquid 
nitrogen and stored at -80°C until further processing. 
 
2.3  Genotyping 
 
For genotyping tail-tips (approx. 4 mm) from three week old mice were cut and stored at 
-20°C until further processing. Genotyping PCRs were kindly performed by                   
S. Kirchmann-Hecht at the Center of Pharmacology, Institute II, University Hospital of 
Cologne.  
 
2.3.1 Genomic deoxyribonucleic acid (gDNA) purification 
 
For gDNA purification KAPA Express Extract system, included in the KAPA Mouse 
Genotyping Hot Start Kit (PEQLAB Biotechnologie GmbH, Erlangen, Germany), was 
used according to the manufacturer’s protocol. gDNA extracts were stored at -20°C. 
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2.3.2 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction allows amplification of DNA fragments of specific gDNA 
regions in order to analyze and identify these regions. gDNA was amplified with the 
KAPA2G Fast Hot Start Genotyping Mix with dye, the second KAPA Mouse Genotyping 
Hot Start Kit component. KAPA2G Fast Hot Start Genotyping Mix (2 x) is a ready-to-use 
master mix and contains a Hot Start DNA polymerase, a buffer, dNTPs (0.2 mM each at 
1 x), MgCl2 (1.5 mM at 1 x), stabilizers and two inert dyes, which allow a direct PCR 
analysis of reaction products without use of an additional loading solution. Only primers 
and templates had to be added. Reaction setup, cycling parameters and primers can be 
found in table 2.1 - 2.3. 
 
Table 2.1 DNA amplification protocol for genotyping: reaction setup 
Components IRS2-k.o. ob/ob Rad-k.o. 
Final 
concentration 
PCR grade H2O 7.75 µl 8 µl 9.5 µl  
KAPA2G Fast Hot 
Start Genotyping 
Mix 2 x 
12.5 µl 12.5 µl 12.5 µl 1 x 
Primer  
1.25 µl / 
 primer 
1.25 µl / 
 primer 
0.5 µl /  
primer 
0.5 µM  
Template gDNA 1 µl 2 µl 1 µl  
 
Table 2.2 DNA amplification protocol for genotyping: cycling parameters 
Cycling step 
Target temperature / incubation time No. of cycles 
IRS2-k.o. ob/ob Rad-k.o.  
Initial denaturation 95°C /  3 min 95°C /  3 min 94°C /  3 min 1 
Denaturation 95°C / 15 sec 95°C / 15 sec 94°C / 30 sec  
Annealing 61°C / 15 sec 60°C / 15 sec 57°C / 30 sec 35 
Elongation 72°C / 20 sec 72°C / 20 sec 72°C / 40 sec  
Final elongation 72°C /  5 min 72°C / 10 min 72°C /  5 min 1 
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Table 2.3 Primer pairs for genotyping (Sigma-Aldrich, St. Louis, MO, USA). Rad and IRS primers were described 
previously (Chang et al., 2007, Kido et al., 2000). Ob/ob primers were designed using the freeware Primer 3 
(Whitehead Institute for Biomedical Research, Cambridge, MA, USA).  
Primer name Sequence (5’-3’) 
IRS 2 forward (F) primer 10 µM GAA GAC AGT GCG TAC ATG CGA ATG 
IRS 2 reverse (R) primer 10 µM CCT CAT GGA GGA AAG CAC TGC TG 
IRS 2 neosense primer 10 µM TTC TAT CGC CTT CTT GAC GAG TTC 
Ob/ob F primer 10 µM TGT CCA AGA TGG ACC AGA CTC 
Ob/ob R primer 10 µM ATC CAG GCT CTC TGG DTT CT 
Rad F mutant primer 25 µM GAG CAC GTA CTC GGA TGG AAG C 
Rad R mutant primer 25 µM  GCG ATA GAA GGC GAT GCG CTG C 
Rad F wildtype primer 25 µM AGT CTG AAC AGG GGT CTA CGA GTG 
Rad R wildtype primer 25 µM TCT GGC CCT GTG TCC GAG TTC 
 
2.3.3 Restriction enzyme digestion / gel electrophoresis 
 
Ob/ob mice genotyping products were subjected to a restriction enzyme digestion with 
HindIII (10 U/µL, ER0501, Thermo Fisher Scientific) for 1 h at 37°C (table 2.4), followed 
by 20 min at 60°C, before loading on a 3% agarose gel placed into a gel electrophoresis 
chamber containing TBE buffer (table 2.5). 
 
Table 2.4 Restriction enzyme digestion of ob/ob PCR products 
Components Final volume 
PCR grade H2O 7 µl 
10 x BufferR (supplied with 
HindIII) 
2 µl 
HindIII (10 U/µL)  1 µl 
PCR product 10 µl 
Table 2.5 Electrophoresis buffer for PCR products 
TBE buffer Final concentration 
Tris  89 mM 
Boric acid 89 mM 
EDTA 2 mM 
pH 7.6  
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PCR products generated for genotyping of IRS 2-k.o. and Rad-k.o. mice were directly 
loaded on a 2% agarose gel. During electrophoresis for 1 h at 100 mA PCR products 
migrated towards the anode, small fragments showing slower migration rates than 
bigger fragments. To facilitate detection the double-stranded DNA intercalating dye 
ethidium bromide was added. For visualization AlphaDigiDoc®Pro Imaging System 
(Alpha Innotech, Santa Clara, CA, USA) and a 100 bp or 1 kbp DNA ladder (GeneRuler 
100 bp DNA Ladder, SM0241 / GeneRuler 1 kbp DNA Ladder, SM0311, Thermo Fisher 
Scientific) were used. Table 2.6 shows the expected band sizes of PCR products. 
 
Table 2.6 Expected band sizes of PCR products 
Expected band size Wildtype Mutant 
IRS 2 300 bp 400 bp 
Ob/ob 180 bp 83 bp and 99 bp 
Rad 507 bp 347 bp 
 
2.4  Cardiac myocytes isolation assay  
 
The isolated perfused mammalian heart preparation, widely known as the Langendorff 
perfused heart, was established in the late 19th century by Oscar Langendorff. The 
method was developed on the basis of the isolated perfused frog heart and originally 
used for the study of heart physiology (Langendorff, 1895, Taegtmeyer, 1995, Zimmer, 
1998). The animal's heart is removed from its body and retrograde perfused via the 
aorta in order to keep it alive for several hours. This preparation method has been 
subjected to various modifications. For instance, the method has been modified in order 
to isolate cardiac myocytes. The aorta is cannulated as well, but retrograde perfused 
with an enzyme solution to digest the heart into individual cells.  
In this study single ventricular myocytes were isolated by using a modification of a 
method described previously (Heubach et al., 1999, Foerster et al., 2003). Isolated cells 
were subjected to patch-clamp analysis and cardiac myocytes purification assays. In 
detail, solution A (table 2.7) was prepared as stock solution in tenfold concentration and 
stored at 4°C until use. On each experimental day glucose was added freshly to   
solution A and diluted 1:10 with aqua destillata. The pH was adjusted to 7.4 with NaOH. 
To obtain solution B (table 2.7), 500 mg BSA was added to 500 ml of solution A. The 
perfusion column and organ bath (figure 2.1) were filled with solution B, preheated to 
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37°C using a water bath and perfused with oxygen 100%. The length of the column 
defined the perfusion pressure. Circa 30 minutes prior to cervical dislocation mice were 
treated with heparin (7.5 IU/g, intra peritoneal) to prevent post-mortem thrombus 
formation. Preparation and cannulation of the aorta followed immediately after cervical 
dislocation in ice-cold solution A. The aorta was placed over the tip of a blunt injection 
needle and tied with a binder yarn before being connected to the column (figure 2.1). 
Then the whole heart was perfused with solution B for 5 min in order to remove the 
blood from the coronary arteries. Afterwards the heart was perfused under constant 
pressure with an enzyme solution prepared in solution B (solution C, table 2.7). Duration 
of digestion depended on the amount of solution passing the coronary arteries 
estimated by the drop rate. After 5 min of digestion drop rate was determined first and 
subsequently in an one-minute distance. End point of digestion was reached when drop 
rate was doubled or after a maximum perfusion time of 15 min or when the outward 
appearance of the heart (e.g. paleness, slightly edematous tissue) indicated sufficient 
perfusion. To obtain numerous healthy cardiomyocytes the heart had to be light-colored, 
soft and flaccid when palpated after perfusion. The digested heart was taken quickly 
from the cannula, aorta and atria were removed and ventricles were cut into small 
pieces in solution B. The tissue pieces were gently triturated with a cut-off plastic 
transfer pipette for about 5 min to gain individual cells. Cells were filtered through a    
250 µm mesh cell collector into a falcon tube and left for 20 min at room temperature to 
settle. Ca2+ concentration was increased (from 0 µM to 100 µM to 200 µM to 400 µM) 
every 20 min to select Ca2+ tolerant cells which were rod-shaped and quiescent. Cells 
were maintained at room temperature and taken for patch-clamp analysis for up to 6 h. 
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Table 2.7 Solutions for cardiac myocytes isolation 
Solution A Final concentration 
NaCl 133 mM 
KCl 4 mM 
NaH2PO4 * 1 H2O 1.2 mM 
MgSO4 * 7 H2O 1.2 mM 
HEPES 10 mM 
Glucose 12.1 mM 
In H2O, pH 7.4 with NaOH  
 
 
Solution B Final concentration 
BSA 1 mg/ml 
In solution A  
  
Solution C Final concentration 
Collagenase type 1 41.6 U/ml 
Collagenase type 2 47.4 U/ml 
CaCl2-solution 0.1 M 25 µM 
In solution B  
 
 
Figure 2.1 Cardiac myocytes isolation system: (A) setup; (B) exemplary cannulated heart; (C) visualization of a 
proper cannulated heart (heart figures modified from Louch et al., 2011).  
column
organ bath
water bath
aortic valve
coronary
arteries
A
CB
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2.5  Cardiac myocytes purification assay / Percoll density gradient 
centrifugation 
 
Equilibrium density gradient centrifugation is used for purifying cell fractions (Lodish et 
al., 2007). In this study it was planned to separate the enzymatically isolated 
cardiomyocytes prior to perform quantitative real-time PCR (qRT-PCR) experiments.  
Percoll (GE Healthcare, Solingen, Germany) is a commercially available medium for 
that purpose. It is composed of colloidal silica coated with nondialyzable 
polyvinylpyrrolidone. The density range of Percoll medium/gradient encompasses all 
densities of the sample particles. Each particle sediments to its isopycnic position where 
its density is equal to the surrounding gradient density. Particle size is not relevant given 
that the density of the particles is always smaller than medium density. Thus sample 
particles are separated only on the basis of differences in density. The gentle 
centrifugation conditions allow separation of cells without loss of viability and 
morphological integrity.  
For Percoll density centrifugation a Percoll stock solution was prepared by adding    
40.5 ml of Percoll to 4.5 ml ADS buffer 10 x (table 2.8). Out of this stock solution two 
Percoll solutions with different densities were diluted in ADS buffer 1 x. In a 15 ml falcon 
tube a layer consisting of a 4 ml 40.5% Percoll solution was layered over a 3 ml 58.5% 
Percoll layer. For better visualization phenol red was added to the bottom layer. After 
Langendorff isolation of cardiac myocytes cell suspension obtained was centrifuged at 
330 g for 3 min. The pellet was resuspended in 2 ml ADS buffer 1 x. Subsequently, the 
cell suspension was added to the gradient and centrifuged at 1850 g for 30 min (room 
temperature). Four fractions of cells were obtained: cells on the top of 40.5% Percoll 
(fraction 1), cells within the 40.5% Percoll (fraction 2), a layer of cells at the interface of 
the two layers of Percoll (fraction 3) and cells within the 58.5% Percoll layer (fraction 4). 
Purified cardiac myocytes, which should concentrate at fraction 3, could be objected to 
further experiments, e.g. qRT-PCR. 
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Table 2.8 Solutions for Percoll density gravity centrifugation 
ADS buffer (10 x) Final concentration 
NaCl 129 mM 
HEPES 22 mM 
NaH2PO4 * 1 H2O 1 mM 
Glucose 6.2 mM 
KCl 6 mM 
MgSO4 * 7 H2O 0.45 mM 
In H2O, pH 7.4 with NaOH, sterile filtered  
 
2.6  Messenger ribonucleic acid (mRNA) analysis of murine ventricle 
samples 
 
For gene analysis on transcriptional level mRNA was isolated from murine ventricles, 
reverse transcribed into cDNA and quantified via qRT-PCR. In a qRT-PCR the 
amplification of cDNA via PCR and the detection of amplification products occur 
simultaneously.  
 
2.6.1 Primer design and efficiency tests 
 
Specific primer pairs for the Cavα1-subunit of the L-type calcium channel Cav1.2 (gene 
ID: Cacna1c), the auxiliary beta-subunits Cavß1, Cavß2, Cavß3 (gene ID: Cacnb1-
Cacnb3) and the housekeeping genes S 29 (ribosomal protein S 29, gene ID: Rps 29), 
HPRT (Hypoxanthine-guanine phosphoribosyltransferase) and GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) were described previously in other 
publications or in the following dissertations of our own group: Böhnke, 2012; Dizayee, 
2011; Fabisch, 2010. Primers for the RGK proteins Rad (gene ID: Rrad), Gem, Rem 1, 
Rem 2 were designed using the software tool Roche Assay Design Center (Roche 
Diagnostics), the freeware Primer 3 (Whitehead Institute for Biomedical Research, 
Cambridge, MA, USA) or taken from earlier publications, as well (table 2.9). To avoid 
detecting genomic DNA, primers were designed intron-spanning or intron-flanking. 
Primers were validated for specificity, hairpins and dimers utilizing the freeware 
NCBI/Basic Local Alignment Search Tool (NCBI, Bethesda, Maryland, USA) and 
NetPrimer PREMIER Biosoft (PREMIER Biosoft, Palo Alto, California). 
Before starting the experiments, primers (Sigma-Aldrich, table 2.9) were tested for 
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amplification efficiencies, as well. Efficiencies of two genes were compared by preparing 
a dilution series for both genes from a murine ventricle cDNA sample. The threshold 
cycle (Ct) values obtained by qRT-PCR were blotted against the log template amount. 
Resulting slopes were taken to calculate PCR efficiency:  
 
Efficiency [%] = 10 (-1/slope) - 1 x 100 
 
If efficiencies are comparable, the blotted curves of both genes go in parallel (Bustin et 
al., 2009). The differences in Ct values of the target and the reference gene will be 
constant independent of template amount (figure 2.2). 
 
Table 2.9 qRT-PCR primers (100 µM). Primers were diluted 1:10 before pipetting to the master mix. Final 
concentration used: 0.75 µM. Forward and reverse primers are marked with F and R. 
Primer Sequence (5’-3’) Source 
S29  (F) ATG GGT CAC CAG CAG CTCT A 
(Böhnke, 2012, Fabisch, 2010) 
S29 (R) AGC CTA TGT CCT TCG CGT ACT 
HPRT (F) TGA CAC TGG CAA AAC AAT GCA 
(Fabisch, 2010) 
HPRT (R) GGT CCT TTT CAC CAG CAA GCT 
GAPDH (F) CAT GGC CTT CCG TGT TCC TA 
(Bai et al., 2013) 
GAPDH (R) CCT GCT TCA CCA CCT TCT TGA T 
Cav1.2  (F) TCC GAA CAT TAC AAC CAG CCT (Fabisch, 2010, Böhnke, 2012, 
Dizayee, 2011) Cav1.2 (R) GCT GTA CAT CTT CAG GAG CA 
Rad (F) AAG ACG GAC CTG AAG CAG AA 
Roche Assay design center  
Rad (R) CAT CCT GTT CCC AAA TGT CA 
Rem 1 (F) AAAC AAG ACC GAG ACC CTC A 
Roche Assay design center  
Rem 1 (R) CAC TGA CAG CGT TCT CTC GT 
Rem 2 (F) AGC ACT TTG TTC TTC CAG CA 
Primer 3  
Rem 2 (R) CAG TTT CTC TGG CTT CTG TTT C 
Gem (F) GAC AGC ATG GAC AGC GAC T 
Roche Assay design center  
Gem (R) ACG ACC AGG GTA CGC TCA TA 
Cavß1 (F) TGG ACA GCC TTC GTC TGC T 
(Dizayee, 2011) 
Cavß1 (R) TGG AAC TGG AGT TGT CAC CT 
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Primer Sequence (5’-3’) Source 
Cavß2 (F) GGG AGG CAG TAC GTA GAG AAG CT 
(Böhnke, 2012, Dizayee, 2011) 
Cavß2 (R) TGC AAA TGC AAC AGG TTT TGT C 
Cavß3 (F) TGG AGT CAA CTT TGA GGC CA 
(Dizayee, 2011, Böhnke, 2012) 
Cavß3 (R) TCC CGA TCC ACC AGT CAT TG 
 
 
 
Figure 2.2  Determination of primer efficiencies: if efficiencies of two genes are comparable, the blotted curves of 
both genes go in parallel and the differences in Ct values (ΔCt) will be constant independent of template amount 
(ΔCt1 = ΔCt2). Resulting slopes of the blotted dilution series are necessary to calculate PCR efficiencies. 
 
2.6.2 Isolation of mRNA 
 
Isolation of mRNA from murine ventricle was performed with the RNeasy® Fibrous 
Tissue Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol 
with the following modifications: approx. 30 mg of frozen cardiac apex was 
homogenized with an Ultra Turrax ® (IKA, Staufen, Germany) in 300 µl buffer RLT. On-
column DNase digestion was skipped due to the following gDNA elimination step during 
reverse transcription. Each step of the protocol was performed at room temperature. 
The RNA was eluted in a volume of 60 µl RNase-free water and stored at -80°C.  
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2.6.3 Determination of mRNA quality  
 
Quality and quantity of the purified mRNA were controlled using the Nano Drop 2000c 
UV-Vis Spectrophotometer (Thermo Fisher Scientific).  
An additional quality check followed via agarose gel electrophoresis. Ribosomal RNA 
(rRNA) was separated into 18 S rRNA (~ 1.9 kbp) and 28 S rRNA (~ 4.7 kbp). RNA 
quality was marked by two sharp bands of which the 28 S rRNA band was twice as 
intense as the 18 S rRNA band (Taylor et al., 2010).  
Check of RNA integrity was performed as described earlier (Gründemann and Koepsell, 
1994). For short, RNA samples and RNA ladder were mixed with three sample volumes 
of 4/3 DLG denaturating solution (table 2.10) and incubated for 1 h at 50°C. Main 
components of the 4/3 DLG are DMSO and deionized glyoxal. Glyoxal reacts with the 
base guanin and prevents base-pairing with cytosin. Consequently, the so-called 
glyoxilation of the single-stranded RNA avoids formation of secondary structures. After 
incubation 1 µl Orange G loading dye was added to 4 µl of denaturated sample solution 
and RNA ladder, respectively. Subsequently, samples were loaded on a 1% agarose 
gel (0.5 mM iodoacetic acid sodium salt included) in BES buffer, that was run at 90 mV. 
Iodoacetic acid sodium salt, an alkylating agent, was used to protect the RNA against 
RNases. BES buffer is a low-ionic strength buffer, which also prevents base pairing. 
After approx. five minutes the buffer was circulated constantly using a mini pump to 
avoid the development of a pH gradient. For visualization ethidium bromide staining and 
detection via AlphaDigiDoc®Pro Imaging System (Alpha Innotech) were used. Ethidium 
bromide staining of RNA was reported to react with glyoxal, resulting in a loss of 
fluorescence (Gründemann and Koepsell, 1994). Therefore the dye was always added 
freshly to the 4/3 DLG denaturating solution. 
 
Table 2.10 Solutions for RNA integrity check 
BES buffer (1 x) Final concentration 
BES 10 mM 
EDTA 0.1 mM 
pH 6.7; treated with DEPC-H2O  
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4/3 DLG  Final concentration 
DMSO 50 % (v/v) 
Deionized glyoxal (40 %) 1 M 
In BES buffer (1 x)  
 
4/3 DLG denaturating solution Final volume 
4/3 DLG 50 µl 
Ethidium bromide solution (0.25 %) 1 µl 
  
RNA ladder Final volume 
RNA ladder 1 µg/µl; 0.5-10 kb 10 µl 
DEPC-H2O 10 µl 
4/3 DLG denaturating solution 60 µl 
 
Orange G loading dye Final concentration 
Glycerol 50 % (v/v) 
DEPC-H2O 50 % (v/v) 
Orange G 2.5 mg/ml 
 
2.6.4 Reverse transcription into complementary DNA (cDNA)  
 
The reverse transcription step was carried out in duplicate with the QuantiTect® 
Reverse Transcription Kit (Qiagen), as outlined in the manufacturer’s protocol. In brief, 
400 ng total RNA was used in a final volume of 20 µl. Samples were prepared on ice. 
Reverse transcription was performed in a mastercycler (Eppendorf AG, Hamburg, 
Germany) using following conditions:  
 
5 min at 42°C for genomic DNA elimination 
19 min at 42°C for reverse transcription  
3 min at 95°C  to inactivate reverse transcriptase 
 
cDNA was stored at -20°C.  
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2.6.5 Quantitative real-time PCR (qRT-PCR) 
 
qRT-PCR was performed to quantify mRNA. This method possesses high sensibility for 
the detection of low target amounts (Bustin, 2000) and facilitates detection in the early 
exponential phase of PCR “in real time” during each PCR cycle. Real-time PCR 
reactions were carried out in a thermo cycler that permits fluorescence-based detection 
technologies. In this study the dye SYBR Green that fluoresces upon binding to double-
stranded DNA was used for quantifying.  
In qRT-PCR a starting amount of cDNA is amplified in a distinct number of cycles, 
consisting of denaturation, primer annealing and template elongation. Proportional to 
the amount of PCR product generated in each extension cycle, the fluorescence 
increases. In early cycles, there is no detectable fluorescence increase due to PCR 
products; this nonspecific signal is defined as background. The so-called threshold level 
is set above background and within the detectable log-linear phase of the reaction. 
Once there is a significant increase in fluorescence, so that the amplification plot 
crosses the threshold, the corresponding cycle is registered as the so-called threshold 
cycle (Ct) value. Respectively, the intensity of fluorescence generated at a given cycle 
is indicative of the template amount (figure 2.3).  
 
 
Figure 2.3 A typical qRT-PCR amplification plot: the increase in fluorescence is blotted versus the cycle number. 
A threshold level is set sufficiently above background within the exponential growth phase and the number of cycles 
required to reach threshold, Ct, is registered (modified from Kubista et al., 2006). 
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qRT-PCR was carried out in the Light Cycler®2.0 System (Roche Diagnostics 
Deutschland GmbH). Experiments were performed in triplicates using the QuantiTect 
SYBR® Green PCR Kit (Qiagen). Master mix solution (table 2.11) and primer pair 
dilutions (1:10 each) were prepared on ice. After pipetting the master mix into a Light 
Cycler® glass capillary, 1.5 µl per forward and reverse primer (0.75 µM final 
concentration per primer) were added. Before starting the thermo cycler (Light 
Cycler®2.0 System, Roche Diagnostics Deutschland GmbH), glass capillaries were 
spun down using the LightCycler® carousel centrifuge.  
After preincubation and 45 cycles of amplification (each consisting of denaturation, 
annealing and elongation), melting curve analysis was performed to check for product 
purity and to exclude primer dimers (table 2.12). Each experiment contained a control 
reaction in which no reverse transcriptase was added (detection of DNA contamination) 
and a further control with missing template (detection of general contamination). 
 
Table 2.11 Composition of reaction mix 
Master mix solution (per target / primer pair) Volume 
QuantiTect SYBR® Green PCR Master mix (2 x) 10 µl 
cDNA template 1 µl 
RNase-free water 6 µl 
 
Table 2.12 qRT-PCR protocol 
Cycling step 
Target 
temperature 
Incubation time 
Temperature 
transition rate 
No. of 
cycles 
Preincubation 95°C 15 min 20°C / sec 1 
Denaturation 94°C 15 sec 20°C / sec 
45 Annealing 58°C 25 sec 20°C / sec 
Elongation 72°C 10 sec 20°C / sec 
Melting curve 
analysis 
64°C 1 min 20°C / sec 1 
Inactivation of 
polymerase 
95°C   1 
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After qRT-PCR random samples were checked for correct cDNA amplification on a 
1.3% agarose gel (electrophoresis in TAE buffer 1 x at 100 V and detection via ethidium 
bromide; table 2.13). 
 
Table 2.13 Electrophoresis buffer for qRT-PCR products 
TAE buffer Final concentration 
Tris pH 7.6 40 mM 
Acetic acid 20 mM 
EDTA 1 mM 
 
2.6.6 qRT-PCR: data analysis 
 
At the beginning of data analysis the expression of S 29, HPRT and GAPDH was 
compared in order to find appropriate housekeeping genes. In general, housekeeping 
genes should be stably expressed. Their mRNA amounts should correlate with the total 
amounts of mRNA present in the samples (Bustin et al., 2009). 
 
The Pfaffl method (REST-2009©) 
 
For relative quantification of mRNA expression levels the Pfaffl method was used, 
available as the relative expression software tool REST-2009© (Qiagen, Hilden, 
Germany; see also Pfaffl et al., 2002). This method was chosen because it takes into 
account different primer efficiencies as well as several reference genes in order to 
correct the quantification ratio. In the present study data were normalized to S29, 
GAPDH and HPRT simultaneously (see also appendix, chapter 8.5.4). The software 
tool compares two groups (e.g. wildtype vs. mutant) with up to 16 data points per group 
and calculates the relative expression ratio between them. REST-2009© subsequently 
tests the group differences for significance. The statistical test used is based on the Pair 
Wise Fixed Reallocation Randomization Test©. A randomization test makes no 
assumptions about distributions and is only based on the fact that samples are 
randomly allocated. The randomization test repeatedly and randomly reallocates (2000 
times) the observed Ct values for the housekeeping and the target genes to the Ct 
values for control and mutant groups, and notes the apparent expression ratio each 
time. Because it is impractical to test for all possible allocations of data to the two 
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groups, only random samples are tested. If 2000 random reallocations are taken for 
analysis, the software tool gives a good estimate of the p-value < 0.05. REST-2009© 
analysis provides a 95% confidence interval for the expression levels as well as 
Whisker box plots for a visual representation of variation for each gene (Pfaffl et al., 
2002).  
 
In the current study data were also analyzed via 2–ΔΔCt analysis in order to provide a 
commonly accepted visual representation of variation for each gene via bar graphs 
(inclusive error bars).  
 
The 2–ΔΔCt or comparative method  
 
The 2–ΔΔCt or comparative method can be also used for relative quantification of a single 
transcription difference between two groups (Livak and Schmittgen, 2001). This method 
is based on two assumptions: first, the reaction is occurring with 100% efficiency and 
second, DNA amplification is constant among the samples (VanGuilder et al., 2008). 
The 2–ΔΔCt method only allows normalization against a single gene and primer efficiency 
cannot be included into analysis. In the present study S 29 was used as normalization 
gene (see also appendix, chapter 8.5.4).  
 
For relative quantification, the difference between the Ct values of the target gene and 
the housekeeping gene was calculated first:  
 
Δ Ct  = Ct (target gene) - Ct (housekeeping gene) 
 
Then, Δ Ct was used to compare gene expression in different samples, e.g. mutant vs. 
wildtype: 
 
ΔΔ Ct = Δ Ct (mutant) – Δ Ct (wildtype) 
 
An altered gene expression in mutant mice compared to wildtype mice was calculated 
as follows: 2–ΔΔCt .  
 
A 2–ΔΔCt value of 1 means no expression change, 2 stands for a twofold upregulation 
and 0.5 for a twofold downregulation of expression. In the present study significant 
expression changes of the 2–ΔΔCt analysis are supplemented in the appendix.   
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2.7  Protein analysis of murine ventricle samples 
2.7.1 Positive controls for Cav1.2 protein and Rad protein 
 
Cav1.2 protein  
A positive control for Cav1.2 protein was generated via a calcium phosphate based 
transfection method in tsa201 cells (human embryonal kidney cells; kindly provided by 
A. Koschak, LFU Innsbruck, Austria), followed by cell lysis and Co-immunoprecipitation 
(Co-IP).  
Calcium phosphate transfection: transfection was kindly performed by C. Fried at the 
Center of Pharmacology, Institute II, University Hospital of Cologne. Before being 
transfected the tsa201 cells were split in DMEM-high glucose medium (Gibco, Thermo 
Scientific), supplemented with 10% FCS (Biochrom, Berlin, Germany) and 
Penicillin/Streptomycin (50 U/ml / 50 µg/ml; PAA Laboratories GmbH, Cölbe, Germany). 
At the time of transfection attached cells were about 30-40% confluent. The desired 
plasmid DNA was first bound on the surface of a calcium phosphate precipitate. This 
precipitate was built up by mixing HBS buffer (table 2.14), containing phosphate ions, 
and a calcium chloride solution.  
In brief, the ice-cold transfection mix contained 950 µl HBS buffer and approx. 20 µg of 
the following plasmid DNA sequences in a subunit molar ratio of 1:1:1 (inserted in 
pcDNA3 expression vectors): CACNA1c (rat), CACNA2D1 (human) and CACNB3 
(human). The CACNA1c plasmid was kindly provided by E. Bourinet, Institute for 
Functional Genomics, Montpellier, France (GenBankTM accession number M67515; 
(Altier et al., 2002)). Into the extracellular S5-H5 loop of domain II of the Cav1.2 
construct a hemagglutinin epitope was inserted. The other plasmids were necessary to 
improve transfection efficiency. After preparation of the transfection mix 50 µl ice-cold 
CaCl2 solution (2.5 M) was added dropwise and vortexed briefly. Subsequently, the 
CaP-DNA complex was able to built up in about 30 min of incubation at room 
temperature. Thereafter, the suspension was transferred dropwise to the cells to be 
transfected. Given that an excess of Ca2+ may be toxic for the cells, they were washed 
twice in PBS (37°C) after 5 hours of incubation at 37 °C and fresh medium was added. 
The next morning medium was changed again (Penicillin/Streptomycin included), but 
instead of 10% only 2% FCS were added. After cells reached 60-70% confluence, they 
were incubated at 28°C for 72 h for protein expression.  
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Table 2.14 Composition of HBS buffer 
HBS buffer Final concentration 
HEPES 21 mM 
NaCl 137 mM 
KCl 49 mM 
Dextrose / glucose 5.5 mM 
Na2HPO4*7H2O 0.75 mM 
pH 6.95 - 7.1 with NaOH  
 
Cell lysis: transfected cell dishes were set back to 37°C incubation temperature for 
approx. 6 h in order to achieve a better cell attachment. 100% confluent cell dishes 
were put on ice for 15 min to prevent endocytosis and protein degradation. Following 
steps were performed on ice or at 4°C: cells were washed twice in 5 ml PBS. Afterwards 
medium was removed and 4 ml PBS added (including 10% SigmaFASTTM Protease 
Inhibitor Cocktail, EDTA-Free, Sigma-Aldrich). Cells were scraped off, transferred to 
microcentrifuge tubes and centrifuged at 3500 rpm for 3 min. Subsequently, the pellet 
was resuspended in 750 µl lysis buffer (table 2.15) and incubated at 700 rpm for 45 min. 
Samples were sonicated (60% pulse, 3 x 3 sec) in order to fragment DNA and to 
remove membrane components of the calcium channel, followed by another 30 min of 
incubation. To pellet non dissolved cell debris the tube was centrifuged at 13000 rpm for 
15 min. 
 
Table 2.15 Composition of cell lysis buffer 
Cell lysis buffer Final concentration 
Tris 50 mM 
NaCl 100 mM 
Triton®X-100 0.2 % (v/v) 
Nonidet®P40 BioChemica 0.2 % (v/v) 
EDTA 10 mM 
SigmaFASTTM Protease Inhibitor Cocktail, EDTA-Free 10 % (v/v) 
pH 7.5  
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CoIP: the supernatant obtained after cell lysis was objected to a CoIP in order to 
concentrate the antigen Cav1.2. In brief, 1.5 ml of the supernatant and 10 µl Anti-HA 
High Affinity antibody (Roche Diagnostics GmbH Deutschland) were incubated for 5 h at 
4°C to form an immune complex. Pierce®Protein A/G Magnetic Beads (Thermo Fisher 
Scientific) were washed twice in 1000 µl lysis buffer. The beads contained a 
recombinant Protein A/G that combined the IgG binding domains of Protein A and 
Protein G. The immune complex was then added to 25 µl of the washed beads and 
incubated over night (4°C). Thereby the complex was immobilized to the beads. The 
next day supernatant was discarded, beads were collected with a magnet and washed 
twice in 1 ml ice-cold PBS-Triton 0.2% for about 5 min. Finally, beads were incubated in 
40 µl 2 x Laemmli buffer (table 2.16) for 10 min at 50°C. After centrifugation at full 
speed for 1 min at 4°C eluted samples were shock frozen in liquid nitrogen and stored 
at -20°C. 5 µl of the solution were used for Western Blot. 
 
Table 2.16 Composition of Laemmli buffer  
Laemmli buffer (4 x) Final concentration 
Tris-HCl 200 mM 
SDS 8 % [w/v] 
Glycerol 40 % [v/v] 
Bromphenol blue 0.1 % [w/v] 
pH 6.8 
 
 
Rad protein  
In order to obtain enough transfectable plasmid DNA, a mouse cDNA clone (pCMv-6-
Entry vector, Rrad-Myc-DDK-tagged, MR204351, Origene Technologies Inc, Rockville, 
MD, USA) was purified by NucleoBond® Xtra Maxi Kit (Macherey Nagel, Dueren, 
Germany) according to the manufacturer’s protocol and the sequence was verified via 
sanger sequencing. 
Ca2+ phosphate transfection and cell lysis were performed as described above 
(transfection of Cav1.2) with following modifications: first, 20 µg of murine rRad (pCMv-6 
vector) were added to 950 µl ice-cold HBS buffer. Secondly, instead of 750 µl lysis 
buffer 150 µl were added to the cell pellet. Without sonification cells were lysed for 1 h 
at 4°C and centrifuged at full speed for 1 min at 4°C. The supernatant obtained after 
centrifugation could be directly used for Western Blot. CoIP was not necessary. 
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2.7.2 Cardiac cell membrane protein preparation assay 
 
The LTCC is an integral cell membrane protein complex (Hofmann et al., 2014). 
Therefore the transmembrane protein content was a particular research interest. 
Consequently, the protein preparation assay used was optimized to isolate mainly 
membrane proteins. The protocol was a modified protocol kindly provided by Prof. Dr. 
V. Flockerzi, Experimental and Clinical Pharmacology and Toxicology, Saarland 
University, Homburg, Germany (personal communication). 
For short, a frozen heart was disrupted with an Ultra Turrax® in 1 ml homogenization 
buffer (table 2.17) and then frozen at -80°C for at least 20 min. The formation of crystals 
during the freezing step should break up tight cell structures. Following steps were 
performed on ice or at 4°C: in order to dissolve the membrane proteins, the thawed 
suspension was homogenized with a Potter S homogenizer (Sartorius, Goettingen, 
Germany) and sheared twice through an injection needle (0.7 mm / 22 G). Fractioning 
procedure was conducted with differential centrifugation at increasingly higher speeds 
(Lodish et al., 2007). In general, large heavy dense particles sediment faster than small 
low dense particles. The dense, nonionic substance sucrose was optimal to achieve a 
good separation. Thus, 0.5 ml of a 0.63 mM sucrose solution (10% protease inhibitor 
cocktail included) were added and several centrifugation steps to eliminate the nuclei 
and the cell debris followed: 2 min at 500 rpm, 2 min at 1000 rpm and 10 min at 3000 
rpm. Subsequently, the supernatant, which contained the total protein fraction, was 
transferred to an ultracentrifuge tube  and centrifuged at 48000 rpm for 45 min 
(OptimaTM TLX Ultracentrifuge, Beckman Coulter Deutschland, Krefeld, Germany; rotor: 
TLA 55). This time the supernatant was discarded and the pellet resuspended in         
50-100 µl 0.25 mM sucrose buffer (table 2.17) using the potter homogenizer. Samples 
were frozen in liquid nitrogen and stored at -20°C or directly used for determination of 
protein content and Western Blot. 
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Table 2.17 Buffers for cardiac cell membrane preparation assay 
Homogenization buffer Final concentration 
Tris-HCl 40 mM 
MgCl2 0.2 mM 
SigmaFASTTM Protease Inhibitor Cocktail, EDTA-Free 10 % (v/v) 
pH 8, 4°C  
 
Sucrose buffer Final concentration 
Tris-HCl 10 mM 
Sucrose 0.25 mM 
SigmaFASTTM Protease Inhibitor Cocktail, EDTA-Free 10 % (v/v) 
pH 7.4, 4°C  
 
2.7.3 Determination of protein concentration  
 
Cardiac cell membrane protein content of purified heart samples was determined via a 
Bradford assay. This colorimetric assay is based on an absorbance shift of the dye 
Coomassie Brilliant Blue G-250. Under acidic conditions the cationic unbound form of 
the dye has an absorption spectrum maximum at 465 nm. When binding to proteins the 
dye converts from red to blue and the absorption spectrum maximum shifts to 595 nm. 
This increase of absorbance at 595 nm is proportional to the amount of protein bound to 
the dye (Bradford, 1976).  
The protein content of the samples was determined using a BSA standard curve. A 
dilution series of the standard protein bovine serum albumin (BSA) with the final 
concentrations 0, 25, 50, 75, 100, 125, 150, 175, 200 µg/ml was prepared in aqua dest. 
added with 0.1% sodium azide. Subsequently, 200 µl of Bradford reagent (table 2.18) 
was added to 20 µl of each BSA concentration. After incubation at 30°C for 2 min, 
extinction was measured at 595 nm with the high performance 
BioTek™Synergy™2Multi-Mode Microplate Reader (Biotek Germany, Bad 
Friedrichshall, Germany). Prior determination of the cardiac protein content, samples 
were diluted 1:50 in aqua dest. added with 0.1% sodium azide and treated same as the 
BSA dilution series. Experiments were performed in triplicates. 
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Table 2.18 Coomassie solution used for Bradford analysis 
Bradford reagent Composition 
Coomassie Brilliant Blue G-250 20 mg 
96 % ethanol 25 ml 
85 % o-phosphoric acid 50 ml 
Deionized H2O Ad 500 ml 
Filtered, stored dark & cold  
 
2.7.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
(SDS-PAGE) 
 
SDS-PAGE describes a method to separate proteins in an electric field. Protein 
samples are prepared in a buffer containing the anionic detergent SDS, which 
denatures and linearizes them and imparts a negative charge to them. This sample 
preparation allows separation of proteins according to their size instead of charge. ß-
mercaptoethanol is added to break disulfide bridges of the proteins. Prepared samples 
are subsequently transferred to an acryl amide gel and exposed to an electric field. 
In general, SDS-PAGE mini gels are ideally prepared with 7% acryl amide for Cav1.2 
protein separation and with 12.5% acryl amide for Rad protein separation. In the current 
study both proteins were separated in one gel by casting a 7% acryl amide gel on an 
already polymerized 10% acryl amide layer (table 2.19). By varying the acryl amide 
content the pore-size of the gel can be altered, thus the electrophoretic mobility. In 
general, smaller proteins migrate faster than larger proteins through the gel. Thus, small 
proteins have to be separated in a gel with high acryl amide content in order to obtain 
an adequate electrophoretic mobility, whereas large proteins migrate insufficient in such 
a gel. For polymerization of the gel TEMED as a catalyzer and APS as a radical initiator 
were necessary. The stacking gel  (table 2.19) was casted above the separating gel in 
order to concentrate samples. In another preparation step protein samples were diluted 
1:1 in Laemmli buffer (4x) containing 5% 2-mercaptoethanol, before being preheated at 
60°C for 6 min. Thereafter an equal amount of 40 or 60 µg per sample was loaded into 
the gel pockets. As a protein standard Spectra Multicolor Broad Range Protein Ladder 
(Life Technologies) was used. The gel was run at 200 V in SDS running buffer (1x) in 
the Mini-PROTEAN Tetra Cell chamber (Bio-Rad Laboratories GmbH, Munich, 
Germany). After SDS-PAGE stacking gel was completely removed and separating gel 
equilibrated in Western Blot transfer buffer for 20 min.  
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Table 2.19 Composition of SDS-PAGE gels and running buffer 
Separating gel Volume Final concentration 
Rotiphorese®Gel 40 
(37.5:1) 
1.75 / 2.5 / 3.125 ml  7 / 10 / 12.5 % 
 
Tris-HCl 3 M pH 8.8 2.5 ml   
SDS 20 % (w/v) 50 µl   
APS 10 % (w/v) 100 µl   
TEMED 10 µl   
H2O Ad 10 ml   
 
Stacking gel Volume 
Rotiphorese®Gel 40 
(37.5:1) 
670 µl 
Tris-HCl 0.5 M pH 6.8 1.25 ml 
SDS 20 % (w/v) 25 µl 
APS 10 % (w/v) 50 µl 
TEMED 5 µl 
H2O 3.075 ml 
 
SDS running buffer (1 x) Final concentration 
Glycin 192 mM 
Tris 25 mM 
SDS 0.1 % (w/v) 
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2.7.5 Western Blot / blocking procedure 
 
Western Blot is a method characterized by the transfer of proteins from a SDS gel onto 
a membrane, where they can be stained with antibodies specific to the target protein. 
Commonly the SDS gel is placed next to the membrane and an electric current is 
applied. Consequently, the proteins that are captured in the gel are forced to migrate 
towards the anode. At the time they reach the membrane, proteins are bound by 
hydrophobic interactions. The specific protein organization obtained after SDS-PAGE is 
maintained. 
Experiments were conducted in the tank blotting system Mini Trans-Blot® Cell (Bio-Rad 
Laboratories GmbH). For blotting of Cav1.2 protein a nitrocellulose (NC) membrane 
(AmershamTMProtranTM Premium NC, 0.45 µm, GE Healthcare) proved to be optimal. 
However, a polyvinylidene fluoride (PVDF) membrane (Immun-Blot® PVDF-Membrane, 
0.2 μm, Bio-Rad Laboratories GmbH) was preferred (mainly due to the smaller pore 
size) in order to blot solely Rad protein or  both proteins simultaneously. The PVDF 
membrane had to be activated by soaking it 1 min in 100% methanol. In addition, 
blotting papers (WhatmanTM 3MM Chromatography Paper, GE Healthcare Life 
Sciences) were necessary to guarantee an equal current and to avoid drying of the pre-
wetted membranes. To prepare the experiment, the NC or PVDF membranes as well as 
the blotting papers had to be equilibrated in transfer buffer (table 2.20). Thereafter the 
so-called blotting sandwich, which describes a distinct composition of SDS gel, 
membrane and blotting papers, was assembled as follows: 
 
 
Figure 2.4 Composition of the blotting sandwich (adapted from Bio-Rad Mini Trans-Blot® Cell Instruction 
Manual).  
  
Anode
Sponge pad
2 x Whatman paper
Membrane
SDS-PAGE gel
2 x Whatman paper
Sponge pad
Cathode
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The SDS-PAGE gel was blotted over night at 100 mA, 4°C. Quality of transfer was 
checked with Ponceau S staining solution. Proteins which might be retained in the gel 
were visualized via a Coomassie staining (table 2.21). 
 
Table 2.20 Western Blot buffer composition 
Transfer buffer  Final concentration 
Boric acid 50 mM 
Methanol 10 % (v/v) 
pH 8.5, 4°C  
 
Table 2.21 Staining solutions 
Ponceau S staining solution Final concentration 
Ponceau S 0.1 % (w/v) 
Acetic acid 5 % (v/v) 
  
Coomassie staining solution Final concentration 
Coomassie Brilliant Blue G-250 0.25 % (w/v) 
Acetic acid 10 % (v/v) 
MeOH 50 % (v/v) 
H2O 40 % (v/v) 
 
After destaining of the membrane in tris buffered solution, containing 0.1% tween 20 
(TBS-T 0.1 %; table 2.22), it was blocked in 5% milk powder (MP) in TBS (1 h at room 
temperature). This blocking solution reduced unspecific binding of antibodies and thus 
background signals. 
 
Table 2.22 Composition of TBS and TBS-T 
TBS Final concentration 
Tris-HCl 50 mM 
NaCl 150 mM 
pH 7.5  
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TBS-T 0.1 % Final concentration 
TBS 99.9 % (v/v) 
Tween 0.1 % (v/v) 
pH 7.5  
 
2.7.6 Antibody incubation and protein detection 
 
Proteins transferred onto a membrane can be detected with antibodies specific to the 
target protein and linked assays, e.g. a chemiluminescence reaction assay.  
For short, the primary antibody (table 2.23) was applied to the blocked membrane and 
incubated over night at 4°C with constant agitating. Both proteins of interest  were 
incubated separately with the corresponding antibodies. For this, membrane was cut 
horizontally at the level of the 100 kDa band of the protein standard. Following the first 
incubation, membrane piece was washed in TBS-T 0.1% (3 x 5 min) and exposed to the 
secondary antibody. Unbound secondary antibody was also washed off after 1.5 hours 
of incubation at room temperature. Subsequently, protein detection was possible 
because of a chemiluminescence reaction between the horseradish peroxidase (HRP) 
coupled to the secondary antibody and the substrate luminol, included in the detection 
kit SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Scientific). 
Chemiluminescence was captured with the MultiImage®  II system (Alpha Innotech) and 
manifested in visible bands with variable densities. Each membrane was detected in 
total, thus providing results for Cav1.2 and Rad in the same image recorded. 
 
Table 2.23 Antibodies for specific protein detection 
Antibody name 
Host 
species 
Clonality Application 
ANTI-RRAD  
(Sigma Aldrich; 
SAB2502049) 
Goat Polyclonal 
1:500 in 2.5 % MP in TBS-T  
0.05 % (+ 0.1 % sodium azide) 
Anti-Calcium Channel 
(Sigma Aldrich; C1603) 
Rabbit Polyclonal 
1:200 in 1 % MP in TBS-T 0.1 %  
(+ 0.1 % sodium azide) 
Swine Anti-Rabbit         
Ig-HRP (Dako; P0399) 
Donkey Polyclonal 1:5000 in 5 % MP in TBS 
Swine Anti-Rabbit          
Ig-HRP (Dako; P0399) 
Swine Polyclonal 1:2000 in 5 % MP in TBS 
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2.7.7 Western Blot: data analysis 
 
Bradford measurements were analyzed with Gen5TM Data Analysis Software (BIOTEK 
Deutschland, Berlin, Germany). Western Blot images were interpreted by quantitative 
comparing of the band densities using ImageJ software tool (National Institutes of 
Health, New York City, NY, USA).  
 
2.8  Electrophysiology  
 
2.8.1 Patch-clamp technique  
 
The patch-clamp technique was first described by Erwin Neher and Bert Sakmann in 
1976. They detected single-channel current activity in acetylcholine-activated channels 
of frog skeletal muscle membranes via the cell-attached method (Neher et al., 1978). A 
small part of the cell membrane is electrically isolated by attaching a glass electrode 
onto its surface via gentle suction, resulting in a high resistance gigaohm seal. Upon 
receipt of a gigaohm seal, several patch-clamp configurations are possible: cell-
attached, inside-out, outside-in or whole-cell (Hamill et al., 1981). This study was 
focused on the whole-cell voltage-clamp configuration, discovered by Kenneth Cole and 
H. J. Curtis and further developed by Alan Hodgkin and Andrew Huxley (Hodgkin et al., 
1952). The whole-cell voltage-clamp configuration enables detection of ion channel 
current density among the whole cell membrane (see also chapter 2.8.4).  
A simplified scheme of the voltage-clamp method is depicted in figure 2.5. With 
obtainment of a stable gigaohm seal, the cell-attached configuration is achieved.  Once 
the small part of the attached membrane is ruptured by further suction, the pipette 
contents equilibrate with the cell’s cytoplasm and impose an artificial ionic potential 
across the membrane. In this way, the voltage across the entire cell membrane is 
patched (whole-cell mode) and the current density of all the channels expressed at the 
membrane surface can be monitored. Using the voltage-clamp mode, the membrane 
potential of the cell (the pipette voltage, Vp) can be set to a user-specific value, the so-
called command potential (Vcom or Vclamp). The current (Icell) required to maintain the 
command voltage, is recorded through a voltage drop across the feedback resistor (RF) 
of the amplifier. The resulting output voltage (Vout) is linearly proportional to the 
measured current. Hence, the measured current is proportional to the compensating 
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current. Detected currents are in a range of pA, therefore amplifiers are used for a 
better resolution.  
 
Figure 2.5 Simplified schematic of a traditional patch-clamp amplifier in voltage-clamp mode;                          
Rmem = membrane resistance, Cmem = membrane capacity, Rp = pipette resistance, Cp = pipette capacity, Icell = 
measured current, Vp = pipette voltage, Vclamp = command potential, RF = feedback resistor, Vout = output voltage 
(modified from Harrison et al., 2015).  
  
2.8.2 Patch-clamp setup 
 
As outlined in figure 2.6 (A), electrophysiologic experiments are carried out in a faraday 
cage that insulates the setup from surrounding electrical fields. To reduce artefacts, the 
inverted microscope (Nikon Eclipse Ti-U, Nikon instruments, Japan) is placed on a 
vibration-cushioned table and all instruments are isolated and grounded. Furthermore, 
the setup possesses a hydraulic micromanipulator (MHW-103, Narishige International, 
Tokyo, Japan) to move the micropipette in the desired position. The headstage 
preamplifier (CV 203BU, Axon Instruments, Sunnyvale, CA, USA) has an integrated 
capacitor-feedback that is able to measure the current as the rate of voltage increase 
across the capacitor. The main amplifier (Axopatch 200B, Axon Instruments), the 
analog-digital converter (Digidata 1440A, Axon Instruments) and the computer are 
positioned outside the faraday cage (figure 2.6 (B)). The main amplifier fortifies the 
measured signals, enables ultra low-noise recordings and includes a control unit, that 
allows diverse regulation, e.g. cell capacitance compensation. The analog-digital 
converter receives the analog signals from the amplifier and transforms them into digital 
signals, that can be captured by pClamp10.2 software (Axon Instruments) installed on 
the computer. Recording electrode and bath electrode consist of silver wires coated with 
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AgCl (AG-15W, Science Products GmbH, Hofheim, Germany). Coating was performed 
by immersing the wire into a 3 M KCl solution; the applied voltage of 1 mA permits an 
oxidation reaction: Ag + Cl- ↔ AgCl + e-. 
 
Figure 2.6 Patch-clamp setup (A): (1) inverted fluorescence microscope (2) faraday cage (3) vibration-cushioned 
table (4) hydraulic micromanipulator (5) headstage preamplifier with pipette holder (B): (6) main amplifier (7) 
AC/DA-converter (8) computer containing acquisition and analysis software. 
 
2.8.3 Patch pipettes 
  
The chemical composition of the glass used for preparation of patch pipettes is 
important to reduce the background noise level. Moreover, its ability to form pipettes 
with appropriate tip size and taper is crucial to achieve a good seal resistance between 
pipette and cell membrane (Rae and Levis, 1992). At the day of experiment pipettes 
were prepared out of borosilicate glass capillaries (1.7 mm OD; 1.133 mm ID; 0.283 mm 
wall thickness; Hilgenberg, Malsfeld, Germany) using a horizontal pipette puller (P-97, 
Sutter instruments). Fire-polishing of the micropipette tips was performed using a 
microforge (MF-83, Narishige International). Smoothing of the glass tips was necessary 
to ensure stable seal formation. In case of whole-cell recordings the pipette resistance 
should be in the range of 1.7-3.0 MΩ; the resistance is a useful indicator for the pipette 
tip size, i.e. the lower the resistance the larger the tip size and vice versa.  
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2.8.4 Whole-cell recordings: solutions and data acquisition 
 
Whole-cell patch-clamp experiments were performed to detect the calcium current 
density of enzymatically isolated cardiac myocytes. Furthermore, the whole-cell mode 
also allows the description of kinetic properties of the membrane ion channels.  
Bath and pipette solutions (table 2.24) were prepared freshly on each experimental day. 
Composition of bath solution was orientated on physiological extracellular ionic 
concentrations. Pipette solution contained cesium ions to block potassium channels, 
EGTA as a calcium chelator and ATP to prevent rapid calcium current rundown (Belles 
et al., 1988). Approx. 100 µl of cardiomyocyte cell suspension was transferred to a 
tissue culture dish (polystyrene, 35 x 10 mm) and covered with 3 ml of bath solution. 
Rod-shaped and quiescent myocytes were patched after having settled. Glass pipettes 
were filled with pipette solution in two steps (tip and back filling) and bubbles were 
completely removed via gentle tapping. Pipettes were connected to the pipette holder 
containing the recording electrode. To avoid clogging of the pipette tip, a small positive 
pressure was applied. 5 mV depolarization steps were repeatedly applied via the patch-
clamp amplifier and the pipette immersed in the bath solution (figure 2.7 (A)). The 
approach of the pipette tip to the cell membrane was controlled by the change in pipette 
resistance. The pipette resistance was described by a visible rectangle pulse; the higher 
the pulse the lower the resistance.  
To reach cell-attached configuration, the pipette was positioned over a cell and its 
pressure released shortly before contacting the cell membrane. Gigaohm seal formation 
was achieved either spontaneously or by gentle suction, indicated by a fast reduction 
and finally extinction of the rectangle pulse (figure 2.7 (B)). This cell-attached patch-
clamp configuration is essential for preventing leak currents and allows for tight voltage 
control of the cell membrane. After achieving a stable gigaohm seal, membrane 
potential was set to -80 mV and fast capacity transients, that are mainly associated with 
pipette capacitance, were compensated (figure 2.7 (C)). A further suction was required 
to rupture the membrane and merge into the whole-cell mode (figure 2.7 (D)); the 
pipette solution then was in contact with the cytoplasm and equilibrated. Whole-cell 
capacitance transients, reflecting the passive charging of the cell, were adjusted with 
the appropriate amplifier controls. Membrane capacitance was automatically determined 
by pClamp 10.2 software. The amplifier was set as follows:   V-Clamp mode, whole-cell 
configuration ß 1, output gain alpha 2, lowpass bessel filter 2 kHz.  
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Figure 2.7 Capacity transients observed going whole-cell: (A) a rectangular test pulse of 5 mV amplitude is 
applied to the patch-clamp input in order to monitor the capacity transients. Fast capacity transient currents in a cell-
attached configuration before (B) and after (C) compensation occur due to pipette resistance. (D) Whole-cell 
configuration is indicated by the appearance of large capacity transients at the leading and trailing edges of the pulse 
(adapted from Ogden and Stanfield, 1987). 
 
Table 2.24 Patch-clamp solutions for whole-cell measurements 
Bath solution Final concentration 
NaCl 137 mM 
CsCl 5.4 mM 
CaCl2 * 2 H2O 2 mM 
MgCl2 * 6 H2O 1 mM 
Glucose 10 mM 
HEPES 10 mM 
pH 7.4 with NaOH  
 
 
Pipette solution Final concentration 
CsCl 120 mM 
Mg-ATP 4 mM 
MgCl2 * 6 H2O 1 mM 
EGTA 10 mM 
HEPES 5 mM 
pH 7.2 with CsOH  
(A) 
 
 
 
(B) 
 
 
 
(C) 
 
 
 
(D) 
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2.8.5 Whole-cell recordings: pulse protocols 
 
I/V curve pulse protocol 
To evaluate the relation of current and voltage of Cav1.2 channels, a so-called current-
voltage curve pulse protocol (I/V protocol) was used (figure 2.8 and 2.9 (B)). The cell 
was held at -80 mV and depolarized for 45 ms to the first level of -40 mV in order to 
inactivate sodium channels. Subsequently, 150 ms test pulse voltages were applied, 
ranging from -40 mV to +50 mV with 10 mV increment. After each of these test pulses 
the cell was repolarized to the resting potential of -80 mV. Pulse intervals were 3 sec. 
Sampling rate per pulse was 5 kHz. Further amplifier parameters were set as follows: 
additional gain x 2, lowpass filter frequency 500 Hz.  
The peak current amplitudes were analyzed in order to obtain an I/V curve, to calculate 
the potential of half maximal (in-)activation V 0.5(in)act and to determine the slope factor. 
The time constant of the inactivation kinetics tau (τ) was analyzed, too.  
 
                               
Figure 2.8 I/V curve pulse protocol. The cell was held at -80 mV and depolarized for 45 ms to the first level of       
-40 mV. Subsequently, 150 ms test pulse voltages were applied, ranging from -40 mV to +50 mV with 10 mV 
increment. 
 
Figure 2.9 Exemplary original traces (A) recorded with the I/V curve pulse protocol (B). For analysis, the peak 
current amplitudes were determined. 
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A high-quality I/V relationship was prerequisite for further experiments, i.e. 
determination of recovery from inactivation and steady-state inactivation, respectively. 
These pulse protocols were run in order to determine kinetic properties, that are 
characteristic for LTCCs switching between open, closed and inactive state. 
 
Recovery from inactivation 
Recovery from inactivation was examined by a double-pulse step protocol with 15 
sweeps, as outlined in figure 2.10 and 2.11 (B). With a prepulse the holding potential of    
-45 mV was set to 0 mV for 100 ms to induce calcium currents close to maximum 
amplitude (current I1, figure 2.11 (A)). After this prepulse membrane potential was set 
back to -45 mV for varying time intervals ranging from 25 ms to 375 ms (with 25 ms 
increment per sweep). Subsequently, a second test pulse of 50 ms to 0 mV was applied 
(current I2, figure 2.11 (A)). Thereafter, cells were held at -45 mV until the sweep ends 
(sweep duration: 1024 ms). During the increasing time intervals channels recovered 
partially in a time-dependent manner, i.e. I2 and the ratio of I2 and I1 were enhanced 
with prolonging interval duration. Three sec time intervals between sweeps at -45 mV 
allowed complete recovery of all channels and thus (close to) maximum current 
response again. Sampling rate per sweep was 2 kHz. Further amplifier parameters were 
set as follows: additional gain x 2, lowpass filter frequency 500 Hz. The relative current 
after 375 ms of recovery, the time constant tau (τ) and the half-time were determined. 
 
    
Figure 2.10 Pulse protocol for recovery from inactivation. With a prepulse the holding potential of -45 mV was 
set to 0 mV for 100 ms. After this prepulse the membrane potential was set back to -45 mV for varying time 
intervals with 25 ms increment per sweep: sweep 1 starts with 25 ms time interval duration (A) and the last sweep 
ends with 375 ms time interval duration (B). Subsequently, a second test pulse of 50 ms to 0 mV was applied. 
Thereafter, cells were held at -45 mV until the sweep ends.  
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Figure 2.11 Exemplary original traces (A) recorded with the recovery from inactivation protocol (B). For analysis, 
the peak current amplitudes I1 and I2 were determined. 
 
Steady-state inactivation 
Steady-state inactivation kinetics of the cell was determined using a step protocol 
consisting of 13 sweeps, as demonstrated in figure 2.12 and 2.13 (B). Corresponding to 
the I/V-protocol, the membrane potential was initially set to -80 mV (for 5 ms) and then 
depolarized to -40 mV (for 25 ms) for sodium current inactivation. Thereafter, maximum 
current density (I1, figure 2.13 (A)) of the calcium channels was induced via a 200 ms 
prepulse to 0 mV. Steady-state inactivation was induced by conditional test pulses 
ranging from -60 mV to +60 mV for 2000 ms (in 10 mV steps per sweep). Immediately 
after this the -80 mV / -40 mV / 0 mV protocol was repeated to quantify the still inducible 
currents (I2, figure 2.13 (A)). Sweep interval was 10 sec at -80 mV. Sampling rate per 
sweep was 2 kHz. Further amplifier parameters were set as follows: additional gain x 2, 
lowpass filter frequency 500 Hz. The voltage of half maximum inactivation V 0.5inact and 
the slope factor were calculated. 
 
 
Figure 2.12 Steady-state inactivation pulse protocol. Membrane potential was initially set to -80 mV and then 
depolarized to -40 mV for 25 ms. Thereafter, a 200 ms prepulse to 0 mV followed. Steady-state inactivation was 
induced by conditional test pulses ranging from -60 mV to +60 mV. After each conditional test pulse, the -80 mV /  
-40 mV / 0 mV protocol was repeated. 
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Figure 2.13 Exemplary original traces (A) recorded with the steady-state inactivation protocol (B). For analysis, 
the peak current amplitudes I1 and I2 were determined. 
 
2.8.6 Whole-cell recordings: data analysis 
 
For data analysis Clampfit 10.2 software (Axon Instruments) and GraphPad Prism®6  
(GraphPad Software, La Jolla, CA, USA) were used. 
 
To determine current-voltage dependency, the peak current amplitude of each test 
pulse was measured and corrected by the leak current of the corresponding potential. 
By dividing the leak-corrected peak current amplitude by the cell capacitance and thus 
normalizing to cell size, the I/V relationship was obtained. To determine the potential of 
half maximal activation V 0.5act and the slope factor, I/V curves were fitted to a combined 
Boltzmann and Ohm relation using the following equation: 
 
IV = Gmax (V-Vrev)/(1+exp[(V 0.5act-V)/k]) 
IV: current density at voltage V 
k: slope factor 
Gmax: maximal slope conductance 
 
Vrev: reversal potential
 
V 0.5act: half maximal activation voltage 
 
The time constant of the inactivation kinetics tau (τ) was calculated by a mono-
exponential fit of the slow inactivation phase of the raw calcium current traces according 
to following equation:  
 
It = I0 + (plateau-I0)*(1-exp(-k*t)) 
It: current density at time t 
I0: “starting” current density  
t: time 
k: slope factor 
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The recovery from inactivation curve was determined by calculating the second peak 
current amplitude (I2) at 0 mV after varying test pulse time intervals and normalizing it to 
the respective first peak current amplitude (I1) measured during the prepulse. The 
relative currents after varying recovery intervals, the time constant tau (τ) and the half-
time were determined by a mono-exponential fit of the data. 
 
The steady-state inactivation curve was assessed by the peak current amplitude (I2) 
obtained at 0 mV after variable conditional test pulse potentials, normalized to the peak 
current amplitude (I1) measured at the beginning of each sweep. The voltage of half 
maximum inactivation V 0.5inact and the slope factor of steady-state inactivation were 
determined by fitting a Boltzmann function (k-sigmoidal) to the data: 
 
Iv=Imax/(1+exp[(V0.5inact-V)/-k]) 
IV: current density at voltage V 
V 0.5inact: half maximal inactivation voltage 
k: slope factor 
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3 Results 
 
The investigated mouse lines (ob/ob, Rad-k.o., ob/ob x Rad-k.o. and IRS 2-k.o. mice) 
were compared to age-matched wt animals (C57BL/6J). For each comparison the same 
wt cohort was used (at 16 and 28 weeks, respectively). 
All data are given as geometrical mean ± standard error of the mean (SEM). If not 
mentioned otherwise Student’s t-test was used for statistical analysis. P-values < 0.05 
were defined to indicate statistically significant differences. 
An overview of all results in more detail is given in the appendix (tables 8.1–8.10). 
Additional information about results of method validation can be found in the appendix, 
too. 
 
3.1  Offspring statistics 
 
Over a period of 3.5 years our own breedings were observed with respect to mean litter 
size and distribution of sexes and genotypes. In all breedings distribution of sexes was 
similar, as outlined in figure 3.1. 
 
                     
Figure 3.1 Distribution of sexes: sexes were similarly distributed in most breedings (hz = heterozygous,               
k.o. = knockout). 
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Averages of offspring per litter of the different breeding schemes did not differ as well (in 
one-way ANOVA; Bonferroni’s Post Test; figure 3.2). 
 
                        
Figure 3.2 Mean litter sizes: averages of offspring per litter of the different breeding schemes did not differ           
(n = 6–55 litter; in one-way ANOVA; Bonferroni’s Post Test). 
 
Mendelian inheritance stands for heredity transmission of genes from one generation to 
the next following the laws proposed by Gregor Johann Mendel. According to Mendel 
genotypes of descendants are expected to split in distinct ratios. For example, 
genotypes of descendants should be distributed 1:1 in breedings consisting of a 
heterozygous (hz) and a k.o. mouse. The predicted Mendelian ratio in breedings with 
only hz animals is 1:2:1, with hz offspring dominating. As demonstrated in table 3.1, all 
genotypes were distributed as expectable according to these ratios. 
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Table 3.1 Genotype distributions: all genotypes were distributed as expectable according to the Mendelian Law. 
Breeding scheme  
Number of  
genotyped mice 
 Genotype distribution  
 wt : hz : k.o. 
IRS 2-hz x IRS 2-k.o.    64         1.0 : 0.6 
IRS 2-hz x IRS 2-hz   32 1.0 : 2.1 : 0.9 
Ob/+ x ob/+ 210 1.0 : 2.2 : 1.3 
Rad-hz x Rad-k.o.   51         1.0 : 0.5 
Rad-hz x Rad-hz 125 1.0 : 1.4 : 0.8 
Ob/+ x Rad-k.o. 129 1.0 : 1.6 : 1.0 
 
3.2  Phenotype characterization 
 
Regarding the behavior of IRS 2-k.o. and Rad-k.o. mice there was no obvious 
difference compared to C57BL/6J control animals. Ob/ob and ob/ob x Rad-k.o. mice 
showed a different feeding behavior. These animals appeared to be mainly focused on 
food uptake and thus gained an intense weight with progressing age (figure 3.3; chapter 
3.3.1 and 3.5.1). Moreover, increased urination was noticeable.  
 
 
Figure 3.3 Phenotype of ob/ob mice: ob/ob mice gained remarkably weight because of feeding behavior. 
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3.3  Ob/ob mice  
 
3.3.1 Blood glucose, body weight, ventricle weight and ventricle-to-body 
weight ratio 
 
As illustrated in figure 3.4 (A), 16 week old ob/ob mice’ (non-fasting) blood glucose 
values were significantly elevated compared to age-matched wt animals (ob/ob:        
270 ± 29 mg/dl, N = 20 vs. wt: 158 ± 5 mg/dl, N = 58). At 28 weeks of age blood glucose 
of ob/ob mice dropped significantly compared to younger mice of the same genotype, 
but still exceeded that of age-matched wt (ob/ob: 203 ± 18 mg/dl, N = 33 vs. wt: 168 ± 6 
mg/dl, N = 41; p = 0.05). Already at an age of 16 weeks body weight of ob/ob mice was 
nearly twice than that of age-matched wt littermates (ob/ob: 46.6 ± 2.0 g, N = 20 vs. wt: 
24.4 ± 0.5 g, N = 62). At an age of 28 weeks body weight was even more than doubled 
compared to wt (ob/ob: 60.3 ± 1.5 g, N = 33 vs. wt: 27.6 ± 0.6 g, N = 42; figure 3.4 (B)). 
Ventricle weights of ob/ob and age-matched wt mice were not significantly different at 
both ages (figure 3.4 (C)). Ventricle-to-body weight ratios were determined in order to 
detect a putative cardiac hypertrophy (figure 3.4 (D)). As expected, ob/ob mice showed 
significantly decreased ratios (2.8 ± 0.2 mg/g at 16 and 28 weeks, N = 13 and 16) in 
comparison to wt animals (5.4 ± 0.2 mg/g, N = 36 at 16 weeks and 5.2 ± 0.2 mg/g,        
N = 21 at 28 weeks), but there was no difference between young and old ob/ob mice. 
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Figure 3.4 Blood glucose, body weight, ventricle weight and ventricle-to-body weight ratio of ob/ob mice: 
young ob/ob mice had significantly higher blood glucose values compared to wt (A). Body weights of ob/ob mice 
were (nearly) twice than that of wt (B). Ventricle weights of ob/ob and wt mice were similar (C). As expected, ob/ob 
mice showed significantly decreased ventricle-to-body weight ratios in comparison to wt animals (D) (N = 20-62 for 
(A, B); N = 13-36 for (C, D); * = p < 0.05 vs. age-matched wt). 
 
3.3.2 Functional properties of cardiac whole-cell LTCC currents 
 
To investigate the functional properties of the isolated cardiomyocytes patch-clamp 
experiments were performed with rod-shaped and mainly quiescent cells. Patched cells 
isolated from ob/ob and wt mice had similar mean cell capacitances at both ages 
investigated (appendix, chapter 8.3.1). Therefore, experiments were comparable and 
there was no hint towards cellular hypertrophy. Only recordings of stable-patched cells 
were analyzed. Measurements reflecting strong leak currents were discarded. The I/V 
relationship always was the first protocol of a cell measured according to the pulse 
protocol in figure 2.8. Representative I/V recordings for ob/ob and wt mice are depicted 
in figure 3.5.   
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Figure 3.5 Example of representative and good quality I/V recordings for wt (A, B) and ob/ob (C, D) mice at 
16 and 28 weeks of age, respectively. 
 
As demonstrated in figure 3.6, at all applied test potentials the maximum whole-cell 
Ca2+ current densities were similar in ob/ob and age-matched wt mice at both ages 
(ob/ob: -10.75 ± 0.65 pA/pF, n = 10 vs. wt: -10.92 ± 0.90 pA/pF, n =17 at 16 weeks of 
age and ob/ob: -8.44 ± 0.43 pA/pF, n = 11 vs. wt: -8.91 ± 0.54 pA/pF, n = 13 at 28 
weeks of age). The potential of half maximal activation (V0.5act) was slightly altered in 
both age groups. In 16 week old ob/ob mice V0.5act was significantly shifted to the left    
(ob/ob: -11.72 ± 0.60 mV vs. wt: 8.69 ± 1.06 mV), while in older mice V0.5act was 
significantly shifted to the right (ob/ob: -4.86 ± 0.67 mV vs. wt: -7.51 ± 0.96 mV). 
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Figure 3.6 Current density-voltage relationships of ob/ob mice: the I/V curves revealed that the maximum whole-
cell Ca
2+
 current densities were similar in ob/ob and wt mice. In young ob/ob mice V0.5act was significantly shifted to 
the left (A), while in older animals V0.5act was significantly shifted to the right (B) (n = number of patched cells; 
number of mice: N = 5-10 for wt, N = 4-5 for ob/ob). 
 
Ventricular whole-cell LTCCs of 16 week old ob/ob mice showed a significantly faster 
time-dependent inactivation at -10 mV as well as a significantly slower inactivation at  
10 mV (figure 3.7 (A)). At 28 weeks of age time-dependent inactivation was significantly 
slowed at -10 mV and significantly faster in the range of 10 to 40 mV (figure 3.7 (B)). 
 
        
Figure 3.7 Time-dependent inactivation properties of ob/ob mice: the time constant of the inactivation kinetics 
tau was slightly changed in ventricular whole-cell LTCCs of 16 week old ob/ob mice (A). Whole-cell LTCCs 
inactivated significantly faster in the range of 10 mV to 40 mV in cells of 28 week old ob/ob mice (B) (n = number 
of patched cells; number of mice: N = 5-10 for wt, N = 4-5 for ob/ob; * = p < 0.05 vs. age-matched wt). 
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Voltage-dependent inactivation/steady-state inactivation properties of ventricular whole-
cell LTCCs of ob/ob and wt mice were comparable at both ages investigated (figure 
3.8). 
 
        
Figure 3.8 Steady-state inactivation properties of ob/ob mice: steady-state inactivation properties of ventricular 
whole-cell LTCCs of ob/ob and wt mice were comparable at both age groups (n = number of patched cells; number 
of mice: N = 4 for wt, N = 2-3 for ob/ob). 
 
At both age groups recovery from inactivation was similar in ob/ob and wt mice. The 
relative current after 375 ms of recovery reached mean values in the range of 0.76-0.84 
(figure 3.9). 
 
        
Figure 3.9 Recovery from inactivation properties of ob/ob mice: recovery from inactivation revealed no 
significant differences between ob/ob and wt mice at both age groups (n = number of patched cells; number of mice: 
N =  5-8 for wt, N =  4-5 for ob/ob). 
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3.3.3 Cardiac mRNA expression levels  
 
Compared to age-matched wt mice RGK mRNA expression was not significantly altered 
in ventricles of ob/ob mice, though there was a numerical increase of Rad mRNA 
expression (1.55 ± 0.27, p = 0.19 at 16 weeks of age and 1.50 ± 0.23, p = 0.09 at         
28 weeks of age in 2–ΔΔCt  analysis; N = 5-6; figure 3.10). 
 
        
 
Figure 3.10 Ventricular expression of RGK mRNA in ob/ob mice: RGK mRNA was not significantly altered in 
ventricles of ob/ob and wt mice at both ages (N = 5-6 mice per group). 
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As outlined in figure 3.11, ventricular expression of Cav1.2 mRNA was significantly 
reduced in ventricles of 28 week old ob/ob mice (0.76 ± 0.65-0.93 in REST-2009© 
analysis; N = 5-6). 
 
 
Figure 3.11 Ventricular expression of Cav1.2 mRNA in ob/ob mice: in 28 week old ob/ob mice ventricular 
expression of Cav1.2 mRNA was significantly reduced (N = 5-6 animals per group; * =  p < 0.05 vs. age-matched wt 
in REST-2009© analysis). 
 
Since Cavß-subunits (Cavß1, Cavß2, Cavß3) are involved in LTCC expression and 
function their expression levels were investigated, too. qRT-PCR analysis revealed a 
significant downregulation of Cavß1- and Cavß2- but not Cavß3-subunit mRNA in 
ventricles of 16 week old ob/ob mice (Cavß1 = 0.57 ± 0.30-0.82, Cavß2 = 0.47 ± 0.32-
0.74 in REST-2009© analysis; N = 5-6). At 28 weeks of age all Cavß-subunits were 
significantly downregulated compared to age-matched wt (Cavß1 = 0.54 ± 0.35-0.90, 
Cavß2 = 0.68 ± 0.52-0.86, Cavß3 = 0.63 ± 0.38-0.90 in REST-2009© analysis; N = 5-6; 
figure 3.12). 
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Figure 3.12 Ventricular expression of the Cavß-subunits mRNA in ob/ob mice: qRT-PCR analysis detected a 
significant downregulation of Cavß1- and Cavß2- but not Cavß3-subunits in ventricles of 16 week old ob/ob mice. At 
28 weeks of age all Cavß-subunits were significantly downregulated compared to age-matched wt (N = 5-6 animals 
per group; * =  p < 0.05 vs. age-matched wt in REST-2009© analysis).   
 
3.4  Rad-k.o. mice 
 
3.4.1 Blood glucose value, body weight, ventricle weight and ventricle-to-
body weight ratio 
 
Rad-k.o. mice’ (non-fasting) blood glucose was significantly lower compared to wt 
animals (Rad-k.o.: 140 ± 4 mg/dl at 16 weeks, N = 27 and 151 ± 5 mg/dl, N = 49 at 28 
weeks vs. wt: 158 ± 5 mg/dl, N = 58 at 16 weeks and 168 ± 6 mg/dl, N = 41 at 28 
weeks; figure 3.13 (A)). Young Rad-k.o. mice weighed significantly more than age-
matched wt animals (Rad-k.o.: 26.9 ± 0.7 g, N = 27 vs. wt: 24.4 ± 0.5 g, N = 62; figure 
3.13 (B)). As demonstrated in figure 3.13 (C), 28 week old Rad-k.o. mice had 
significantly lower ventricle weights compared to age-matched wt littermates (Rad-k.o.: 
120.9 ± 8.3 mg, N = 21 vs. wt: 142.7 ± 6.4 mg, N = 21). Rad-k.o. mice’ ventricle-to-body 
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weight ratios thus were significantly decreased compared to wt animals at both ages 
(Rad-k.o.: 4.6 ± 0.1 mg/g at 16 and 28 weeks, N = 21 each vs. wt: 5.4 ± 0.2 mg/g,         
N = 36 at 16 weeks and 5.2 ± 0.2 mg/g, N = 21 at 28 weeks, figure 3.13 (D)).  
        
        
Figure 3.13 Blood glucose, body weight, ventricle weight and ventricle-to-body weight ratio of Rad-k.o. mice: 
Rad-k.o. mice had significantly lower blood glucose values compared to wt (A). Young Rad-k.o. mice weighed 
significantly more than age-matched wt (B). Ventricle weights of older Rad-k.o. mice were significantly lower in 
comparison to wt (C). Ventricle-to-body weight ratios were significantly decreased in Rad-k.o. mice at both ages 
investigated (D) (N = 27-62 for (A, B); N = 21-36 for (C, D); * = p < 0.05 vs. age-matched wt in REST-2009© 
analysis). 
 
3.4.2 Functional properties of cardiac whole-cell LTCC currents 
 
At both ages investigated mean cell capacitances of cardiomyocytes from Rad-k.o. and 
wt mice were similar (appendix, chapter 8.3.1). Therefore, experiments appeared to be 
comparable and cellular hypertrophy was excluded. Only recordings of stable-patched 
cells were analyzed. Representative I/V recordings for Rad-k.o. mice are illustrated in 
figure 3.14.  
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Figure 3.14 Example of representative and good quality I/V recordings for Rad-k.o. mice at 16 (A) and 28 (B) 
weeks of age.  
 
As depicted in figure 3.15, the knockout of Rad protein caused the expected increase in 
whole-cell Ca2+ current density compared to wt mice (Rad-k.o.: -20.12 ± 1.49 pA/pF,     
n = 5 vs. wt: -10.92 ± 0.90 pA/pF, n = 17 at 16 weeks of age and Rad-k.o.:                        
-21.58 ± 5.05 pA/pF, n = 2 vs. wt: -8.91 ± 0.54 pA/pF, n = 13 at 28 weeks of age). At 
both ages V0.5act was significantly shifted to the left and the slope factor was significantly 
decreased (V0.5act at 16 weeks: -14.74 ± 1.33 mV for Rad-k.o. mice vs. -8.69 ± 1.06 mV 
for wt mice; V0.5act at 28 weeks: -16.13 ± 0.08 mV for Rad-k.o. mice vs. -7.51 ± 0.96 mV 
for wt mice; slope factor at 16 weeks: 3.97 ± 0.22 for Rad-k.o. mice vs. 5.05 ± 1.02 for 
wt mice; slope factor at 28 weeks: 3.37 ± 0.53 for Rad-k.o. mice vs. 5.01 ± 0.5 for wt 
mice). 
 
          
Figure 3.15 Current density-voltage relationships of Rad-k.o. mice: the knockout of Rad protein caused the 
expected increase in whole-cell Ca
2+
 current density at both ages (n = number of patched cells; number of mice:      
N = 5-10 for wt, N = 2-3 for Rad-k.o., * = p < 0.05 vs. age-matched wt). 
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Whole-cell LTCCs of 16 week old Rad-k.o. mice showed a significantly faster          
time-dependent inactivation at -10 mV, but significantly slower kinetics at 40 mV (figure 
3.16 (A)). Time-dependent inactivation was significantly faster at 0 mV in cells of 28 
week old Rad-k.o. mice (figure 3.16 (B)). 
        
Figure 3.16 Time-dependent inactivation properties of Rad-k.o. mice: whole-cell LTCCs of 16 week old Rad-
k.o. mice showed a significantly slowed time-dependent inactivation at -10 mV and significantly faster kinetics at   
40 mV (A). Time-dependent inactivation was significantly faster at 0 mV in cells of 28 week old Rad-k.o. mice (B) 
(n = number of patched cells; number of mice: N = 5-10 for wt, N = 2-3 for Rad-k.o.; * = p < 0.05 vs. age-matched 
wt). 
 
Voltage-dependent inactivation (slope factor) of whole-cell LTCCs differed significantly 
in 28 week old Rad-k.o. mice compared to age-matched wt animals (Rad-k.o.:              
3.76 ± 0.28, n = 3 vs. wt: 4.70 ± 0.20, n = 9; figure 3.17 (B)).  
          
Figure 3.17 Steady-state inactivation properties of Rad-k.o. mice: 16 week old Rad-k.o. mice showed no 
significant change in steady-state inactivation compared to wt (A). In older mice voltage-dependent inactivation 
differed significantly compared to age-matched wt (B) (n = number of patched cells; number of mice: N = 4 for wt, 
N = 3 for Rad-k.o.; * = p < 0.05 vs. age-matched wt). 
 Results 
- 75 - 
As illustrated in figure 3.18 (A), recovery from inactivation was altered in Rad-k.o. mice 
at 16 weeks of age. Tau as well as the half-time values were significantly augmented 
compared to age-matched wt (tau: 206.20 ± 27.75 and half-time: 142.89 ± 19.24 for 
Rad-k.o. mice vs. tau: 150.28 ± 8.87 and half-time: 104.17 ± 6.15 for wt mice). The 
relative current after 375 ms of recovery (I2/I1) was significantly decreased (Rad-k.o.: 
0.70 ± 0.06 vs. wt: 0.81 ± 0.02). At 28 weeks of age recovery from inactivation was not 
significantly altered (figure 3.18 (B)). 
 
          
Figure 3.18 Recovery from inactivation properties of Rad-k.o. mice: the recovery from inactivation was 
significantly altered in young Rad-k.o. mice (A). At 28 weeks of age recovery from inactivation was not significantly 
altered (B). (n = number of patched cells; number of mice: N = 5-8 for wt, N = 2-3 for Rad-k.o.; * = p < 0.05 vs. age-
matched wt). 
 
3.4.3 Cardiac mRNA expression levels 
 
As expected Rad mRNA was not detectable in ventricles of Rad-k.o. mice (see also 
appendix). Gem was upregulated about twofold at both ages (1.92 ± 1.29-2.82 at            
16 weeks of age and 2.13 ± 1.74-2.67 at 28 weeks of age in REST-2009©  analysis;         
N = 6; figure 3.19 (A)). Analysis of Rem 1 detected an increased expression in 
ventricles of 28 week old Rad-k.o. mice (1.28 ± 1.05-1.67 in REST-2009© analysis;      
N = 6; figure 3.19 (B)). 
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Figure 3.19 Ventricular expression of RGK mRNA in Rad-k.o. mice: in Rad-k.o. mice Gem was upregulated 
about twofold at both ages (A). Analysis of Rem 1 detected an increased expression in ventricles of 28 week old 
Rad-k.o. mice (B) (N = 6 animals per group; * =  p < 0.05 vs. age matched wt in REST-2009© analysis).   
 
Cav1.2 mRNA expression was significantly reduced by nearly 50% in hearts of Rad-k.o. 
mice at the age of 28 weeks (0.50 ± 0.35-0.68, p < 0.05 in REST-2009©; N = 6; figure 
3.20). 
 
 
Figure 3.20 Ventricular expression of Cav1.2 mRNA in Rad-k.o. mice: Cav1.2 mRNA was significantly reduced 
by nearly 50% in hearts of Rad-k.o. mice at the age of 28 weeks (N = 6 animals per group; * =  p < 0.05 vs. age 
matched in REST-2009© analysis). 
 
At both ages Cavß2-subunit mRNA was significantly reduced in Rad-k.o. mice ventricles 
compared to wt animals (0.69 ± 0.49-1.03 at 16 weeks of age and 0.40 ± 0.29-0.56 at 
28 weeks of age in REST-2009© analysis; N = 6; figure 3.21 (B)). The expression of the 
other Cavß-subunits was not significantly altered (figure 3.21 (A,C)). 
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Figure 3.21 Ventricular expression of the Cavß-subunits mRNA in Rad-k.o. mice: at both ages the Cavß2-
subunit mRNA was significantly reduced in Rad-k.o. mice ventricles compared to wt animals (B). The expression of 
the other Cavß-subunits was not significantly altered (A, C). (N = 6 animals per group; * =  p < 0.05 vs. age matched 
in REST-2009© analysis).   
 
3.5  Ob/ob x Rad-k.o. mice  
3.5.1 Blood glucose value, body weight, ventricle weight and ventricle-to-
body weight ratio 
 
As demonstrated in figure 3.22 (A), ob/ob x Rad-k.o. mice had significantly increased 
(non-fasting) blood glucose levels compared to wt animals at both ages investigated 
(ob/ob x Rad-k.o.: 291 ± 26 mg/dl, N = 25 at 16 weeks and 276 ± 43 mg/dl, N = 9 at 28 
weeks vs. wt: 158 ± 5 mg/dl, N = 58 at 16 weeks and 168 ± 6 mg/dl, N = 41 at 28 
weeks). In both age groups ob/ob x Rad-k.o. mice‘ body weight was at least doubled 
compared to wt mice (ob/ob x Rad-k.o.: 51.1 ± 0.9 g, N = 25 at 16 weeks and                 
59.7 ± 1.6 g, N = 9 at 28 weeks vs. wt: 24.4 ± 0.5 g, N = 62 at 16 weeks and              
27.6 ± 0.6 g, N = 42 at 28 weeks, figure 3.22 (B)). Young ob/ob x Rad-k.o. mice 
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weighed significantly less than older mice of the same genotype. Ventricle weights of 28 
week old ob/ob x Rad-k.o. mice (170.8 ± 7.9 mg, N = 8) were significantly increased 
compared to age-matched wt (142.7 ± 6.4 mg, N = 21) and to younger animals of the 
same genotype (136.8 ± 4.7 mg, N = 16), as depicted in figure 3.22 (C). Similar to ob/ob 
mice, ob/ob x Rad-k.o. mice had significantly decreased ventricle-to-body weight ratios 
compared to wt, but were similar in this regard when comparing young and old         
ob/ob x Rad-k.o. mice (figure 3.22 (D)). The decreased ratios were attributable to the 
increased body weight. 
 
          
          
Figure 3.22 Blood glucose, body weight, ventricle weight and ventricle-to-body weight ratio of ob/ob x Rad-
k.o. mice: ob/ob x Rad-k.o. mice had significantly higher blood glucose values compared to wt (A). Body weights 
of ob/ob x Rad-k.o. mice were (nearly) twice than that of wt (B). Ventricle weights of old ob/ob x Rad-k.o. were 
significantly elevated compared to wt (C). Ventricle-to-body weight ratios were significantly decreased in          
ob/ob x Rad-k.o. mice. This was most likely due to the increased body weight (D) (N = 9-62 for (A, B); N = 8-36 
for (C, D); * = p < 0.05 vs. age-matched wt). 
 
 Results 
- 79 - 
3.5.2 Functional properties of cardiac whole-cell LTCC currents in young 
mice 
 
Cardiomyocytes isolated from 16 week old ob/ob x Rad-k.o. and wt mice had similar 
mean cell capacitances at both ages investigated (appendix, chapter 8.3.1). Therefore, 
experiments were comparable and cellular hypertrophy was excluded. Only recordings 
of stable-patched cells were analyzed. An I/V recording representative for ob/ob x Rad-
k.o. mice can be seen in figure 3.23.  
 
Figure 3.23 Example of a representative and good quality I/V recording for ob/ob x Rad-k.o. mice at 16 weeks 
of age. 
 
Compared to age-matched wt animals ob/ob mice lacking Rad showed a significant 
increase in whole-cell Ca2+ current density (ob/ob x Rad-k.o.: -21.48 ± 1.10 pA/pF, n = 5 
vs. wt: -10.92 ± 0.90 pA/pF, n =17; figure 3.24). This increase was similar to age-
matched Rad-k.o. mice with a wt background (Rad-k.o.: -20.12 ± 1.49 pA/pF, n = 5). In 
young ob/ob x Rad-k.o. mice V0.5act was significantly shifted to the left and the slope 
factor was significantly decreased compared to age-matched wt (V0.5act:                           
-17.06 ± 1.71 mV for ob/ob x Rad-k.o. mice vs. -8.69 ± 1.06 mV for wt mice; slope 
factor: 3.65 ± 0.30 for ob/ob x Rad-k.o. mice vs. 5.05 ± 1.02 for wt mice). 
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Figure 3.24 Current density-voltage relationship of ob/ob x Rad-k.o. mice: ob/ob x Rad-k-o. mice showed the 
expected significant increase in whole-cell Ca
2+ 
current density (n = number of patched cells; number of mice:        
N = 5-10 for wt, N = 3 for ob/ob x Rad-k.o.; * = p < 0.05 vs. age-matched wt). 
 
Time-dependent inactivation was similar in ventricular myocytes of ob/ob x Rad-k.o. and 
wt mice (figure 3.25). 
 
 
Figure 3.25 Time-dependent inactivation properties of ob/ob x Rad-k.o. mice: time-dependent inactivation was 
comparable in ventricular myocytes of ob/ob x Rad-k.o. and wt mice (n = number of patched cells; number of mice: 
N = 5-10 for wt, N = 3 for ob/ob x Rad-k.o.). 
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Voltage-dependent inactivation of 16 week old ob/ob x Rad-k.o. mice was similar to 
age-matched wt animals (figure 3.26). 
 
Figure 3.26 Steady-state inactivation properties of ob/ob x Rad-k.o. mice: voltage-dependent inactivation was 
comparable in ob/ob x Rad-k.o. and wt mice (n = number of patched cells; number of mice: N = 4 for wt, N = 3 for 
ob/ob x Rad-k.o.). 
 
Recovery from inactivation was altered in 16 week old ob/ob x Rad-k.o. mice. Tau as 
well as the half-time value were significantly augmented compared to age-matched wt 
(tau: 224.45 ± 13.70 and half-time: 155.58 ± 9.84 for ob/ob x Rad-k.o. mice vs. tau: 
150.28 ± 8.87 and half-time: 104.17 ± 6.15 for wt mice). The relative current after      
375 ms of recovery (I2/I1) was significantly decreased (ob/ob x Rad-k.o.: 0.70 ± 0.03 vs. 
wt: 0.81 ± 0.02; figure 3.27). 
 
 
Figure 3.27 Recovery from inactivation properties of ob/ob x Rad-k.o. mice: the recovery from inactivation was 
significantly altered in young ob/ob x Rad-k.o. mice. (n = number of patched cells; number of mice: N = 5-8 for wt, 
N = 2 for ob/ob x Rad-k.o.). 
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3.6  IRS 2-k.o. mice  
 
3.6.1 Blood glucose value, body weight, ventricle weight and ventricle-to-
body weight ratio 
 
As illustrated in figure 3.28 (A), IRS 2-k.o. mice showed significantly higher (non-fasting) 
blood glucose values compared to wt animals at both ages investigated (IRS 2-k.o.:   
207 ± 10 mg/dl, n = 62 at 16 weeks and 239 ± 22 mg/dl at 28 weeks, N = 30 vs. wt:    
158 ± 5 mg/dl, N = 58 at 16 weeks and 168 ± 6 mg/dl, N = 41 at 28 weeks). Body 
weight, ventricle weight as well as ventricle-to-body weight ratio of IRS 2-k.o. and wt 
mice were similar (figure 3.28 (B-D)).  
 
        
                 
Figure 3.28 Blood glucose, body weight, ventricle weight and ventricle-to-body weight ratio of IRS 2-k.o. mice: 
IRS 2-k.o. mice had significantly higher blood glucose values compared to wt animals (A). Body weights, ventricle 
weights and ventricle-to-body weight ratios were similar in IRS 2-k.o. and wt mice (B-D) (N = 30-62 for (A, B);     
N = 21-36 for (C, D); * = p < 0.05 vs. age-matched wt). 
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3.6.2 Functional properties of cardiac whole-cell LTCC currents 
 
Cardiomyocytes isolated from IRS 2-k.o. and wt mice had similar mean cell 
capacitances at both ages investigated (appendix, chapter 8.3.1). Therefore, 
experiments were comparable and there was no hint towards cellular hypertrophy. Only 
recordings of stable-patched cells were analyzed. Representative I/V recordings for IRS 
2-k.o. mice are demonstrated in figure 3.29. 
 
        
Figure 3.29 Example of representative and good quality I/V recordings for IRS 2-k.o. mice at 16 (A) and 28 (B) 
weeks of age. 
 
The analysis of current density-voltage relationship revealed that the maximum whole-
cell Ca2+ current density was significantly reduced in IRS 2-k.o. mice at the age of 16 
weeks compared to age-matched wt animals (IRS 2-k.o.: -7.79 ± 0.79 pA/pF, n = 11 vs. 
wt: -10.92 ± 0.90 pA/pF, n =17; figure 3.30 (A)). Compared to younger IRS 2-k.o. mice 
whole-cell Ca2+ current density was increased at an age of 28 weeks and no longer 
significantly different to age-matched control (IRS 2-k.o.: -11.22 ± 1.27 pA/pF, n = 11 vs. 
wt: -8.91 ± 0.54 pA/pF, n = 13; figure 3.30 (B)). Moreover, V0.5act was significantly shifted 
to the left in recordings of 28 week old mice (IRS 2-k.o.: -10.88 ± 0.89 mV vs. wt:           
-7.51 ± 0.96 mV). 
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Figure 3.30 Current density-voltage relationships of IRS 2-k.o. mice: maximum whole-cell Ca
2+ 
current density 
of 16 week old IRS 2-k.o. mice was significantly decreased compared to wt (A). At 28 weeks of age Ca
2+
 current 
density was no longer different to wt and V0.5act was significantly shifted to the left (B) (n = number of patched cells; 
number of mice: N = 5-10 for wt, N = 4-7 for IRS 2-k.o.; * = p < 0.05 vs. age-matched wt). 
 
As illustrated in figure 3.31 (A), time-dependent inactivation was similar in 16 week old 
IRS 2-k.o. and wt mice. At 28 weeks of age IRS 2-k.o. mice revealed significantly faster 
inactivation kinetics in the range of 10 mV to 40 mV (figure 3.31 (B)).  
 
        
Figure 3.31 Time-dependent inactivation properties of IRS 2-k.o. mice: at 16 weeks of age no significant 
changes could be detected between IRS 2-k.o. and wt mice (A). At 28 weeks of age whole-cell LTCCs of IRS 2-k.o. 
mice revealed significantly faster inactivation kinetics in the range of 10 mV to 40 mV (B) (n = number of patched 
cells; number of mice: N = 5-10 for wt, N = 4-7 for IRS 2-k.o.; * = p < 0.05 vs. age-matched wt). 
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Voltage-dependent inactivation was comparable in 16 week old IRS 2-k.o. and wt mice 
(figure 3.32 (A)). In 28 week old IRS 2-k.o. mice V0.5inact was significantly shifted to more 
negative potentials (IRS 2-k.o.: -29.23 ± 1.06 mV, n = 4 vs. wt: -25.31 ± 0.84 mV, n = 9; 
figure 3.32 (B)). 
        
Figure 3.32 Steady-state inactivation properties of IRS 2-k.o. mice: at 16 weeks of age no significant changes 
could be detected between IRS 2-k.o. and wt mice (A). V0.5inact of 28 week old IRS 2-k.o. animals was significantly 
shifted to more negative potentials (B) (n = number of patched cells; number of mice: N = 4 for wt, N = 3 for IRS 2-
k.o.). 
 
At both ages, investigated recovery from inactivation revealed no significant differences 
between IRS 2-k.o. and wt mice. The relative current after 375 ms of recovery reached 
mean values in the range of 0.75-0.87 (figure 3.33).  
        
Figure 3.33 Recovery from inactivation properties of IRS 2-k.o. mice: recovery from inactivation revealed no 
significant differences between IRS 2-k.o. and wt mice at both ages (n = number of patched cells; number of mice: 
N =  5-8 for wt, N =  5-6 for IRS 2-k.o.). 
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3.6.3 Cardiac mRNA expression levels  
 
Rad mRNA was significantly upregulated about twofold in ventricles of 16 week old    
IRS 2-k.o. mice compared to age-matched wt (2.01 ± 1.24-3.37 in REST-2009© 
analysis; N = 5-6; figure 3.34 (A)), while its expression was unchanged at an age of 28 
weeks. At both ages, the mRNA expression of Gem and Rem 1 was not significantly 
altered compared to age-matched wt (figure 3.34 (B, C)). 
 
          
 
Figure 3.34 Ventricular expression of RGK mRNA in IRS 2-k.o. mice: Rad mRNA was significantly upregulated 
about twofold in ventricles of 16 week old IRS-k.o. mice (A). Gem and Rem 1 mRNA expression was not 
significantly changed compared to wt (B,C) (N = 5-6 animals per group; * =  p < 0.05 vs. age-matched wt in REST-
2009© analysis).   
 
At both ages investigated the ventricular expression of Cav1.2 mRNA was similar in  
IRS 2-k.o. and wt mice (figure 3.35). 
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Figure 3.35 Ventricular expression of Cav1.2 mRNA in IRS 2-k.o. mice: Cav1.2 mRNA expression in IRS 2-k.o. 
mice and wt was comparable (N = 5-6 animals per group). 
 
Furthermore, no significant changes in Cavß-subunits expression could be detected 
(figure 3.36). 
         
 
Figure 3.36 Ventricular expression of the Cavß-subunits mRNA in IRS 2-k.o. mice: mRNA expression of LTCC 
ß-subunits in IRS 2-k.o. mice and wt was comparable at both ages (N = 5-6 animals per group). 
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3.6.4 Cardiac protein expression levels  
 
Of note, Western Blot analysis was performed without detection of a housekeeping 
protein due to technical reasons. As a kind of normalization thus, the ratio of intensities 
of Cav1.2 and Rad bands detected in one and the same lane was calculated. Note that 
levels of relative expression in ventricles of IRS 2-k.o. mice always refer to wt probes 
used in the same blot. 
In ventricles of 16 week old IRS 2-k.o. mice the Cav1.2/Rad protein ratio was similar to 
age-matched wt animals (IRS 2-k.o.: 2.54 ± 0.43 vs. wt: 2.40 ± 0.48; N = 4 ventricles 
per genotype; n = 4-7 blots per ventricle). Of note, at 28 weeks of age the Cav1.2/Rad 
ratio was significantly decreased in wt mice compared to younger mice of the same 
genotype (wt: 0.96 ± 0.11 at 28 weeks vs. 2.40 ± 0.48 at 16 weeks; N = 4-5; n = 4-7). 
This putative age-related decrease of the Cav1.2/Rad ratio was not seen in 28 week old 
IRS 2-k.o. mice (IRS 2-k.o.: 2.61 ± 0.41 at 28 weeks vs. 2.54 ± 0.43 at 16 weeks;         
N = 4-5; n = 4-7; figure 3.37, (C)). While Cav1.2 protein expression was unaltered 
compared to age-matched wt mice (figure 3.37 (B)), Rad protein expression was 
significantly reduced in ventricles of 28 week old IRS 2-k.o. mice compared to age-
matched wt (IRS 2-k.o.: 59.62 ± 3.17 vs. wt: 100.00 ± 5.49; N = 5; n = 4-5; figure 3.37 
(A)), thus putatively masking the age-dependent effect on the Cav1.2/Rad ratio seen in 
wt mice. 
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Figure 3.37 Ventricular expression of Rad and Cav1.2 protein in IRS 2-k.o. mice: Rad protein expression was 
reduced in ventricles of 28 week old IRS 2-k.o. mice (A), while Cav1.2 protein expression was unaltered (B). An 
age-related decrease of the Cav1.2/Rad ratio, as it was observed in wt mice, was absent in 28 week old IRS 2-k.o. 
mice (C). (N = 4-5 ventricles per genotype; n = 4-7 blots per ventricle). 
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4 Discussion 
 
4.1  LTCC regulation by RGK proteins in the context of T2DM and/or DCM 
 
Cardiovascular disease (CVD) is a leading cause of death for diabetic patients 
(Authors/Task Force et al., 2013, Paneni, 2014, Park and Peters, 2014). Since cardiac 
L-Type Ca2+ channels (LTCCs) are known to be involved in proper excitation-
contraction coupling they are of high interest in the research of CVD. RGK proteins are 
known to regulate LTCCs (Buraei et al., 2015), but so far a diabetic context was 
neglected. This study was designed to shed some light on a putative association of an 
in vivo regulation of RGK protein expression (in particular of Rad) on ventricular LTCC 
expression and function in the context of type 2 diabetes mellitus (T2DM) and/or 
diabetic cardiomyopathy (DCM) in mice. A former study of our group revealed a 
consistent positive correlation between ventricular Rad and Cav1.2 protein expression in 
several mouse models associated with diabetes. E.g. in db/db mice a downregulation of 
both, Rad and Cav1.2 protein was found (Fabisch, 2010). An earlier study in db/db mice 
detected a reduced ventricular whole-cell Ca2+ current density with unchanged single-
channel activity (Pereira, 2006). Since reduction of whole-cell currents was obviously 
due to a significantly decrease of Cav1.2 protein expression, it is tempting to speculate 
that the Rad protein downregulation was an attempt to compensate for the decreased 
current density. 
In human failing hearts a reduced expression of Rad protein was detected, too (Chang 
et al., 2007). In contrast to data from diabetic db/db mice whole-cell Ca2+ current density 
in human heart failure (HF) was only slightly if at all decreased (Mukherjee and Spinale, 
1998). Both, a decrease of plasmalemmal expression of Cav1.2 as well as an increased 
activity of single LTCCs was described ex vivo (Schroeder et al., 1998, Hong et al., 
2012, Takahashi et al., 1992, Gruver et al., 1994) Of note, in both cases a reduced Rad 
expression would be in line with a counterregulation avoiding a reduced Ca2+ influx into 
cardiomyocytes.  
In his thesis work C. Fabisch furthermore described an unchanged Rad and Cav1.2 
protein expression in ventricles of 16 week old ob/ob mice (Fabisch, 2010), which fits 
the corresponding mRNA data determined in the current study. Given the above 
mentioned in vitro data, an unaltered expression should be suggestive of a “normal” 
LTCC function and expression. In fact, we found an unaltered maximum whole-cell 
current density and preliminary single-channel recordings at +10 mV (not shown; data 
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obtained by Jan Matthes, Center of Pharmacology, University Hospital of Cologne) 
suggested unchanged activity, too. However, the leftward-shift of the potential of half-
maximum activation (V0.5act) indicated functional alterations that could not be explained 
further. In older ob/ob mice both, Rad and Cav1.2 expression was significantly 
increased at the protein level (Fabisch, 2010). Assuming the “Cav1.2-antagonistic” 
function of Rad, L-type Ca2+ currents would thus be expected to be not or only slightly 
affected. Indeed, whole-cell recordings revealed an unchanged maximum Ca2+ current 
density compared to age-matched wt myocytes. However, we cannot say whether Rad 
upregulation induced the increase of Cav1.2 or vice versa. The fact that in cells from 
older ob/ob mice whole-cell LTCCs opened at more positive potentials and time- or 
rather calcium-dependent channel inactivation (CDI) was faster in the range of 10 mV to 
40 mV might be explained by the observed increase in Rad protein since similar 
functional changes were described for rat cardiomyocytes overexpressing the human 
Rad protein after adenoviral infection (Wang et al., 2010). The slowed inactivation at -10 
mV might be explained by an interaction with Ca2+/calmodulin (CaM). Pang and 
colleagues suggested RGK proteins to compete with CaM, thus causing a slowed CDI 
(Pang et al., 2010). Since preliminary single-channel data indicated an unchanged 
LTCC activity (not shown; data obtained by Jan Matthes, Center of Pharmacology, 
University Hospital of Cologne), it is suggested that either Rad inhibited Cav1.2 channel 
trafficking to the surface membrane or completely “silenced” a certain fraction of already 
inserted Cav1.2 pores. Of note, whole-cell recordings detect the sum of currents carried 
by virtually all channels expressed in the plasmalemma. In mammalian cardiomyocytes 
the whole-cell LTCC Ca2+ current density is carried by channels located on the surface 
and in the depth of the T-tubuli, with the latter predominating under normal conditions 
(Horiuchi-Hirose et al., 2011). Single-channel recordings obtained in the conventional 
cell-attached configuration do only detect channels expressed in the surface membrane, 
i.e. channels expressed in the depth of the T-tubuli are neglected. Thus we cannot 
exclude that the activity of T-tubular but not surface channels was actually decreased. 
In fact, very recent data showed a differential regulation of surface and T-tubular single 
LTCCs in ventricular myocytes from human and rat (non-diabetic) hearts (Sanchez-
Alonso et al., 2016). In the current study we find that in ventricles of 28 week old ob/ob 
mice Rad mRNA expression was unchanged and Cav1.2 mRNA was significantly 
decreased, while both appeared to be increased at the protein level (Fabisch, 2010). 
Many studies showed an apparently poor correlation between mRNA and protein 
expression levels (Koussounadis et al., 2015, Su et al., 2015). Discrepancies were 
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attributed to post-transcriptional modifications of mRNA, different half-lives of proteins 
as the result of varied protein synthesis and degradation and inaccuracies in 
experiments (Greenbaum et al., 2003). The present study also revealed that the mRNA 
amount of the accessory LTCC subunits Cavß1 and Cavß2 was nearly halved in 
ventricles of ob/ob mice at both ages investigated. If mRNA and protein expression data 
would correlate in this case, these findings would suggest a reduced surface expression 
of LTCCs and/or a decreased stimulation, i.e. a reduced channel open probability, a 
rightward shift of V0.5act or altered channel gating kinetics (Buraei and Yang, 2013). It 
might also be speculated that the Cavß-subunit regulated the Rad inhibitory effect since 
Cavß is required for an inhibition (Buraei and Yang, 2015). Since Rad and Cav1.2 
expression changed with age (and/or duration of diabetes) in ob/ob mice while Cavß 
(mRNA) expression remained unaltered a relationship between these findings seems to 
be rather unlikely. 
Whole-cell recordings of Rad-k.o. myocytes indicate the extent of an inhibitory effect of 
Rad on LTCCs. Manning et al. showed a significantly increased current density and a 
shift of steady-state activation to more negative potentials (Manning et al., 2013). Data 
obtained in the current study confirm these earlier findings. Compared to age-matched 
wt mice the mean peak current density of 16 week old mice was increased by about 
84%. The mean peak current density of older mice was even augmented by 142% 
compared to age-matched wt. The leftward shift of V0.5act observed by Manning et al. 
and us strengthens our hypothesis of a connection between the rightward shift of V0.5act 
and (relative) Rad overexpression observed in 28 week old ob/ob mice. This is 
supported by findings of Wang et al. who showed that adenoviral induction of Rad 
(over-) expression caused a rightward shift of steady-state activation in cultured rat 
cardiomyocytes (Wang et al., 2010). While Manning et al. did not state the age of the 
mice they investigated our data suggest an age-related effect (or “decompensation”) of 
Rad deficiency in ventricular myocytes. An age-dependent effect is furthermore 
suggested by the observation that recovery from inactivation was decelerated only in 
Rad-k.o. mice at an age of 16 weeks. We for the first time analyzed mRNA levels of 
RGK proteins and LTCC Cavß-subunits in Rad-k.o. mice, which could give a hint 
towards further mechanisms in LTCC regulation and RGK interplay. At 16 weeks of age 
Gem mRNA was upregulated about twofold and Cavß2 mRNA was downregulated. This 
could be a first response to protect the heart against an increased LTCC function. In 
older mice Rem 1 mRNA expression was increased, too. In addition to reduced Cavß2 
mRNA Cav1.2 mRNA was downregulated at 28 weeks of age. Of note, Manning et al. 
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(2015) observed a reduction of Cav1.2 protein expression. But again Manning et al. did 
not state the age of the mice they investigated. Taken together, the increased current 
density rather seems to be due to an increased activity of single LTCCs. Further studies 
have to test for this hypothesis. At this point it has to be mentioned that the extent of 
inhibition and the kind of interaction with Cav1.2 may vary depending on the particular 
RGK protein. In Rem 1-k.o. mice the increase in current density appeared weaker 
compared to our study (approx. +20%) and V0.5act was shifted to more positive potentials 
(Magyar et al., 2012).  
In 16 week old ob/ob x Rad-k.o. mice whole-cell patch-clamp data were similar to age-
matched Rad-k.o. mice: compared to age-matched wt mice the mean peak current 
density was increased by about 97%, V0.5act was shifted to more negative potentials and 
the recovery from inactivation was slowed, too. These findings suggest that the role of 
Rad (and thus the effects of lacking Rad) is similar on a wildtype and an ob/ob 
background - at least at an age of 16 weeks. Given the increased Rad (and Cav1.2) 
expression in older ob/ob mice it would be of particular interest to test for a putative 
additive effect of Rad deficiency and Cav1.2 increase. 
In 16 week old IRS 2-k.o. mice whole-cell Ca2+ current density was significantly 
decreased compared to age-matched control, although Rad and Cav1.2 protein 
expression appeared to be unchanged. Thus, another mechanism underlying the 
decreased current density has to be assumed. mRNA analysis of accessory Cavß-
subunits and of the other RGK proteins also did not reveal a hint towards the origin of 
current density reduction in young IRS 2-k.o. mice. In comparison to young IRS 2-k.o. 
mice 28 week old mice of the same genotype showed a significantly increased Ca2+ 
current density, that was no longer different compared to age-matched controls. Of 
interest, the putative age-related decrease of the Cav1.2/Rad ratio, which was observed 
in wt mice, was not seen in 28 week old IRS 2-k.o. mice. The finding that at an age of 
28 weeks Cav1.2 protein expression was unaltered compared to age-matched wt mice, 
while Rad protein expression was significantly reduced indicates an (age-dependent) 
loss of LTCC inhibition by Rad in IRS 2-k.o. mice. This interpretation is supported by our 
finding that V0.5act was significantly shifted to more negative potentials similar to data 
obtained from Rad-k.o. mice. The increase in whole-cell Ca2+ current density compared 
to younger mice thus indicates a compensatory mechanism based upon regulation of 
Rad expression. Note, that in human heart failure unchanged current density and 
decreased expression of Rad suggest a similar mechanism (Chang et al., 2007, 
Mukherjee and Spinale, 1998). Further studies should investigate putative changes of 
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single ventricular LTCC activity in IRS 2-k.o. and/or Rad-k.o. mice. Again it is important 
to consider that Western Blot data represent the expression of the total cardiac 
membrane protein fraction, including T-tubular and sarcolemmal membrane proteins. 
We were not able to discriminate whether the decrease in Rad protein affected single-
channel activity or Cav1.2 channel trafficking to the surface membrane or both, 
respectively. Experiments in order to differentially investigate the T-tubular and 
sarcolemmal expression of LTCCs would thus be helpful as well as single-channel 
measurements. Besides, Western Blot studies were limited because Coomassie 
staining of the already blotted SDS gels sometimes revealed an incomplete transfer of 
protein to the blotting membrane. But given that PVDF membrane protein binding 
capacity was not exhausted and that measurements were performed within the linearity 
of the detection system (figure 8.16, appendix), it is assumed that proteins were 
transferred equally within one blot. In contrast to our data C. Fabisch observed an 
unchanged protein expression ratio in ventricles of 28 week old IRS 2-k.o. mice (C. 
Fabisch; unpublished data). However, it should be noted that in the current study the 
Cav1.2-to-Rad ratio was calculated by detecting the intensities of Cav1.2 and Rad bands 
in one and the same lane, while C. Fabisch detected the proteins separately. The 
protein levels we obtained correlate poorly with the respective mRNA levels. While in 
young IRS 2-k.o. mice Rad mRNA was upregulated about twofold, Rad protein 
remained unchanged. In older mice Rad mRNA expression was no longer altered 
compared to age-matched wt, but Rad protein was decreased. It might be speculated 
that Rad mRNA was subject to post-transcriptional modifications or that protein 
degradation was enhanced. Of note, the current study was limited because of the use of 
whole-ventricle homogenates for expression analyses via qRT-PCR. Purification 
experiments in order to separate cardiomyocytes from other cell types failed. Thus we 
cannot exclude that the change in Rad mRNA expression was (partly) attributed to 
“non-cardiomyocytes”.  
Taking together, the increase of both, Rad and Cav1.2 protein in old ob/ob mice while 
unchanged maximum Ca2+ current density suggests a functional role of Rad in LTCC 
regulation. However, we cannot say whether Rad upregulation induced the increase of 
Cav1.2 or vice versa. Our data obtained from Rad-k.o. mice confirm the inhibitory 
function of Rad and furthermore indicate an age-related effect. Whole-cell recordings of 
ob/ob x Rad-k.o. myocytes further suggest that the role of Rad or rather the effect of a 
Rad deficiency is similar on a wildtype and an ob/ob background. Our data received 
from 28 week old IRS 2-k.o. mice are suggestive of a compensatory effect of Rad 
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protein on LTCC function, i.e. an attempt to compensate for a reduced calcium current 
density independent of the Cav1.2 expression. The reduced Rad protein expression 
appeared to provoke effects similar to that observed in the total Rad deficiency in Rad-
k.o. mice. Although the current study suggests LTCC regulation by Rad in two different 
diabetic mouse models, not all results could be explained only by assuming the “Cav1.2-
antagonistic” or compensatory function of Rad. Our data suggest that there is no 
uniform, diabetes-associated mechanism of Rad-Cav1.2 interaction. Putative influencing 
factors that might also be involved in LTCC regulation are discussed in the following 
section. 
 
4.2  Further molecular mechanisms that might be involved in LTCC 
regulation 
 
Cardiac electrophysiological properties are amongst others regulated by the 
sympathetic nervous system (Yu et al., 2011). As a compensatory reaction to the 
reduced cardiac output in heart failure (HF) the renin-angiotensin-aldosterone system 
(RAAS) and the sympathetic nervous system are activated (King et al., 2012). An 
activation of the sympathetic nervous system increases the levels of catecholamines, 
endogenous agonists of adrenoceptors (α1, α2, ß1, ß2 and ß3). The β1-adrenergic 
receptor is predominantly expressed in the heart (Madamanchi, 2007). In general, 
stimulation of ß-adrenergic receptors leads to an activation of protein kinase A (PKA). 
PKA then phosphorylates several targets like troponin I, LTCCs or PLN, resulting in 
enhanced cardiac contractility (Madamanchi, 2007). Phosphorylation of LTCCs by PKA 
has been subject to various studies, indicating that either the Cavα1-subunit or the 
Cavß-subunits can mediate the ß-adrenergic stimulation (Hofmann et al., 2014). In HF 
the heart appears to be protected against chronic adrenergic (over-) stimulation via an 
impaired ß-adrenergic signaling and decreased PKA activity (Najafi et al., 2016). Rad-
k.o. mice display a rather improved cardiac function. Nevertheless ß-adrenergic 
response is impaired (Manning et al., 2013), similar to findings from human HF 
(Schroeder et al., 1998, Chen et al., 2002). Since Rad is phosphorylated by Ca2+/CaM-
dependent protein kinase II, PKA and protein kinase C (Moyers et al., 1998), this RGK 
protein might be also involved in the adrenergic regulation of cardiac LTCCs. PKD1, a 
protein kinase downstream of α(1)-adrenergic signaling, was shown to phosphorylate 
Rem 1 upon α(1)-adrenergic stimulation with the release of the inhibitory effect of     
Rem 1 as a consequence (Jhun et al., 2012). Of note, Withers et al. showed that                  
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α-adrenergic activation stimulated phosphorylation of Rem 1 but not of Rad. However, 
Rad was phosphorylated upon β-adrenergic receptor stimulation, a process that could 
be blocked by PKA inhibition. Indeed, CoIPs indicated that Rad phosphorylation 
weakened LTCC association (Withers et al., 2015). In 10 week old ob/ob mice             
ß-adrenergic responsiveness was impaired and PKA activity was significantly 
depressed (Minhas et al., 2005). Thus, Rad protein might have been less 
phosphorylated and LTCC inhibition weakened. Of note, our preliminary single-channel 
data from ob/ob mice do not hint at an altered adrenergic LTCC regulation. Garcia-
Barrado and colleagues investigated ß-cell function and lipolysis in IRS 2-k.o. mice and 
demonstrated an impaired adrenergic signaling in combination with altered 
adrenoceptor expression levels (Garcia-Barrado et al., 2011). Such experiments with 
ventricular tissue of IRS 2-k.o. mice have not been performed so far. However, insulin-
induced phosphorylation of ß-adrenergic receptors was shown to be dependent on     
IRS 2 with lack of IRS 2 leading to an attenuated cAMP/PKA activity in cardiomyocytes 
(Fu et al., 2014). To sum it up, altered adrenergic signaling can affect cardiac LTCC 
expression and function. RGK proteins might be involved since they are a well-known 
targets of PKA. However, so far our data do not indicate altered adrenergic regulation of 
LTCCs in the investigated mouse models. 
 
In several studies it was suggested that PI3K/Akt signaling positively regulates LTCCs 
in ventricular myocytes (Ballou et al., 2015). In this context Viard et al. showed that an 
increase of PIK3 and Akt/PKB triggered Cav1.2 channel trafficking to the plasma 
membrane and that the Cavß2-subunit was required to support this regulation by PI3K 
in particular (Viard et al., 2004). Catalucci et al. suggested that an Akt-dependent 
phosphorylation of the Cavß2-subunit protects Cav1.2 from degradation and thus 
increases whole-cell current density (Catalucci et al., 2009). Recently Rusconi et al. 
published that the Cav1.2 amount and the Akt-dependent phosphorylation status of 
Cavβ2 were correlated and that Cavß2 underwent conformational changes upon 
phosphorylation which induced an increased current density (Rusconi et al., 2016). Two 
diabetic mouse models exhibited alterations in LTCC current density probably caused 
by a decrease in insulin/PI3K/Akt signaling: in type 1 diabetic Ins2Akita mice LTCC 
current density was reduced, including shifts in the voltage dependence of (in)activation 
to more positive potentials. Intracellular delivery of PI(3,4,5)P3 normalized these 
parameters to control levels and further experiments led to the hypothesis that Cav1.2 
surface expression was reduced, whereas the total amount of protein was unaltered (Lu 
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et al., 2007). In db/db mice a defect in insulin signaling was suggested to be partly 
responsible for a depressed current density because infusion with PI(3,4,5)P3, Akt1 or 
Akt2 increased the current density (Lu et al., 2011). Similar to human T2DM patients an 
excessive myocardial insulin signaling activity (IRS1-PI3K-activity) was shown in ob/ob 
mice. This went in parallel with an activation of the insulin receptor. Total Akt levels 
were unchanged, but basal Akt phosphorylation was increased and insulin-stimulated 
Akt phoshorylation was blunted (Cook et al., 2010). Given this interplay between insulin-
signaling, Akt and Cavß2-subunits it would be desirable to check for the downregulation 
of Cavß2-subunits we observed at the mRNA level at the protein level or even to look at 
the phosphorylation of auxiliary LTCC subunits. Studies performed with IRS 2-k.o. mice 
demonstrated an insulin-dependent decrease in PI3K activity in liver and skeletal 
muscle (Withers et al., 1998). Cardiac PI3K activity has not been evaluated in IRS 2-k.o. 
mice yet. But a cardiac-specific k.o. of IRS 2 (CIRS 2 mice) revealed a lower cardiac 
PI3K activation (Riehle et al., 2014). In IRS 2-k.o. mice compensation for insulin 
resistance appeared to be impaired because hyperinsulinemia was accompanied by a 
ß-cell decrease of 42% compared to wt (Kubota et al., 2000, Withers et al., 1998). The 
decrease of cardiac whole-cell current density we observed in young IRS 2-k.o. mice 
might thus be attributed to an altered insulin signaling. Of note, a transgenic mouse 
overexpressing Rad in skeletal muscle and maintained on a high-fat diet developed 
more severe glucose intolerance and insulin resistance than control mice (Ilany et al., 
2006). It is thus tempting to speculate that the reduced Rad expression observed in 
hearts of older IRS 2-k.o. mice was to reverse the decrease of ventricular Ca2+ currents 
by re-establishing insulin signaling. Taken together, several studies indicated an 
influence of PI3K/Akt signaling on LTCC regulation in ventricular myocytes. It was 
shown that an Akt-dependent phosphorylation of the Cavß2-subunit protects Cav1.2 
from degradation. Since our whole-cell patch-clamp data obtained from young IRS 2-
k.o. mice could not be explained only by assuming the “Cav1.2-antagonistic” function of 
Rad, here insulin signaling might be relevant for LTCC regulation, too. Of interest, in 
IRS 2-k.o. mice compensation for insulin resistance appeared to be impaired. 
 
In ob/ob hearts strong evidence for oxidative stress was detected which worsened 
cardiac efficiency (Boudina et al., 2005, Li et al., 2006, Gharib et al., 2016). Increased 
mitochondrial oxidative stress was also observed in atrial tissue of T2DM patients 
(Anderson et al., 2009, Anderson et al., 2011). Moreover, in human muscle biopsies of 
patients with sporadic amyotrophic lateral sclerosis oxidative stress triggered Rad 
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upregulation (Halter et al., 2010). Thus, oxidative stress might be a contributing factor to 
the upregulation of Rad protein observed in ventricles of 28 week old ob/ob mice.  
 
4.3  Reliability of investigated mouse models – relevance and metabolic 
determinants for human T2DM & DCM 
 
In T2DM patients hyperglycemia develops slowly and worsens over time as a response 
to insulin resistance and compensatory hyperinsulinemia (Wang et al., 2014). Insulin 
resistance is associated with metabolic, structural and functional changes in the heart 
that may lead to DCM and HF (Abel et al., 2012). In humans, overweight/obesity is 
known to be a main risk factor for developing T2DM (Chatzigeorgiou et al., 2009, Wang 
et al., 2014). But it is disputable to what extent leptin and its signaling pathways 
contribute to the development of the disease. To date, eleven pathogenic mutations 
have been reported in the human leptin gene (Wasim et al., 2016). Interestingly, obese 
T2DM patients often reveal elevated leptin levels compared to non-diabetic obese 
humans (Wang et al., 2014). Amongst other reasons hyperleptinemia may be evoked by 
insulin resistance and may lead to leptin resistance (Ren, 2004). The specific cardiac 
effects of leptin are not fully elucidated and many studies reveal controversial results. 
But it is sure that leptin can have beneficial as well as detrimental effects on cardiac 
function (Feijoo-Bandin et al., 2015, Hall et al., 2015, Martinez-Martinez et al., 2014, 
Martin et al., 2008). In the ob/ob mouse model leptin deficiency appears to be a relevant 
factor for T2DM and DCM since replacement of leptin corrects many diabetic 
manifestations and improves left ventricle remodeling (Lindstrom, 2007, Barouch et al., 
2003). Ob/ob mice develop obesity which then appears to predispose them to the 
development of diabetes-associated disturbances. These animals already exhibit mild 
hyperglycemia by four weeks of age and become severe hyperglycemic not later than at 
15 weeks of age (Buchanan et al., 2005). Of note, in the current study the elevation of 
blood glucose of 28 week old ob/ob mice was less pronounced compared to younger 
ob/ob animals. According to The Jackson Laboratory hyperglycemia may be transient in 
ob/ob mice, but individual variability exists (Leiter, 1992). On the other hand, another 
study did not find an attenuation of hyperglycemia with progressing age (Van den Bergh 
et al., 2008). In addition, it has to be taken into account that, similar to human T2DM 
patients, the phenotype of a mouse model may vary due to differences in the genetic 
background, gender and age (Cefalu, 2006). For example, the severity of diabetes in 
ob/ob mice obviously varies depending on the genetic background (Coleman, 1978, 
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Haluzik et al., 2004). Although ob/ob mice develop T2DM associated changes earlier in 
life compared to humans they are accepted as an appropriate model for studying T2DM 
as well as DCM since as human patients ob/ob mice are hyperinsulinemic and develop 
severe insulin resistance (Lindstrom, 2007, Buchanan et al., 2005). In contrast to 
humans the pancreatic ß-cell morphology and amount differ. The insulin release 
capacity remains high throughout life (Bock et al., 2003, Kim et al., 2009, Lindstrom, 
2007, Del Guerra et al., 2005). Interestingly, long-term microvascular complications 
observed in diabetic humans such as nephropathy, neuropathy and retinopathy and/or 
macrovascular complications due to atherosclerosis are absent in ob/ob mice (Wang et 
al., 2014). Therefore ob/ob mice might rather reflect the “prediabetic” phenotype, e.g. as 
common for the metabolic syndrome. However, similar to human diabetic patients 
hearts of ob/ob mice exhibit metabolic, structural and functional changes (Gharib et al., 
2016, Sloan et al., 2011, Fukui et al., 2013, Buchanan et al., 2005, Christoffersen et al., 
2003, Mazumder et al., 2004, Boudina et al., 2005, Li et al., 2006, Fauconnier et al., 
2005, Minhas et al., 2005, Ren et al., 2010, Barouch et al., 2006). Both T2DM patients 
and ob/ob mice exhibit an excessive myocardial insulin signaling activity (Cook et al., 
2010). Studies in mice and humans reveal an important role of myocardial insulin 
signaling in the context of cardiac hypertrophy and heart failure (Riehle and Abel, 2016). 
Based on our current findings though we cannot exclude that the increase of heart 
weight observed in older ob/ob mice is physiologic due to the vast increase of body 
weight. Other studies revealed a hypertrophy in this mouse model (Ren et al., 2010, 
Barouch et al., 2003). Since furthermore a major definition criteria, the absence of 
hypertension, is fulfilled ob/ob mice, this mouse model can be taken as a model of DCM 
(Mark et al., 1999, Fukui et al., 2013, Barouch et al., 2003).  
Concerning the IRS 2 gene data in literature are inconsistent and rare in identifying 
human polymorphisms that might be associated with T2DM (Jiang et al., 2015). But it is 
known that the protein expression may be altered in diabetic humans (Hirashima et al., 
2003). According to diabetic patients IRS 2-k.o. mice are hyperglycemic, 
hyperinsulinemic, insulin resistant as well as hyperleptinemic (Sesti et al., 2001, Burks 
et al., 2000, Withers et al., 1998, Kubota et al., 2000). Most likely depending on the 
genetic background several studies showed conflicting findings regarding body weight 
of IRS 2-k.o. mice (Garcia-Barrado et al., 2011, Masaki et al., 2004, Burks et al., 2000, 
Kubota et al., 2000, Withers et al., 1998). In the current study body weight of IRS 2-k.o. 
mice was similar to wt. There was no evidence for cardiac hypertrophy since ventricle 
weights as well as ventricle-to-body weight ratios were similar to wt, too. To our 
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knowledge no further data on cardiac morphology or function on the background of a 
global IRS 2-k.o. has been published, but premature death was observed (Withers et 
al., 1998). Of note, mice with a cardiac-specific k.o. of IRS 2 exhibit cardiac hypertrophy 
(Riehle et al., 2014). Several mouse models associated with disturbances of the IRS 
signaling have pathophysiological disturbances within the heart: for the cardiac-specific 
IRS 2-k.o. mouse model a reduced cardiac efficiency was shown (Riehle et al., 2014). 
Mice with a cardiac-specific k.o. of both, IRS 1 and IRS 2 die within 11 weeks. These 
mice have an impaired mitochondrial function, increased autophagy and apoptosis, 
myocyte loss and heart failure (Riehle et al., 2013, Qi et al., 2013). Mice with a global 
k.o. of both proteins appear to be not viable since no born animals rendered this 
genotype (Withers et al., 1999). The current study observed a significantly reduced 
whole-cell Ca2+ current density in young IRS 2-k.o. mice. This may suggest a 
disturbance in the contractile machinery, too. Indeed, genetically engineered mice 
expressing a lower level of cardiac L-type calcium channels develop hypertrophy and 
heart failure (Goonasekera et al., 2012). The observed normalization of calcium current 
density to wt levels in IRS 2-k.o. at 28 weeks of age might then be interpreted as anti-
hypertrophic. However, in mice where cardiac calcium current density is reduced due to 
the knockout of an auxiliary beta-subunit the expression of the Cav1.2 channel pore was 
unchanged and these animals did not develop ventricular hypertrophy (Meissner et al., 
2011). 
To sum it up, ob/ob as well as IRS 2-k.o. mice are valuable mouse models in studying 
T2DM (King, 2012, Chatzigeorgiou et al., 2009, Lee and Cox, 2011). Both mouse 
models provide useful knowledge about different phenotypes and the underlying 
pathomechanisms that are prevalent in humans. Ob/ob mice also share many traits with 
the hearts of humans with DCM. So far it has not been evaluated whether the IRS 2-k.o. 
mouse model also represents a suitable model for DCM. One has to keep in mind that 
the transfer of murine data to humans should be done very carefully, though mouse 
models are helpful to understand the role of insulin signaling and other 
pathways/molecules in the regulation of cardiac function.  
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4.4  Limitations of the study 
 
In the current study we wanted to consider the putative influence of a time-dependent 
onset of T2DM disease progression and following complications by using two different 
age groups. However, the ages 16 and 28 weeks were chosen arbitrarily. In the 
development of human DCM not only age but also gender appears to be an influencing 
factor. Of note, female T2DM patients seem to be more affected (Jia et al., 2016). But 
so far there is no evidence that sex difference is relevant for DCM in mice. E.g. in db/db 
mice no hints were found (Pereira, 2006). The present study was not designed to take a 
closer, separate look on gender and thus did not have the respective statistical power. 
However, in IRS 2-k.o. mice there is a gender difference regarding blood glucose 
(Withers et al., 1998). Given the discussed putative cardiac effects of insulin a gender-
specific analysis should be considered. It should also be noted that the comparability of 
protein expression data obtained in the current study and in C. Fabisch’s thesis work is 
limited due to differences in the used protocols (Fabisch, 2010). Furthermore, in the 
current project the completion of protein and mRNA data was not possible due to time 
constraints (protein data for Rad-k.o mice; mRNA and protein data for ob/ob x Rad-k.o. 
mice). 
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5 Conclusion & outlook 
 
The current study indicates an interaction between Rad and LTCCs in two different 
diabetic mouse models. The obtained findings mostly correspond with a “Cav1.2-
antagonistic” or compensatory function of Rad on LTCC expression and/or function. 
However, in young IRS 2-k.o. mice another mechanism underlying the decreased 
current density has to be assumed. Thus, our data suggest that there is no uniform, 
diabetes-associated mechanism of Rad-Cav1.2 interaction. Differences between the 
investigated mouse models might be attributed to differences in the underlying 
pathomechanisms. Further work is required for clarification e.g. of the 
pathophysiological importance of the disrupted insulin and leptin signaling pathways. 
Changes at the level of receptors or ligands might be compensated by the other 
signaling pathway while impairment downstream at the level of IRS 2 might severely 
affect insulin signaling here. It would be important to determine different phosphorylation 
states of the receptors and downstream signaling molecules such as IRS, Akt, PI3K or 
STAT in the heart, in particular for IRS 2-k.o. mice. It is probably more an interplay of 
parameters and not a single parameter that is crucial for LTCC regulation in DCM. 
Besides, the effect of an altered Rad protein expression on LTCC (expression and/or) 
function has not been conclusively clarified in the current study yet - further studies 
should investigate putative changes of single ventricular LTCC activities in 
cardiomyocytes of ob/ob and IRS 2-k.o. mice. It would also be reasonable to investigate 
other rodent mouse models associated with T2DM. Taken together, further research is 
necessary to evaluate the role of a Rad-Cav1.2 interaction in a diabetic context. 
Anyway, RGK proteins, e.g. Rad, might be promising targets to develop therapeutic 
strategies for the treatment of cardiac diseases.  
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6 Summary 
 
Cardiovascular disease (CVD) is a leading cause of death for diabetic patients. Diabetic 
cardiomyopathy (DCM) is characterized by an abnormality of myocardial diastolic or 
systolic function in diabetic subjects without the major heart failure risk factors 
hypertension and/or (overt) coronary artery disease. The pathophysiology of DCM 
remains largely unclear and needs to be further elucidated in order to develop targeted 
therapeutic strategies. Since cardiac L-Type calcium channels (LTCCs) are known to be 
involved in proper excitation-contraction coupling, they are of high interest in the 
research of CVD, such as DCM and resulting heart failure (HF). 
In human (non-diabetic) HF whole-cell Ca2+ current density of ventricular LTCCs was 
unchanged. Both, a decrease of plasmalemmal expression of Cav1.2 as well as an 
increased activity of single LTCCs was described ex vivo. These findings suggest 
changes in both expression and function of LTCCs. In contrast, in a mouse model 
associated with DCM (the so-called db/db mice with leptin receptor deficiency) whole-
cell Ca2+ current density was reduced, while single-channel activity was unchanged. It 
has been shown that RGK proteins, like the diabetes-associated Rad, might be involved 
in LTCC regulation, both regarding its function and expression. Rad expression is 
reduced in human HF and whole-cell calcium current densities are increased in 
cardiomyocytes of Rad-k.o. mice. Though previous data suggest that the ventricular 
expression levels of Rad and Cav1.2 proteins are positively correlated in several mouse 
models with diabetes-associated metabolic disturbances, the effect of Rad on cardiac 
LTCCs in a diabetic context remains unclear.  
To address Rad-LTCC interaction in a diabetic context two of the previously screened 
mouse models were investigated in the present study: leptin-deficient obese ob/ob mice 
and mice lacking IRS 2, respectively. Though experiments with Rad-k.o. and Rem 1-k.o. 
mice suggest an impressive inhibitory effect of RGK proteins on native cardiac LTCCs, 
it remains unclear whether differential expression of RGK proteins might be 
compensatory, causative or both regarding LTCC regulation. Thus, the present study 
aims at the role of in vivo regulation of Rad expression on ventricular LTCC expression 
and function. For this, ventricular L-type calcium current densities were obtained by 
patch-clamp recordings and compared to those of wildtype littermates in the context of 
ventricular expression levels of Rad and Cav1.2 mRNA and protein. In order to further 
evaluate the role of Rad in ob/ob mice, we generated and analyzed ob/ob mice lacking 
Rad. In summary, it should be elucidated whether there is a unifying effect of Rad on 
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LTCCs in diabetic hearts that might suggest a mechanism underlying diabetic 
cardiomyopathy.  
Mice of different ages (16 and 28 weeks) were chosen for experiments to take time-
dependent onset of obesity and disease progression of T2DM into account. Since the 
expression of the other RGK proteins and LTCC ß-subunits (Cavß1- Cavß3) might have 
contributed to an altered LTCC regulation, their expression levels were checked as well.  
In old ob/ob mice both, Rad and Cav1.2 expression was significantly upregulated at the 
protein level, while whole-cell Ca2+ current density was unaltered compared to age-
matched control. Since preliminary single-channel data indicated an unchanged LTCC 
activity, it is suggested that either Rad inhibited Cav1.2 channel trafficking to the surface 
membrane or completely “silenced” a certain fraction of already inserted Cav1.2 pores. 
However, we cannot say whether Rad upregulation induced the increase of Cav1.2 or 
vice versa. Our data obtained from Rad-k.o. mice confirm the inhibitory function of Rad 
protein on LTCCs and furthermore indicate an age-dependent effect. Whole-cell 
recordings of ob/ob x Rad-k.o. myocytes further suggest that the role of Rad is similar 
on a wildtype and an ob/ob background.  
In young IRS 2-k.o. mice whole-cell Ca2+ current density was significantly decreased 
compared to age-matched control. Since Rad and Cav1.2 protein expression appeared 
to be unchanged another mechanism underlying the decreased current density has to 
be assumed, e.g. altered insulin signaling. In comparison to young IRS 2-k.o. mice older 
mice of the same genotype showed a significantly increased Ca2+ current density, that 
was no longer different compared to age-matched control. Of interest, the putative age-
related decrease of the Cav1.2/Rad ratio, which was observed in wt mice, was not seen 
in 28 week old IRS 2-k.o. mice. The finding that at an age of 28 weeks Cav1.2 protein 
expression was unaltered compared to age-matched wt mice, while Rad protein 
expression was significantly reduced indicates an (age-dependent) loss of LTCC 
inhibition by Rad in IRS 2-k.o. mice. It is tempting to speculate that this is an attempt to 
compensate for a reduced calcium current density independent of the Cav1.2 
expression. Of note, in human heart failure unchanged current density and decreased 
expression of Rad suggest a similar mechanism. 
To sum it up, the current study indicates interaction between Rad and LTCCs in two 
different diabetic mouse models. The obtained findings mostly correspond with a 
“Cav1.2-antagonistic” or compensatory function of Rad on LTCC expression and/or 
function, but our data suggest that there is no uniform, diabetes-associated mechanism 
of Rad-Cav1.2 interaction. Differences between the investigated mouse models might 
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be attributed to differences in the underlying pathomechanisms. Further work is required 
for clarification e.g. of the pathophysiological importance of the disrupted insulin and 
leptin signaling pathways. Changes at the level of receptors or ligands might be 
compensated by the other signaling pathway while impairment downstream at the level 
of IRS 2 might severely affect insulin signaling here. It is probably more an interplay of 
parameters and not a single parameter that is crucial for LTCC regulation in DCM. 
Anyway, RGK proteins, e.g. Rad, might be promising targets to develop therapeutic 
strategies for the treatment of cardiac diseases. 
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8 Appendix 
 
8.1  Exemplary genotyping results 
 
All mice included in this study were genotyped unambiguously. Figures 8.1-8.3 show 
exemplary genotyping results. 
 
Figure 8.1 Exemplary genotyping results for IRS 2-k.o. mice: DNA fragments were visualized at 300 bp for 
the wildtype band and at 400 bp for the mutant band (hz = heterozygous, wt = wildtype, k.o. = knockout, bp = 
base pairs). 
 
Figure 8.2 Exemplary genotyping results for ob/ob mice: bands were detected at 83 bp and 99 bp for mutant 
and at 180 bp for wildtype (hz = heterozygous, wt = wildtype, k.o. = knockout, bp = base pairs). 
 
 
Figure 8.3 Exemplary genotyping results for Rad-k.o. mice: wildtype was identified via a band at 507 bp and 
mutant via a band at 347 bp (hz = heterozygous, wt = wildtype, k.o. = knockout, bp = base pairs). 
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8.2  Overview: blood glucose values, body weights, ventricle weights and 
ventricle-to-body weight ratios  
 
Table 8.1 Overview of blood glucose levels, body weights, ventricle weights and ventricle-to-body weight 
ratios of the investigated mouse lines (* = p < 0.05 mutant vs. age-matched wt in Student’s t-test; # = p < 0.05 
vs. 28 week old mice of the same genotype in Student’s t-test; values = mean ± SEM; N = number of mice). 
Genotype, age 
Blood 
glucose 
level [mg/dl]  
Body 
weight [g]  
Ventricle 
weight [mg]  
Ventricle-to-body 
weight ratio [mg/g]  
 
Wildtype,  
16 weeks 
158 ± 5 
(N = 58) 
24.4 ± 0.5
#
 
(N = 62) 
127.9 ± 5.3 
(N = 36) 
5.4 ± 0.2 
(N = 36) 
 
IRS 2-k.o.,  
16 weeks 
207 ± 10* 
(N = 62) 
25.7 ± 0.5
#
 
(N = 63) 
128.3 ± 3.4 
(N = 34) 
5.0 ± 0.1 
(N = 34) 
 
Ob/ob,  
16 weeks 
270 ± 29*
,#
 
(N = 20) 
46.6 ± 2.0*
,#
 
(N = 20) 
124.4 ± 3.9
#
 
(N = 13) 
2.8 ± 0.2* 
(N = 13) 
 
Rad-k.o.,  
16 weeks 
140 ± 4* 
(N = 27) 
26.9 ± 0.7* 
(N = 27) 
121.4 ± 4.1 
(N = 21) 
4.6 ± 0.1* 
(N = 21) 
 
Ob/ob x Rad-
k.o., 16 weeks 
291 ± 26* 
(N = 25) 
51.1 ± 0.9*
,#
 
(N = 25) 
136.8 ± 4.7
#
 
(N = 16) 
2.7 ± 0.1* 
(N = 16) 
 
Wildtype,  
28 weeks 
168 ± 6 
(N = 41) 
27.6 ± 0.6 
(N = 42) 
142.7 ± 6.4 
(N = 21) 
5.2 ± 0.2 
(N = 21) 
 
IRS 2-k.o.,  
28 weeks 
239 ± 22* 
(N = 30) 
27.6 ± 0.9 
(N = 30) 
126.3 ± 5.6 
(N = 23) 
4.8 ± 0.2 
(N = 23) 
 
Ob/ob,  
28 weeks 
203 ± 18 
(N = 33) 
60.3 ± 1.5* 
(N = 33) 
157.7 ± 4.6 
(N = 16) 
2.8 ± 0.2* 
(N = 16) 
 
Rad-k.o.,  
28 weeks 
151 ± 5* 
(N = 49) 
27.9 ± 0.5 
(N = 49) 
120.9 ± 8.3* 
(N = 21) 
4.6 ± 0.1* 
(N = 21) 
 
Ob/ob x Rad-
k.o., 28 weeks 
276 ± 43* 
(N = 9) 
59.7 ± 1.6* 
(N = 9) 
170.8 ± 7.9* 
(N = 8) 
2.8 ± 0.1* 
(N = 8) 
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8.3  Whole-cell patch-clamp experiments 
8.3.1 Mean cell capacitances of patched cells 
 
Patched cells had a mean cell capacitance (Cm) of 157 ± 6 pF (n = 85; number of 
patched cells). In one-way ANOVA (Bonferroni’s Post Test) membrane capacities of 
patched cells did not differ significantly independent of mouse genotype and age 
from that cells were isolated (figure 8.4). Therefore experiments were technically 
comparable and there was no evidence of cellular hypertrophy. 
                   
Figure 8.4 Mean cell capacities (Cm):  in one-way ANOVA (Bonferroni’s Post Test) membrane capacities of 
patched cells did not differ significantly independent of mouse genotype and age from that cells were isolated. 
Therefore experiments were technically comparable and there was no evidence of cellular hypertrophy              
(n = 2-17 per group). 
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8.3.2 Overview: whole-cell patch-clamp results 
 
Table 8.2 Maximum current density (mean Imax) and potential of mean Imax determined out of raw data 
points of the I/V curve (* = p < 0.05 mutant vs. age-matched wildtype in Student’s t-test;                              
values = mean ± SEM; n = number of patched cells). 
Genotype, age Mean Imax [pA/pF] V [mV] at mean Imax  
Wildtype, 16 weeks (n = 17) -10.92 ± 0.90 2.94 ± 1.43  
IRS 2-k.o., 16 weeks (n = 11) -7.79 ± 0.79* 0.91 ± 1.63  
Ob/ob, 16 weeks (n = 10 ) -10.75 ± 0.65 0.00 ± 0.00  
Rad-k.o., 16 weeks (n = 5) -20.12 ± 1.49* -4.00 ± 2.45*  
Ob/ob x Rad-k.o., 16 weeks (n = 5) -21.48 ± 1.10* -8.00 ± 2.00*  
Wildtype, 28 weeks (n = 13) -8.91 ± 0.54 4.62 ± 1.44  
IRS 2-k.o., 28 weeks (n = 11) -11.22 ± 1.27 1.82 ± 1.22  
Ob/ob, 28 weeks (n = 11) -8.44 ± 0.43 10.00 ± 1.91*  
Rad-k.o., 28 weeks (n = 2) -21.58 ± 5.05* -5.00 ± 5.00*  
 
Table 8.3 Potential of half maximal activation V0.5act, slope factor, maximum current density (mean Imax) 
and potential of mean Imax determined out of fitted I/V curve (* = p < 0.05 mutant vs. age-matched wildtype 
in Student’s t-test; values = mean ± SEM; n = number of patched cells). 
Genotype, age 
Potential of 
half maximal 
activation 
V0.5act [mV] 
Slope 
factor  
Mean Imax 
[pA/pF] 
  
V [mV] at 
mean Imax 
 
 
Wildtype, 16 weeks (n = 17) -8.69 ± 1.06 5.05 ± 0.25 -11.13 ± 0.91 1.86 ± 1.12  
IRS 2-k.o., 16 weeks  
(n = 11) 
-8.71 ± 1.26 5.60 ± 0.60 -7.89 ± 0.81
*
 1.69 ± 1.24  
Ob/ob, 16 weeks (n = 10 ) -11.72 ± 0.59* 4.17 ± 0.18* -11.04 ± 0.69 -1.67 ± 0.67*  
Rad-k.o., 16 weeks (n = 5) -14.74 ± 1.33* 3.97 ± 0.10* -20.72 ± 1.62* -4.49 ± 1.30*  
Ob/ob x Rad-k.o., 16 weeks 
(n = 5) 
-17.06 ± 1.71
*
 3.65 ± 0.13
*
 -21.71 ± 1.53
*
 -5.31 ± 1.84
*
  
Wildtype, 28 weeks (n = 13) -7.51 ± 0.96 5.01 ± 0.14 -9.12 ± 0.55 3.12 ± 0.88  
IRS 2-k.o., 28 weeks  
(n = 11) 
-10.88 ± 0.89
*
 5.11 ± 0.21 -11.51 ± 1.30 0.53 ± 1.06  
Ob/ob, 28 weeks (n = 11) -4.86 ± 0 .67* 5.32 ± 0.18 -8.71 ± 0.44 5.67 ± 0.60*  
Rad-k.o., 28 weeks (n = 2) -16.13 ± 0.08* 3.37 ± 0.37* -22.24 ± 5.36* -6.60 ± 0.83*  
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Table 8.4 Time-dependent inactivation: Tau (determined out of fitted raw calcium current traces; * = p < 0.05 
mutant vs. age-matched wildtype in Student’s t-test; values = mean ± SEM; n = number of patched cells). 
Genotype, 
age 
Tau (τ) 
-10 mV 0 mV 10 mV 20 mV 30 mV 40 mV  
Wildtype,  
16 weeks 
(n = 17) 
 37.44 
± 2.82  
31.67 
± 1.54 
40.14 
± 1.37 
49.28  
± 1.45 
55.08 
± 1.50 
54.53 
± 1.46 
 
IRS 2-k.o.,  
16 weeks 
(n = 11) 
34.90 
± 3.31 
32.22 
± 1.19 
42.04  
± 1.68 
51.74 
± 1.61 
57.21 
± 1.48 
55.45 
± 1.98 
 
Ob/ob,  
16 weeks 
(n = 10 ) 
25.10 
± 1.41
*
 
33.09 
± 1.32 
44.78 
± 1.58
*
 
53.92 
± 1.58 
57.80 
± 1.25 
56.00 
± 0.94 
 
Rad-k.o.,  
16 weeks  
(n = 5) 
24.49 
± 2.71
*
 
27.67 
± 1.01 
36.62 
± 1.35 
46.63 
± 1.22 
55.87 
± 1.00 
61.76 
± 2.34
*
 
 
Ob/ob x Rad-
k.o., 16 
weeks  
(n = 5) 
28.12 
± 6.08 
34.12 
± 4.35 
43.27 
± 3.30 
48.59 
± 3.10 
55.23 
± 4.26 
61.08 
± 4.77 
 
Wildtype, 
 28 weeks  
(n = 13) 
36.16 
± 3.27 
35.58 
± 1.01 
46.56 
± 1.21 
57.29 
± 1.80 
62.65 
± 1.82 
60.57 
± 1.92 
 
IRS 2-k.o.,  
28 weeks  
(n = 11) 
32.34 
± 2.61 
33.11 
± 1.12 
40.88 
± 1.14
*
 
49.68 
± 1.65
*
 
54.45 
± 1.92
*
 
53.75 
± 2.03
*
 
 
Ob/ob,  
28 weeks  
(n = 11) 
54.48 
± 5.48
*
 
34.09 
± 1.28 
40.12 
± 1.09
*
 
47.27 
± 1.17
*
 
51.87 
± 1.20
*
 
51.97 
± 1.32
*
 
 
Rad-k.o.,  
28 weeks  
(n = 2) 
22.27 
± 5.84
 
28.66 
± 1.64
* 
40.13 
± 3.46
 
52.47 
± 3.90
 
61.33 
± 2.70
 
67.50 
± 0.95
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Table 8.5 Potential of half maximal inactivation V0.5inact and slope factor determined out of fitted SSI curve 
(* = p < 0.05 mutant vs. age-matched wildtype in Student’s t-test; values = mean ± SEM; n = number of patched 
cells). 
Genotype, age 
Potential of half 
maximal inactivation 
V0.5inact [mV] 
Slope 
factor  
 
Wildtype, 16 weeks (n= 7) -25.20 ± 1.01  4.65 ± 0.38  
IRS 2-k.o., 16 weeks (n = 4) -24.94 ± 1.33 4.05 ± 0.53  
Ob/ob, 16 weeks (n = 4) -26.27 ± 0.67 5.05 ± 0.38  
Rad-k.o., 16 weeks (n = 4) -28.17 ± 2.18 3.85 ± 0.21  
Ob/ob x Rad-k.o., 16 weeks (n = 4) -28.73 ± 1.21 4.20 ± 0.47  
Wildtype, 28 weeks (n = 9) -25.31 ± 0.84 4.70 ± 0.20  
IRS 2-k.o., 28 weeks (n = 4) -29.23 ± 1.06* 5.52 ± 0.38  
Ob/ob, 28 weeks (n = 12) -24.77 ± 0.71 4.53 ± 0.28  
Rad-k.o., 28 weeks (n = 3) -23.95 ± 1.56 3.76 ± 0.28*  
 
Table 8.6 Plateau, tau, half-time (determined out of fitted recovery curve) and the relative current after 
375 ms of recovery time (I2/I1) (* = p < 0.05 mutant vs. age-matched wildtype in Student’s t-test; values = 
mean ± SEM; n = number of patched cells). 
Genotype, age Plateau tau Half-time 
I2/I1 after 
375 ms 
 
Wildtype, 16 weeks (n = 22) 0.87 ± 0.02 150.28 ± 8.87 104.17 ± 6.15 0.81 ± 0.02  
IRS 2-k.o., 16 weeks (n = 7) 0.87 ± 0.03 155.17 ± 10.89 107.58 ± 7.55 0.81 ± 0.03  
Ob/ob, 16 weeks (n = 10) 0.82 ± 0.02 151.22 ± 8.28 104.82 ± 5.74 0.78 ± 0.02  
Rad-k.o., 16 weeks (n = 4) 0.82 ± 0.04 206.20 ± 27.75* 142.89 ± 19.24* 0.70 ± 0.06*  
Ob/ob x Rad-k.o.,  
16 weeks (n = 4) 
0.85 ± 0.03 224.45 ± 13.70* 155.58 ± 9.48* 0.70 ± 0.03*  
Wildtype, 28 weeks (n = 12) 0.81 ± 0.03 159.91 ± 6.31 110.84 ± 4.37 0.76 ± 0.02  
IRS 2-k.o., 28 weeks (n = 9) 0.81 ± 0.04 155.74 ± 9.01 107.95 ± 6.24 0.75 ± 0.04  
Ob/ob, 28 weeks (n = 12) 0.84 ± 0.02 173.26 ± 7.70 120.08 ± 5.34 0.76 ± 0.02  
Rad-k.o., 28 weeks (n = 2) 0.87 ± 0.00 156.70 ± 27.30 108.61 ± 18.89 0.79 ± 0.04  
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8.4  Cardiac myocytes purification assay  
 
Equilibrium density gradient centrifugation with Percoll medium is generally used in 
order to purify cell fractions. In this study it was planned to purify the enzymatically 
isolated adult murine ventricular myocytes. 
After Percoll density gravity centrifugation, four fractions of cells were obtained, as 
described in chapter 2.5. All layers were analyzed visually under a microscope. Dead 
cells were apparent in the interface between fraction 1 and fraction 2, but 
concentrated at the bottom of the tube. Despite several variations of centrifugation 
time and/or Percoll density experiments failed: cardiac myocytes, which should 
concentrate in fraction 3, were also visible in equal parts in fraction 2. Besides, other 
living cell types were also observable in the middle fractions, though representing a 
minor part (figure 8.5). Any change of the protocol worsened the outcome of the 
assay, i.e. resulted in diffuse cell distributions or no more living cardiomyocytes. Due 
to failure of purification of adult murine ventricular myocytes, for further expression 
analyses whole-ventricle homogenates were used. 
 
 
Figure 8.5 Fractions obtained after Percoll density gravity centrifugation: cardiac myocytes, which should 
concentrate in fraction 3, were also visible in equal parts in fraction 2. Other cell types were visible in these 
fractions as well. 
 
  
fraction 1
fraction 2
fraction 3
fraction 4
Appendix 
- 129 - 
8.5  qRT-PCR experiments 
 
The ventricular mRNA expression of the RGK proteins, Cav1.2 and the Cavß-subunits 
was detected via qRT-PCR. As expected Rem 2, which has been described to be 
highly expressed in brain and kidney (Liput et al., 2016, Finlin et al., 2000), was not 
detectable in ventricular tissue and thus was only measured the first experiments to 
detect a putative unexpected expression under diseased conditions. As control 
mRNA a murine brain cDNA sample was used. 
Data were obtained from N = 5–6 animals per group, 2-3 mice per sex assumed. To 
improve validity of the results maximal one mice per litter was used. 
 
8.5.1 Primer efficiency tests 
 
For primer efficiency tests three different cDNA dilution series were used (consisting 
of four or five dilutions, respectively). For each dilution series cDNA was reverse 
transcribed from a different adult murine ventricle sample. Per dilution series and 
primer pair one or two efficiency tests were conducted. 
Efficiencies of two genes were compared by blotting the Ct values obtained via qRT-
PCR against the log template amount of the cDNA dilution series used. The obtained 
standard curves almost went in parallel (figure 8.6). Therefore efficiencies were 
considered as comparable (Bustin et al., 2009). Calculated mean primer efficiencies 
were within a range of 86% and 99% (figure 8.7). 
                                   
Figure 8.6 Primer efficiency I: the tested primers showed comparable efficiencies with almost parallel standard 
curves. 
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Figure 8.7 Primer efficiency II: calculated primer efficiencies were within a range of 86% and 99%. 
 
8.5.2 Quality of isolated mRNA 
 
The quality of isolated mRNA is essential for obtainment of reliable qRT-PCR data. 
Each mRNA sample was checked via UV-Vis spectrophotometer. Only mRNA with a 
260 nm/280 nm ratio between 1.8 and 2.0 was used for further experiments. A ratio 
of 2.1–2.2 was also accepted if separation into 18 S rRNA (~ 1.9 kbp) and 28 S rRNA 
(~ 4.7 kbp) in agarose gel electrophoresis proved to be of good quality. Solely RNA, 
which showed two sharp bands with 28 S rRNA band intensity doubled compared to 
18 S rRNA, was taken for reverse transcription into cDNA. This additional check was 
not applied to all samples, only randoms were picked out. The results demonstrate 
that the method used to isolate mRNA was suitable to obtain intact mRNA without 
contaminations (figure 8.8). 
 
                          
Figure 8.8 Qualitative RNA analysis of murine ventricle samples: in intact total RNA 18 S and 28 S RNA 
bands are clearly visible in a ratio of 1:2 (kbp = kilo base pairs). 
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8.5.3 Quality of cDNA / qRT-PCR results 
 
After completion of a qRT-PCR cycling protocol a melting curve analysis of all 
samples was attached to check for product purity and to exclude primer dimers 
(chapter 2.6.5). Each qRT-PCR conducted showed clear melting curves specific for 
the particular target (figure 8.9). A random sample of cDNA probes was picked out 
and applied on an agarose gel to check for correct product size. cDNA products 
detected were within the expected range of 60–160 bp band size (figure 8.10). 
 
                 
Figure 8.9 Detection of melting curve analysis, exemplary for Rad, Rem 1 und S 29: melting curves were 
specific for the particular target, e. g. the curves for Rad always appeared at 82°C, for Rem 1 at 84°C and for      
S 29 at 88°C. 
 
                                               
Figure 8.10 Detection of cDNA bands: cDNA was detected via agarose gel electrophoresis in order to check for 
correct product size. E. g. the addition of Rad primer pairs to the reaction setup resulted in cDNA with 105 bp 
amplicon length (bp = base pairs).  
marker Rad  HPRT S29   Cav1.2 
100 bp
200 bp
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8.5.4 Stability of housekeeping gene expression  
 
At the beginning of data analysis the expression of S 29, HPRT and GAPDH was 
compared in order to find an appropriate housekeeping gene. Although GAPDH is 
one of the most commonly used housekeeping genes, its stable expression in 
diabetic heart tissue is questionable. GAPDH is an enzyme that is necessary in the 
glycolytic pathway (Barber et al., 2005). In diabetic tissues the expression can be 
altered, e.g. GAPDH was downregulated in the heart of type 1 diabetic dogs. 
(Barroso et al., 1999, Alexander et al., 1988). However, in the investigated samples 
GAPDH expression was stable. As illustrated in figure 8.11, S 29, HPRT and GAPDH 
were expressed stably throughout all genotypes and ages. Therefore data of the 
present study were normalized to S29, GAPDH and HPRT simultaneously (REST-
2009© analysis). The mean Ct value of S 29 (mixed genotypes and ages, n = 59) 
showed the smallest coefficient of variation, thus demonstrating S 29 as the most 
stable expressed reference gene (S29: 2.57%, HPRT: 3.08%, GAPDH : 3.34%, n = 
57-59). Hence S 29 was used as normalization gene for 2–ΔΔCt analysis. 
 
                           
Figure 8.11 Stability of housekeeping gene expression: S 29, HPRT and GAPDH were expressed stably 
throughout all genotypes and ages (HPRT/S29/GAPDH: n = 5-8 per genotype and age group).  
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8.5.5 Overview: qRT-PCR results  
Table 8.7 Overview of relative mRNA expression levels of Rad, Gem and Rem 1 compared to age-matched 
wildtype (* = p < 0.05 in hypothesis test of REST-2009© software tool [S29, HPRT and GAPDH as reference 
genes]; # = p < 0.05  in Student’s t-test of delta Ct values [S29 as reference gene]; values = mean ± SEM;  
N = 5-6 ventricles per genotype and age group; nd = not detectable).  
Genotype, 
age 
Rad mRNA 
expression 
Gem mRNA 
expression 
Rem 1 mRNA 
expression 
REST-
2009© 
2 
–ΔΔCt 
 
REST- 
2009© 
2 
–ΔΔCt
 
REST- 
2009© 
2 
–ΔΔCt
  
IRS 2-k.o.,  
16 weeks 
2.01*  
± 1.24 – 3.37  
2.06# 
± 0.17  
1.46  
± 1.02– 2.20 
1.44  
±  0.09 
1.46 
± 0.95 – 2.45 
1.45 
± 0.13 
 
Ob/ob, 
16 weeks 
1.42 
± 0.89 – 2.41 
1.55 
± 0.27 
1.22 
± 0.78–1.91 
1.36 
± 0.26 
0.87 
± 0.59–1.48 
0.96  
± 0.17 
 
Rad-k.o.,  
16 weeks 
nd nd 
1.92* 
± 1.29–2.82  
2.07# 
± 0.23  
1.17  
± 0.74–1.77 
1.19  
± 0.08 
 
IRS 2-k.o.,  
28 weeks 
1.22  
± 1.02–1.58 
1.24 
± 0.11 
1.15 
± 0.96–1.46 
1.15 
± 0.11 
1.24  
± 0.97–1.65 
1.24 
± 0.13 
 
Ob/ob,  
28 weeks 
1.24 
± 0.95–1.77 
1.50  
± 0.23 
0.91 
± 0.63–1.20 
1.04 
± 0.12 
0.96 
± 0.77–1.19 
1.08 
± 0.08 
 
Rad-k.o.,  
28 weeks 
nd nd 
2.13*  
± 1.74–2.67  
2.58# 
± 0.28 
1.28* 
± 1.05–1.67 
1.46  
± 0.16 
 
 
Table 8.8 Overview of relative mRNA expression levels of Cav1.2 compared to age-matched wildtype (* = p 
< 0.05 in hypothesis test of REST-2009© software tool [S29, HPRT and GAPDH as reference genes];                
# = p < 0.05  in Student’s t-test of delta Ct values [S29 as reference gene]; values = mean ± SEM; N = 5-6 
ventricles per genotype and age group).  
Genotype, age 
Cav1.2 mRNA expression 
REST-2009© 2 
–ΔΔCt 
  
IRS 2-k.o., 16 weeks 1.23 ±  0.86-1.88 1.20 ± 0.09  
Ob/ob, 16 weeks 0.84 ± 0.52-1.45 0.97 ± 0.19  
Rad-k.o., 16 weeks 1.01 ± 0.70-1.55 1.03 ± 0.07  
IRS 2-k.o., 28 weeks 1.03 ± 0.76-1.46 1.05 ± 0.14  
Ob/ob, 28 weeks 0.76* ± 0.65 – 0.93 0.86 ± 0.12  
Rad-k.o., 28 weeks 0.50* ± 0.35-0.68 0.57# ± 0.10  
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Table 8.9 Overview of relative mRNA expression levels of the Cavß-subunits compared to age-matched 
wildtype (* = p < 0.05 in hypothesis test of REST-2009© software tool [S29, HPRT and GAPDH as reference 
genes]; # = p < 0.05  in Student’s t-test of delta Ct values [S29 as reference gene]; values = mean ± SEM; N = 5-6 
ventricles per genotype and age group).  
Genotype, 
age 
Cavß1 subunit 
mRNA expression 
Cavß2 subunit 
mRNA expression 
Cavß3 subunit 
mRNA expression 
REST-
2009© 
2 
–ΔΔCt 
 
REST- 
2009© 
2 
–ΔΔCt
 
REST- 
2009© 
2 
–ΔΔCt
  
IRS 2-k.o.,  
16 weeks 
1.21 
± 0.75–1.77 
1.23 
± 0.17 
0.74 
± 0.45–1.33 
0.77 
± 0.14 
1.12 
± 0.60–2.31 
1.11 
± 0.16 
 
Ob/ob, 
16 weeks 
0.57* 
± 0.30–0.82 
0.64 
± 0.12 
0.47* 
± 0.32–0.74 
0.50# 
± 0.10 
0.84 
± 0.47–1.63 
0.87 
±0.13 
 
Rad-k.o.,  
16 weeks 
1.22 
± 0.76–1.90 
1.26 
± 0.14 
0.69* 
± 0.49–1.03 
0.70# 
± 0.05 
1.38 
± 0.82–2.52 
1.43 
± 0.11 
 
IRS 2-k.o.,  
28 weeks 
0.88 
± 0.66–1.20 
0.86 
±0.08 
0.63 
± 0.20–1.20 
0.72 
± 0.16 
0.98 
± 0.68–1.38 
0.99 
± 0.12 
 
Ob/ob,  
28 weeks 
0.54* 
± 0.35–0.90 
0.66# 
± 0.15 
0.68* 
± 0.52–0.86 
0.77 
± 0.08 
0.63* 
± 0.38–0.90 
0.75 
± 0.16 
 
Rad-k.o.,  
28 weeks 
0.94 
± 0.49–1.69 
1.19 
± 0.27 
0.40* 
± 0.29–0.56 
0.45# 
± 0.07 
1.01 
± 0,62–1.51 
1.25 
± 0.25 
 
 
Table 8.10 mRNA expression levels of 40 week old IRS 2-k.o. mice (* = p < 0.05 in hypothesis test of REST-
2009© software tool [S29, HPRT and GAPDH as reference genes]; # = p < 0.05  in Student’s t-test of delta Ct 
values [S29 as reference gene]; values = mean ± SEM; N = 5-6 ventricles per genotype and age group).  
Gene 
mRNA expression 
REST-2009© 2 
–ΔΔCt 
  
Rad 0.56 ± 0.35–0.88 0.71 ± 0.16  
Gem 0.72 ± 0.62–0.82 0.92 ± 0.10  
Rem 1 0.53* ± 0.38–0.74 0.69 ± 0.08  
Cav1.2 0.70 ± 0.45–1.10 0.88 ± 0.18  
Cavß1 0.65* ± 0.43–0.86 0.80 ± 0.15  
Cavß2 0.59 ± 0.42–0.96 0.62 ± 0.16  
Cavß3 0.53* ± 0.33–0.88 0.68 ± 0.16  
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8.6  Western Blot experiments 
8.6.1 Positive / negative controls for Rad and Cav1.2 protein 
 
For reliable Western Blot experiments appropriate positive and negative controls are 
necessary. Via a calcium phosphate based transfection method in tsa201 cells and 
subsequent cell lysis, it was possible to obtain clear controls for Rad and Cav1.2 
antibodies. As depicted in figure 8.12, antibodies specific for Rad protein yielded in a 
band at approx. 38 kDa. In murine ventricle samples unspecific bands at approx.     
34 kDa and 49 kDa could be detected in some samples (figure 8.12, lane 2 and 3).  
 
 
Figure 8.12 Rad protein positive control: Rad protein positive control yielded in a band at approx. 38 kDa 
(lane 1). Lane 2 and 3 show bands of murine samples: the Rad protein band appeared at approx. 38 kDa, too. 
 
As expected, a band for Rad protein could not be detected in Rad-k.o. mice (figure 
8.13, lane 3).   
 
 
Figure 8.13 Detection of Rad in murine ventricle samples: in Rad-k.o. mice the antibody against Rad protein 
was not able to bind. No band at approx. 38 kDa could be observed (lane 3). In contrast, different wt mice 
samples showed a band at approx. 38 kDa (lane 1, 2). In each lane equal amounts of template were loaded. The 
upper bands illustrate the Cav1.2 protein expression. 
  
lane 1          lane 2      lane 3
40 kDa
50 kDa
35 kDa
25 kDa
40 kDa
35 kDa
260 kDa
140 kDa
lane1 lane2 lane3  
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A specific positive control for Cav1.2 protein could also be produced and showed a 
band at approx. 260 kDa, as outlined in figure 8.14. 
 
 
Figure 8.14 Cav1.2 protein positive control:  Cav1.2 protein positive control yielded in a band at approx.        
260 kDa (lane 1).  
 
8.6.2 Quality of Bradford analysis 
 
Bradford analysis was conducted to ensure that equal protein amounts could be 
loaded into the pockets of SDS-PAGE gel. Therefore it was important to have a 
reliable Bradford assay. To exclude any influence of the product buffer (0.25 mM 
sucrose solution) measurements of a dilution series of the standard protein BSA in 
the same buffer were compared to measurements in which BSA was solved in H2O. 
Analysis of results revealed that sucrose had no influence on protein determination 
(figure 8.15). 
 
Figure 8.15 Quality of Bradford analysis: for Bradford analysis a dilution series of the standard protein BSA in 
H2O was measured (dilution series 4, 5, 6). To ensure a correct measurement of the samples, that were solved in 
0.25 mM sucrose solution, several dilution series (1-3) of BSA in 0.25 mM sucrose solution were measured, too. 
The measurements revealed that sucrose had no influence on protein measurement.  
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8.6.3 Linearity of the detection system 
 
For relative quantification of Western Blots a linearity within the detection system has 
to be assumed for each gene analyzed. As outlined in figure 8.16, linearity was given 
for both proteins of interest, Cav1.2 and Rad. Lane 2 in figure 8.16 (A) shows optimal 
protein amounts, where bands are clearly visible without being saturated. Moreover, 
both proteins could be determined within one blot. Optimal protein concentrations 
proved to be between 40 and 60 µg, which corresponds to lane 1 to 3. 
 
 
Figure 8.16 Linearity of the detection system. (A) Both proteins of interest, Cav1.2 and Rad, could be detected 
within the linearity of the detection system. Lane 2 shows optimal protein concentrations where bands are clearly 
visible without being saturated. Sample amount per lane (from left to right): 2, 4, 6, 8, 10 µl. (B) Band densities 
of the image (A) were determined via ImageJ software tool and blotted against the template amount. Linear 
regression revealed that linearity was given for the protein amounts used. 
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